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I. INTRODUCTION 
Part I Introduction 
1.1. General Introduction 
Each year in the European Union nearly 2,9 million people are diagnosed with cancer 
and there are over 1,7 million deaths from the disease. Cancer remains an important public 
health problem in Europe (Boyle and Ferlay 2005). The past two decades our knowledge of 
the genetic and epigenetic events involved in the early event of cancerogenesis increased 
considerably. By contrast, despite the appreciation of the clinical relevance of tumour 
metastasis, there is a lack of therapies that can efficiently prevent metastasis (Christofori 
2006). 
During tumour progression, a multitude of cumulative alterations modulates the transition 
from a normal to a malignant state. Tumour cells are not isolated but they are present in a 
micro-environment where stromal cells, like fibroblast, immune cells and endothelial cells; 
extracellular matrices, like collagen and laminin, proteases and growth factors are present. 
There exists a constant cross talk that modulates several cellular activities such as growth, 
differentiation, invasion, ectopic survival and metastasis. Invasion, the hallmark of 
malignancy, implicates the penetration of cancer cells through the basement membrane and 
their survival outside their original tissue. Cancer cells also invade into the circulation (lymph 
or blood) to reach distant organs where they can metastasise (Hanahan and Weinberg 2000). 
Different factors of the ecosystem are implicated in tumour progression, and some will be 
highlighted here: cell-cell adhesion (part II), proteinases and their released fragments (part 
III), angiogenesis (part IV), external or autocrine factors influencing tumour progression (part 
V).  
The cadherins are important target in several processes implicated in tumour progression, 
while some are assigned as invasion suppressors others are invasion promoters (Mareel and 
Leroy 2003). The cadherins are a super family of cell surface molecules that require calcium 
in order to establish cell-cell adhesion. The cadherins are transmembrane proteins which have 
in common the presence of several cadherin domains (CD, ± 110 amino acids) (Tepass, 
2000). Calcium ions form a complex with the different domains and are necessary for the 3D 
configuration. The cadherins form two types of dimers: cis and trans. Cis is when cadherins 
are both present on the same cell and trans is in opposing cells. The cadherin family consists 
of more than 80 members, which are usually indicated by a prefix letter that refers to the 
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tissue or organ in which the molecule was found originally. Some examples are epithelial (E-) 
cadherin is expressed by all epithelial cells, neural (N-) cadherin is expressed in neuronal 
tissue but also by oocytes, spermatocytes, retina, endothelial cells and fibroblasts. Placental 
(P-cadherin) is expressed by basal cells of the epithelial tissue for example the myoepithelial 
of the breast, and Vascular Endothelial (VE)- cadherin is expressed by endothelial cells. 
During embryogenesis and cancer progression cells can change the type of cadherin they 
express. During my work in the laboratory of Experimental Cancerology, I focused on N-
cadherin. In part II an overview is presented about its function during embryogenesis, cell-cell 
adhesion and tumour progression (article 2; Derycke and Bracke 2004). 
In the micro-environment of cancer, cells secrete elevated levels of several proteases, like 
matrix metalloproteinases, serine proteinases and cysteine proteinases (Egeblad and Werb 
2002; Riddick et al. 2005). They are responsible for the cleavage of transmembrane proteins, 
like tyrosine kinase receptor c-erBb2 and cadherins. The ectodomains of these proteins are 
detected in different human biological fluids and can be used as tumour markers, to use for 
diagnosis, prognosis, follow up or therapeutic monitoring of cancer patients (Villanueva et al. 
2006). From 1994 till now several articles (part III) describe already the detection of sE-
cadherin in serum and the correlation with diverse types of cancers, like gastric carcinoma, 
bladder carcinoma, colorectal carcinoma, melanoma and prostate carcinoma and with the 
stage of the tumour (Katayama et al. 1994; Velikova et al. 1997; Griffiths et al. 1996). 
However sE-CAD is not specific for cancer (Pittard et al. 1996) and is so far not used in daily 
practice for the follow up of cancer patients. During my PhD we tried to define soluble N-
cadherin as a more useful tumour marker, reasoning N-cadherin is upregulated in many 
carcinomas (Derycke and Bracke 2004). However until now only one article describes the 
presence of soluble N-cadherin, namely in the vitreous humour (Paradies et al., 1993). We 
developed a detection method which detects the N-cadherin ectodomain in different biological 
fluids, like blood and seminal fluid (article 3). Furthermore, we compared the concentration of 
the N-cadherin ectodomain present in serum from persons with no evidence of disease, cancer 
or other diseases. 
 
Another important process during tumour progression is angiogenesis, the formation of new 
blood vessels. The process of angiogenesis is necessary for the growth of the tumour but also 
for the dissemination of cancer cells to distant organs (Carmeliet and Jain 2000). N-cadherin 
plays here also an important role because it is expressed by the endothelial cells and by the 
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pericytes (Dejana 2005). Recently the group of Luo and Radice concluded that N-cadherin 
controls vasculogenesis upstream of VE-cadherin. Because specific knock-down of N-cadherin 
in endothelial cells results in embryonic lethality at mid-gestation due to severe vascular 
defects. The knock-down of N-cadherin caused indeed a significant decrease in VE-cadherin 
expression (Luo and Radice 2005). We investigated the role of the N-cadherin ectodomain in 
the process of angiogenesis (article 4). N-cadherin as well as its ectodomain is able to 
stimulate neurite outgrowth in a Fibroblast Growth Factor Receptor (FGF-receptor) dependent 
manner (Williams et al., 1994, Utton et al. 2001). However, about the mechanism of the N-
cadherin ectodomain during the different processes of tumour progression nothing is known. 
 
As discussed above the cadherins have a cell-cell adhesion function and are deregulated in 
cancer (part V). The downregulation can happen at different levels: by mutation, by 
hypermethylation of the promoter, transactivation of other cadherins, phosphorylation of the 
catenins, sterical hindrance, proteolysis or endocytosis (Van Aken et al., 2001). Some 
examples of inhibitors of the E-cadherin/catenin complex are epidermal growth factor (EGF), 
which induce tyrosine phosphorylation of β-catenin (Shiozaki et al. 1995) and the matrix 
metalloprotease matrilysin, which induces shedding of the ectodomain (Noë et al. 2001). 
Insulin-like growth factor (Bracke et al. 1993) and 17-β estradiol (MacCalman et al. 1994) and 
natural products like tangeretin (Bracke et al. 1994) are activators of the E-cadherin/catenin 
complex. Another natural product, xanthohumol, originating from hop bells is also 
upregulating the function of the E-cadherin/catenin complex (article 6). The N-
cadherin/catenin complex is regulated by cytokines like EGF (Ackland et al. 2003) and 
interleukin-6 (Gil et al. 2002), the pharmacological agent thalidomide (Thiele et al. 2000) and 
proteases like a disintegrin and metalloproteinase 10 (ADAM10) (Reiss et al. 2005). 
Conditioned medium of cells are a source of cytokines and other paracrine and autocrine 
factors which can modulate the cadherin/catenin complex. Conditioned medium of the human 
squamous carcinoma cells, COLO 16, induces internalization of E-cadherin and scattering of 
human mammary carcinoma cells (Boterberg et al. 2000), while conditioned medium of 
Bowes melanoma cells has the ability to stimulate the aggregation of breast carcinoma cells by 
activation of the E-cadherin/catenin complex (Stove et al. 2005). Heregulinβ1 is a growth 
factor produced by melanocytes and melanoma cells, and is one of the factors responsible for 
stimulated aggregation of the cells. Heregulinβ1, present in the conditioned medium of Bowes 
melanoma, works also as an autocrine factor; it stimulates the proliferation of the melanoma 
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cells (article 5). In this part we discuss also the upregulation of the P-cadherin/catenin complex 
by ICI182,780 in breast carcinoma cells (article 7, Paredes et al. 2004). 
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Integrity, and Ectopic Cell Death in Cancer Cells
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ABSTRACT
Cancer cells continue to grow, lose their differentiation, and are found beyond their tissue boundaries, where
they survive. These phenomena lead to cancer invasion and metastasis and are responsible for the outcome
of the disease in cancer patients. Different factors determine where and when the cells will metastasize. The
surrounding host cells, such as fibroblasts, macrophages, leukocytes, et cetera, and the extracellular matrix
play an important role in the creation of the microenvironment for the cancer cells to invade. Blood and
lymph vessels are not only the transporters of nutrients and metabolites for the primary tumor, these ves-
sels also transport cancer cells to distant sites, where they metastasize. Angiogenesis and host cells are tar-
gets in cancer treatment. To monitor therapy or to predict cancer relapses, circulating tumor markers are
used that reflect the molecular cross-talk between cancer and stromal cells.
Key words: cancer, microenvironment, tumor markers, host cells, angiogenesis
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INTRODUCTION
In adult multicellular organisms, the number and
the differentiation state of the cells is strictly con-
trolled, and tissue integrity is maintained because
cells stay between their tissue boundaries. When
normal cells are brought beyond these boundaries
into an ectopic tissue context, they are even un-
able to survive, a phenomenon known as anoikis.1
In cancer, however, genetic alterations allow cells
to escape from these control mechanisms. Can-
cer cell populations continue to grow progres-
sively in time and space and tend to lose or
change their differentiation characteristics. In
several epithelial cancers, a transition from 
normal epithelial to pathological mesenchymal
marker expression has been described. This
switch is commonly designated as the epithelial
to mesenchymal transition (EMT).2 Most impor-
tant for the clinical outcome is that cancer cells
ignore tissue integrity and have the ability to
overcome ectopic cell death.3 The latter two phe-
nomena lead to cancer invasion and metastasis
and thus compromise the prognosis of the cancer
patient. In this paper, we will focus on molecu-
lar targets that are relevant in the pathogenesis of
cancer invasion and metastasis.
Metastasis Promoter Genes Can be
Activated Early During Tumor Progression
Invasion and metastasis are responsible for the
fatal outcome of the disease in cancer patients.4
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While local invasion by the tumor into the sur-
rounding tissue is the cause of death in brain can-
cer patients, distant metastases are the life-threat-
ening events in the course of melanoma and
prostate cancer progression. Colorectal and blad-
der cancer patients die from both locoregional or
distant tumor invasion and metastasis.
Local tumor invasion is characterized by at
least two changes of function by the cancer cells.
Firstly, these cells express higher levels of mem-
brane-type and secreted proteolytic enzymes in
comparison with their normal epithelioid coun-
terparts. Two families, the matrix metallopro-
teases5 and the plasminogen activators,6 have
been studied extensively. Their contribution to
invasion ranges from breakdown of the extracel-
lular matrix, over release of proinvasive factors,
to cleavage of cell-cell adhesion molecules. Sec-
ondly, cancer cells are more motile than normal
epithelial cells. Control of their actin cytoskele-
ton dynamics by small GTPases (Rac, Rho and
Cdc42) appears to be crucial for motility,7 while
assembly of their cytoplasmic microtubule com-
plex is implicated in direction finding.8 Local tu-
mor invasion is also made possible by disruption
of epithelial cell junctions. E-cadherin, which is
part of the adherens junctions, plays an important
role in maintaining the epithelioid cell organiza-
tion and in preventing invasion.9 Cadherins not
only serve cell-cell adhesion by means of ho-
mophilic interaction between cadherins from
neighboring cells, they also allow outside-in sig-
nalling through the cytoplasmic catenin complex
toward the actin cytoskeleton. Downregulation of
the expression or the function of E-cadherin is a
constant finding in invasive carcinomas,10,11 and
the causal relation between this downregulation
and the onset of invasion has been demonstrated
in models in vitro12 as well as in vivo.13 Although
E-cadherin is considered as an invasion suppres-
sor, other classical cadherins, such as N- and P-
cadherin, now show up as potential invasion pro-
moters. In particular, the switch from E- to
N-cadherin expression can accompany the EMT
phenomenon in invasive tumors derived from
mammary gland epithelium.14 The shedding of
the extracellular part of these cadherins by pro-
teolytic cleavage is intriguing and offers new di-
agnostic candidates as circulating tumor mark-
ers.15
The role of surrounding host cells in the cre-
ation of a microenvironment for the cancer cells
is often underestimated. Fibroblasts, macro-
phages, leukocytes, platelets, and the extracellu-
lar matrix are sources of proinvasive and anti-
invasive molecules that affect the balances be-
tween proteases and their inhibitors, motility fac-
tors and their antagonists, and up- and
downregulators of the cadherin/catenin com-
plexes (Fig. 1). One example of the cross-talk
between cancer cells and host elements are my-
ofibroblasts. They are recruited from fibroblasts
by colon cancer cells via transforming growth
factor- (TGF-), and secrete proinvasive mol-
ecules for the cancer cells (scatter factor/hepa-
tocyte growth factor and tenascin C).16 Enter-
obacteria such as Listeria monocytogenes
demonstrate that environmental factors may con-
tribute to the production of proinvasive peptides
for the colon cancer cells.17
For most tumor types, invasion of cancer
cells at the primary site eventually leads to me-
tastasis formation. The latter is a multistep pro-
cess involving intravasation of cancer cells into
the blood and lymph vessels, transportation
through the circulation, and extravasation at
distant sites. At these sites, cancer cells can start
to grow and invade again, giving rise to sec-
ondary tumors (metastases). Escalation of these
phenomena is the basis of a metastatic cascade,
which will finally kill the patient. This does not
exclude direct seeding from the primary tumor
to different organs as an important mecha-
nism.18
During cancer progression, including the
stages of hyperplasia, dysplasia (carcinoma in
situ), invasive carcinoma, and metastasis forma-
tion, a disequilibrium in promoter and suppres-
sor gene activity is responsible for growth (onco-
genes versus tumor suppressor genes), invasion,
and metastasis. All of those gene alterations can
occur early during cancer development. So, in
lobular carcinoma of the breast, mutations of the
E-cadherin gene, an invasion suppressor, can be
detected as early as in the carcinoma in situ
stage.19 A challenge for the future is the recog-
nition of metastasis genes, as recent data indi-
cate that they can be activated in the early stages
as well.20–21 This is of clinical importance, be-
cause detection of distinct sets of activated me-
tastasis genes in the primary tumor will predict
its metastatic capacity and will be useful to di-
rect the treatment of the individual patient. A
concerted action by the European Community
(METABRE) is now aiming at defining such a
workable set of clinically relevant metastasis
genes and gene products.
An increasing number of recent literature data
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FIG. 1. Cellular components of the breast cancer micro-ecosystem. In normal breast epithelium, luminal cells (LC) and myo-
epithelial cells (MC) adhere to an intact basement membrane (BM). In breast cancer, however, the cancer cells (CC) break through
this membrane and cleave the structural molecules of the interstitial extracellular matrix, such as the collagen fibers (CF). The
cancer cells can invade locally, intravasate, are transported by the circulation, and extravasate to produce distant metastases. In
the metastatic cascade, the cells can establish molecular cross-talks with host cells: fibroblasts (FI), myofibroblasts (MF), mast
cells (MC), dendritic cells (DC), neural cell extensions (NC), macrophages (MP), and adipocytes (AC). Angiogenesis results from
interactions with endothelial cells (EC) and pericytes (PC) and brings in new interacting cells from the circulation, such as poly-
morphonuclear leukocytes (PM), lymphocytes (LY), monocytes (MO), and platelets (PL).
confirm that metastasis is an early phenomenon in
cancer development. In one study, Gerber et al.22
showed the presence of occult tumor cells in lymph
nodes and bone marrow from breast cancer pa-
tients staged pT1-2 N0 M0 (no lymph node nor
systemic metastases, following current diagnostic
methods). Using sensitive immunohistochemical
techniques for cancer cell detection, the authors
found occult cells in 6.4% of the lymph nodes sam-
ples, in 26.0% of the bone marrow samples, and
in 4.8% of both. This makes a total of 37.2% of
all samples containing occult tumor cells.
The Seed and the Soil Hypothesis can be
Translated into Molecular Cross-Talks
Between Cancer Cells and the Surrounding
Host Cells
What is it that decides what organ shall suffer in
a case of disseminated cancer? This question was
raised in 1889 by Paget and answered with his
“seed and soil” hypothesis.23 His answer was that
the microenvironment of each organ (the “soil”)
influences the survival and growth of tumor cells
(the “seed”). This statement can currently be
581
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translated into molecular mechanisms that gov-
ern the interaction between circulating cancer
cells and the potentially metastatic organs, and it
still inspires current research. Again, metastasis
is the result of molecular cross-talks between can-
cer cells and cells from organs, such as the brain,
lungs, bone, liver, and bladder. They decide about
specific homing and survival of the cancer cells.
We will extend on one example of such a cross-
talk that recently caught major attention, namely
angiogenesis.
Angiogenesis is the Result of a Cross-Talk
Between Cancer Cells and Local 
Endothelial Cells
Angiogenesis in the primary tumor is not only
providing to the tumor an afferent influvium of
nutrients and an efferent discharge of toxic
metabolites, the endothelial network is also a
source of afferent growth and proinvasive factors
for the cancer cells. Furthermore, it facilitates the
inflow of host cells, such as tumor-infiltrating
lymphocytes. Also, the newly formed network
enables the intravasation of cancer cells and so
the initiation of metastasis to distant sites. The
establishment of neovascularization in both the
primary tumor and the distant metastases opens
the gate for a mutual cross-talk. Folkman’s group
has shown, for instance, that the primary tumor
releases an angiostatin that inhibits the develop-
ment of distant metastasis.24
When cancer cells extravasate into an organ of
future metastasis, they are able to turn the local
balance between pro- and antiangiogenic factors
from mainly antiangiogenic to a net proangio-
genic outcome. Tumor secretion of proangio-
genic factors, such as vascular endothelial growth
factors (VEGFs) and many others, stimulates en-
dothelial cells from neighboring capillaries to
proliferate and migrate (“sprouting”) toward the
cancer cells. This is the initiation of the forma-
tion of more stable vessels that involves other cell
types such as pericytes as well.25 Here, the simi-
larity of growth, invasion, and differentiation of
angiogenic endothelial cells with cancer cell ac-
tivities is striking.
Both the trigger for the secretion of angiogenic
factors by the cancer cells and the way of inter-
action of these factors with the endothelial cells
have been described in molecular detail. Impor-
tant triggers are hypoxia and low pH in the grow-
ing cancer: These conditions increase the intra-
cellular concentration of hypoxia-inducible
factors (HIF-1 and HIF-1, respectively) by in-
hibiting their ubiquitination at the proteasome
complex, a process which is responsible for pro-
tein degradation by linking the tag ubiquitin to
proteins. While gene transcription is generally
shut down in cells suffering from hypoxia, a num-
ber of genes possess a hypoxia responsive ele-
ment (HRE) in their promoter, which is able to
interact with the HIF-1s. So, the HIF-1s act as
transcription factors for genes implicated in gly-
colysis, erythropoiesis, CXCR4 expression, and
angiogenesis.26 The latter group of (angiogenic)
gene products comprises VEGF, angiopoietin 2,
nitric oxide synthase, and platelet-derived growth
factor receptor. By this mechanism, the threat of
unfavorable conditions for the cancer cells is
rapidly corrected by a supply of oxygen and nu-
trients by newly formed vessels. External condi-
tions, however, are not the only driving force for
the generation of proangiogenic molecules, as ac-
tivation of several oncogenes in the cancer cells
is sometimes overruling the cross-talk with the
surrounding extracellular milieu. These onco-
genes can govern the “oncogenic switch” by
overexpression not only of VEGF, but also of ba-
sic fibroblast growth factor (bFGF), interleukin-
8 (IL-8), placenta-like growth factor (PLGF),
transforming growth factor- (TGF-), platelet-
derived endothelial growth factor (PD-EGF),
pleiotrophin, and others.
Although VEGF is probably the most potent an-
giogenic factor, it owes its specificity to a unique
tyrosine kinase receptor (VEGFR), which is pres-
ent only in endothelial cells. Additional specificity
within this system is obtained from the existence
of at least 4 types of VEGF (A to D) and 3 types
of its receptor (1 to 3). Although VEGFR-1 (or Flt-
1) is sensitive to VEGF-A and VEGF-B (and to
placental growth factor) and induces new blood
vessels, VEGFR-3 (or Flt-4) is sensitive to VEGF-
C and VEGF-D and gives rise to new lymph ves-
sels. VEGFR-2 (or KDR/Flk-1) keeps an interme-
diate position: It is sensitive to all types of VEGF
(except VEGF-B) and can induce both blood and
lymph vessels.27–29 This raises the possibility that
the choice of an individual tumor to metastasize ei-
ther through the blood vessels or the lymphatics is
at least partly determined by the type of VEGF it
secretes: VEGF-A/B secretors would then metas-
tasize mainly through the blood, while VEGF-C/D
secretors would occupy the lymph nodes preferen-
tially. It is too early, however, to conclude whether
this implicates diagnostic, prognostic, and thera-
peutic consequences for the individual patient.
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Angiogenesis is a Target for 
Cancer Therapy
Screening and evaluation of potential inhibitors
of angiogenesis is done in models in vitro and in
vivo. The effect of compounds on the formation
of capillary-like structures by endothelial cells
can be tested in cultures of human umbilical vein
endothelial cells (HUVEC) on Matrigel® in
vitro.30 The effects are easy to evaluate and to
quantify, but questions can be raised about the
relevance of this rather artificial assay. Somewhat
more relevant to the natural situation is the chick
chorioallantois membrane (CAM) assay. Here the
CAM of the chick egg is impregnated locally with
potential modifiers of angiogenesis. Sprouting of
new vessels within the zone of impregnation can
be quantified and compared with a control
zone.31 This CAM assay is meant as a compro-
mise between the purely in vitro HUVEC assay
and the angiogenesis assays in vivo, which in-
clude laboratory animals. An example of the lat-
ter group is the rabbit cornea micropocket assay:
Here the formation of blood vessels is studied in
a normally avascular tissue.32 In the assays, in-
hibition of spontaneous and VEGF-induced an-
giogenesis by test compounds can be quantified,
and the results can be compared with the effect
of PD 173074, a tyrosine kinase inhibitor of the
VEGF receptor.
Two classes of angiogenesis inhibitors can be
considered as candidates for cancer therapy: direct
and indirect ones. Direct inhibitors, such as vitaxin,
angiostatin, and others, prevent vascular endothe-
lial cells from proliferating, migrating or avoiding
cell death in response to a spectrum of proangio-
genic factors, including VEGF, bFGF, IL-8,
platelet-derived growth factor, and PD-EGF. Di-
rect angiogenesis inhibitors are the least likely to
induce acquired drug resistance, because they tar-
get genetically stable endothelial cells rather than
unstable mutating tumor cells. Tumors that are
treated with direct-acting antiangiogenic therapy
did not develop drug resistance in mice so far.
Indirect angiogenesis inhibitors generally pre-
vent the expression or block the activity of a can-
cer protein that activates angiogenesis or block
the expression of its receptor on endothelial cells.
Many of these tumor-cell proteins are the prod-
ucts of oncogenes that drive the oncogenic
switch.
The biological effects of angiogenesis inhib-
itors are expected to be diverse in vivo: reduc-
tion of tumor blood flow and induction of apop-
tosis in both cancer and endothelial cells. Of
special interest is thalidomide, a synthetic seda-
tive; this drug was found to inhibit angiogene-
sis induced by bFGF or VEGF in the rabbit
cornea micropocket assay.33 Thalidomide is
now being tested in more than 160 clinical tri-
als at more than 70 medical centres in the United
States and in Europe. It has become one of the
most effective drugs for treating patients with
multiple myeloma, either as first-line therapy or
for the treatment of patients who are resistant to
conventional chemotherapy. In fact, thalido-
mide is one example of the wide variety of an-
tiangiogenic agents applied clinically.34 These
molecules belong to different classes, possess
different targets, and were found to inhibit an-
giogenesis empirically. Apart from thalidomide,
well-known examples are suramin (binder of
growth factor), endostatin (naturally occurring
inhibitor of angiogenesis), vitaxin (integrin an-
tagonist), marimastat (protease inhibitor), com-
bretastatin-4 (binder of tubulin), and inter-
leukin-6 (cytokine). A better understanding of
the molecular mechanisms of angiogenesis now
offers rationales for the development of new an-
giogenesis inhibitors with more specific targets,
such as antagonists of angiogenesis factors at
the receptor level, inhibitors of the receptor ty-
rosine kinase, and of their downstream sig-
nalling pathways.
New Targets for Antimetastatic Agents 
and New Problems Arising
Apart from angiogenesis, many other examples
of phenomena contributing to tumor growth, in-
vasion, and metastasis exist that offer possible
molecular targets for imaging, follow-up, and
therapy in cancer patients. Recently, the role of
chemokines and their receptors in metastasis was
further elucidated and opened new therapeutic
perspectives for antimetastatic treatments. Breast
cancer cells were shown to express high levels of
a chemokine receptor coined CXCR4, while tar-
get organs for breast cancer metastasis, such as
the liver, secrete the ligand for this receptor:
CXCL12. Signalling through the CXCR4 recep-
tor initiates actin polymerization and pseudopod
formation in the tumor cells, preparing them for
subsequent chemotactic and invasive re-
sponses.35 So, this chemokine-mediated mecha-
nism determines the metastatic destination of cir-
culating cancer cells. Interestingly, antibodies
neutralizing the interaction between CXCR4 and
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CXCL12 are able to reduce metastasis formation
in laboratory animals, indicating that this inter-
action may be another target for antimetastatic
treatments.
Invasion, however, can be driven by more than
one type of cell motility, and cancer cells can
switch from one type to another. Cells can, for
instance, invade into a three-dimensional matrix
by a mechanism that is dependent on the activa-
tion of the small GTPase Rac. These cells assume
a phosphoinositide-3-phosphate-mediated elon-
gated morphology. Upon inhibition of the extra-
cellular protease activity, the cells in the matrix
switch to a mechanism that is dependent on ac-
tivated Rho, another member of the small GT-
Pase family. They become characterized by a
more spherical morphology and migrate by
amoeboid movements.36–38 These findings warn
for the dynamic nature of cancer cell mechanisms
to maintain the invasive and metastatic pheno-
type. So, anti-invasive treatments may fail, be-
cause cancer cells escape through salvage mech-
anisms that are not affected by the treatment.
Finding new targets for therapy clearly risks to
reveal unexpected scenarios in cancer invasion
and metastasis.
Proof of Principle for the Target Role of
Host Cells in Cancer Treatment
The role of host cells as targets for therapy can
be illustrated by the successful application of bis-
phosphonates in clinical practice. These drugs are
used for the treatment of bone metastases, and
they do not affect the metastatic cancer cells as
such, but inhibit bone resorption by the osteo-
clasts. These host cells receive stimulatory sig-
nals from the cancer cells and from bone marrow
macrophages, but bisphosphonates force them to
go into apoptosis.39 Bisphosphonate treatment
thus alleviates cancer pain, and, in some cases,
reduces the size of osteolytic bone metastases, as
measured on radiologic images. Research on the
mechanisms of cancer pain has recently revealed
new targets for therapy. The sensitivity threshold
of the nociceptor from the primary sensory neu-
rons is lowered by inflammatory mediators dur-
ing invasion and metastasis.40 Inhibitors have
now been developed for proteins involved in no-
ciceptor sensitization: cyclooxygenase-2, en-
dothelin receptor, vanilloid receptor-1, purinergic
receptor, and acid-sensing ion channels. Other
classes of molecules that increase the sensitivity
threshold of the nociceptor are osteoprotegerin
and anticonvulsants. The successful introduction
of some of these inhibitors in oncology for treat-
ing cancer pain confirms that not only cancer
cells, but also host cells, express useful thera-
peutic targets that can be considered for the ben-
efit of the cancer patient.
Circulating Tumor Markers Reflect the
Molecular Cross-Talk Between Cancer 
and Stromal Cells
Molecules such as VEGF and CXCL12 are a few
examples of the myriad of tumor markers that have
been launched as tools to monitor therapeutic fol-
low-up or to predict cancer relapses. Circulating
tumor markers are attractive because they can be
determined accurately on a small blood sample,
and because they are highly informative, provided
the interpretation of the result is considering the
different aspects of the cancer environment.
Many circulating tumor markers find their ori-
gin in the cancer cells, and they can be divided
into three main classes: intracellular, membrane-
bound, and secreted molecules (Fig. 2).
Intracellular markers
Some intracellular proteins, such as TdT, NuMA,
estrogen, and progesterone receptor, are mainly
intranuclear molecules. Others are part of the cy-
toplasmic cytoskeleton (cytokeratins) and are de-
tected in the blood as CYFRA 21-1, TPA, TPS,
or cytokeratin 18. The blood concentration of
these nuclear and cytoplasmic markers reflects
tumor growth and tumor mass.
Membrane-bound markers
At the apical cell membrane of polarized epithe-
lia, a number of large proteoglycans (mucins) are
extending into the extracellular space and are
continuously shed from the plasma membrane.
Because of their apical localization and their large
molecular size, these proteoglycans are unable to
cross epithelial cell junctions and the underlying
basement membrane, so their concentration in
normal blood samples is extremely low. In can-
cer, cell polarization is lost, cell junctions disap-
pear, and the basement membrane is fragmented.
In this way, the large glycosaminoglycans gain
access to the circulation, and their blood con-
centration reflects the invasion of the tumor. They
are commonly indicated by “CA” (cancer anti-
gen) followed by a number. In breast carcinoma,
these proteoglycans (CA 15-3, CA 549, TAG-12)
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FIG. 2. Schematic overview of cellular origin of circulating tumor markers. Different markers of epithelial carcinoma cells
(EP), basement membrane (BM), fibroblasts (FI), lymphocytes (LY), extracellular matrix (ECM), and endothelial cells (EN) are
represented. Intracellular markers are TdT (terminal deoxynucleotidyl transferase), NuMA (nuclear mitotic apparatus protein),
ER (estrogen receptor), PR (progesterone receptor), CYFRA21.1 (cytokeratin fragment antigen 21.1), TPA (tissue polypeptide
antigen, TPS (tissue polypeptide antigen), and cytokeratin 18. Membrane-bound markers. In breast carcinoma, CA 15-3 (cancer
antigen), CA 549, CA M29 (carcinoma-associated mucin), CASA (cancer-associated serum antigen), BCM (breast cancer mucin),
MCA (mucin-like cancer-associated antigen), and TAG-12 (tumor associated antigen 12) are found. For gastrointestinal carci-
noma, CA 19-9, CA 195, CA 50, CA 242, CAM 17.1, CAM 26, DU-PAN-2 (a sialytated carbohydrate antigen), M43 (mucin
43), and SPAN-1 (pancreatic cancer-associated antigen) are used. For ovarian carcinoma, CA 125, CA 602, CA 54/61, and OVX1
are used. Other proteoglycans are CA 72-4, CA 130, ST-439 (serum tumor antigen 439), LASA (lipid-associated sialic acid), and
sLeX (sialyl Lewis X blood group antigen). CEA (carcinoembryonic antigen) is a weak cell-cell adhesion molecule. Shedding
of membrane-bound proteins is described for sE-cad (soluble E-cadherin), a cell-cell adhesion molecule, but also for the tyrosine
kinase receptor c-erbB2 (human epidermal growth factor-like receptor (HER2)), PLAP (placental alkaline phophatase), and sE-
LAM-1 (endothelial leucocyte adhesion molecule). Secreted molecules: Smaller proteins and polypeptides are secreted by can-
cer cells and can act as hormones in a paracrine way; examples are: AFP (alfa-fetoprotein), -hCG (human chorionic gonado-
tropin), NSE (neuron-specific endolase), CGA (chromogranin A), IGF-I, and IGF-II (Insulin-like growth factor). Polypeptides
that have an endocrine effect are serotonin, 5-HIAA (5-hydroxyindole acetic acid), catecholamines, calcitonin, and inhibin.
Polypeptides with an unknown destination are -subunits (alpha-subunits of peptidehormones), thyroglobuline, CK-BB (creatin
kinase BB), GAT (galactosyl transferase), and TK (thymidine kinase). Cancer cells also secrete proteases such as PSA (prostate-
specific antigen) and fPSA (free prostate specific antigen), CAT-D (cathepsin D), but also the protease inhibitors TATI (tu-
mor–associated trypsin inhibitor) and SSC (squamous cell carcinoma antigen). Cancer cells communicate with immunological
cells through sIL-2R (soluble interleukin-2 receptor), BTA (bladder tumor antigen) and 2-m (beta2-microglobulin). Angiogenic
signals as VEGF (vascular endothelial growth factor), FGF2 (fibroblast growth factor), and IL6 (interleukin-6) are used for fol-
low-up. Fibroblasts secrete HGF/SF (hepatocyt growth factor/scatter factor) and M-CSF (macrophage colony-stimulating factor)
that affect the cancer cells, and osteoblasts release high amounts of bone AF (alkaline phosphatase). Breakdown product of the
extracellular matrix (ECM) can be detected in the blood circulation; for example, laminin from the basement membrane (BM).
In myeloma, free light chains can act as highly specific markers.
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are extremely large.41 Their counterparts in gas-
trointestinal carcinomas (CA 19-9, CA 50, DU-
PAN-2) are somewhat smaller, but they are heav-
ily glycosylated.42 In contrast to the breast
carcinoma antigens that are assayed as proteins,
the gastrointestinal cancer antigens are immuno-
logically measured as carbohydrate structures.
These moieties belong to the sialyl Lewis anti-
gen family, are expressed by metastasizing can-
cer cells, and are recognized by the endothelial
cells when the former extravasate. So, the circu-
lating cancer antigens from gastrointestinal tu-
mors can be considered as metastasis markers.
Proteoglycans typical for ovarium cancer (CA
125, OVX1) are invasion markers that are poorly
glycosylated.43 CEA (carcinoembryonic antigen)
takes a unique position under the membrane-
bound markers: In normal epithelia, it serves as
a cell-cell adhesion molecule, and it contributes
to the composition of the intestinal flora through
selective adhesion of bacteria.44 In addition to the
already mentioned membrane-bound markers,
enzymatic ectodomain shedding from cell-cell
adhesion molecules (E-cadherin)45,46 or from
peptide receptors (c-erbB2/HER2) can lead to
diffusion of these extracellular fragments into the
circulation.
Secreted molecules
Many proteins and small polypeptides are se-
creted by cancer cells and have proven to be use-
ful markers after diffusion into the circulation.
Some of these molecules (IGF-I, IGF-II, inhibin,
AFP, NSE, -hCG) act as hormones, and affect
growth and invasion through endocrine, paracrine,
or autocrine receptor triggering. Other secreted
markers are proteases (PSA, cathepsin D) or pro-
tease inhibitors (TATI, SSC) and are believed to
be involved in invasion of the cancer cells. An-
other group of circulating markers are direct
cross-talk molecules between the cancer cells and
the host cells. Cancer cells send signals (sIL-2R
ectodomains, BTA, 2-m) toward immunological
cells, and B-lymphocytes sometimes react by pro-
ducing antibodies against mutated cancer cell pro-
teins (anti-p53). Angiogenic signals from the can-
cer cells (VEGF, bFGF, IL-6) toward endothelial
cells generate useful markers for the follow-up of
patients treated with inhibitors of angiogenesis.
Fibroblasts can affect the cancer cells through the
secretion of colony-forming factors, while acti-
vated osteoblasts release high amounts of bone al-
kaline phosphatase (Ostase©). The latter is a use-
ful marker to follow bone metastasis, especially
in patients who develop osteogenic metastases
from prostate carcinoma.
CONCLUSIONS
Invasion and metastasis are the hallmarks of ma-
lignancy. Metastasis can be explained by the seed
and soil theory, wherein angiogenesis seems to
be an important soil element. The cross-talk be-
tween cancer cells and host cells is a target for
therapy, and future revelation of this cross-talk at
the molecular level is likely to open new diag-
nostic marker possibilities and new treatment av-
enues.
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Part II Cadherins 
2.1. Introduction to cadherins 
Cadherins, Ca-dependent adhesion, are transmembrane glycoproteins. The cadherin 
super family consists already of more than 80 members (Tepass 2000); we will focus in this 
part on the classical cadherins. The extracellular part of a classical cadherin consists of 5 
cadherin domains (CD, ±110 amino acids) and in the first cadherin domain, an HAV-
sequence is present. When cadherins form dimers, there is an exchange or swapping of a β 
strand between partner cadherin EC1 domains (Boggon et al.2002). This swapping interaction 
is anchored by the insertion of the side chain of the conserved Trp2 residue into a 
complementary hydrophobic pocket in the partner molecule. This interface has been proposed 
to mediate binding between cadherins presented from opposing cells. The symmetry of the 
interaction ensures that each cadherin-cadherin interface buries two Trp2 side chains, one of 
each cadherin.  
 
Figure 2.1.: (A) Schematic presentation of the formation of classical cadherin dimers from the same 
and opposing cell. (B) Presentation of the C-cadherin ectodomains, joined by cis and trans interfaces, 
observed in a crystal lattice. Molecules from either putative cell surface are shown in blue or pink. Trp 
2 side chain are shown in CPK representation, green spheres are calcium ions and yellow present 
disulfide bonds (adapted from Boggon et al. 2002). 
 
The strand exchange observed in cadherins exemplifies a more general domain-swapping 
strategy, which may enable homophilic interactions with low affinity and high specificity 
(Chen et al. 2005; Patel et al. 2006). The highly conserved cytoplasmic part directly interacts 
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with the catenins in a non-covalent way (Kemler 1993). p120 catenin binds to the 
juxtamembrane domain of cadherins and was originally identified as a substrate of Src 
(Anastasiadis et al. 2000). β-catenin and γ-catenin mutually bind to the same part of the 
cytoplasmic domain and are able to form the link with the actin cytoskeleton via α-catenin. 
Catenins can also be phosphorylated and by this activate different signalling pathways (Daniel 
and Reynolds 1997, Gumbiner 2005).  
Epithelial (E)-cadherin and neural (N)-cadherin are two examples, which belong to the group 
of the classical cadherins. Both play an important role during embryogenesis: at the morula 
stage, all cells express E-cadherin, but during gastrulation E-cadherin is downregulated in the 
primitive streak as cells undergo epithelial-mesenchymal transition (EMT) and concomitantly 
express N-cadherin in the mesoderm (Hatta and Takeichi 1986). N-cadherin’s function during 
gastrulation is required for a proper left-right axis (Garcia-Castro et al. 2000). N-cadherin is 
also implicated in cardiac development (Garcia-Castro et al. 2000), skeletal muscle 
development (George-Weinstein et al. 1997), neural crest migration (Nieto 2001), 
development of the early hematopoietic cells and the retention of these cells in the bone 
marrow (Puch et al. 2001) and cartilage formation (Panda et al. 2001). So, N-cadherin is 
expressed at different time points and tissues in the embryo. In the adult, N-cadherin is 
normally present in myocytes, lens cells, mesothelial cells (Hatta and Takeichi 1986), 
osteoblasts (Cheng et al. 1998), Sertoli cells (Chung et al. 1999), (myo)fibroblasts (Van 
Hoorde et al. 1999), oocytes and spermatozoa (Goodwin et al. 2000) and limb cartilage 
(Packer et al. 1997). 
The best-studied cadherin implicated in cancer is Epithelial (E)-cadherin, a 120 kD protein. 
The E-cadherin gene was identified as an invasion suppressor gene. Transfection of E-
cadherin cDNA in cell culture reverses undifferentiated, invasive cancer to the differentiated 
non-invasive phenotype (Vleminckxs et al. 1991; Takeichi et al. 1993). However, abrogation 
of E-cadherin-mediated cell-cell adhesion by functionally blocking antibodies, silencing of E-
cadherin or by anti-sense constructs restores the invasive capacity (Behrens et al. 1989, 
Vleminckx et al. 1991). Loss of E-cadherin in cancer cells can be associated with a gain of 
expression of another cadherin, like N- (Hazan et al. 2004), placental (P) (Paredes et al. 
2005)- or osteoblast (OB)-cadherin (Shibata et al. 1996; Tomita et al. 2000) leading to an 
invasive, fibroblastic phenotype. We have focussed on the role of N-cadherin known to 
stimulate motility and invasion of cancer cells in the same way as was seen during 
embryogenesis. Most epithelial cancers that express N-cadherin have lost E-cadherin, 
however some cells express still both. In squamous carcinoma cells, E- and N-cadherin are 
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not expressed at the same time. When N-cadherin was transfected, E-cadherin expression 
decreased and when an antisense construct for N-cadherin was introduced E-cadherin 
expression was upregulated (Islam et al. 1996). Furthermore, transfection of N-cadherin in the 
E-cadherin positive breast carcinoma cells, MCF-7, resulted in a co-expression of both 
cadherin molecules, and by this cells became metastatic. N-cadherin increased the adhesion to 
endothelial cells and accelerated cell migration and invasion in vitro and in vivo (Hazan et al. 
2000). FGF-2 synergistically increased migration in these cells by activation of the mitogen 
activated protein kinase (MAPK) pathway leading to MMP9 gene transcription and invasion 
(Suyama et al. 2002). However, the mammary gland of transgenic mice expressing N-
cadherin in the mammary epithelium appeared normal. To investigate the role of N-cadherin 
in mammary tumours, neu was overexpressed through breeding, and there were no 
histological differences observed between the -/ neu and the N-cadherin/neu mice (Knudsen et 
al. 2005). In many human tumours, N-cadherin expression was found, and we divided them in 
four groups (reviewed by Derycke and Bracke 2004 and table 2.1). The “De novo expression” 
group consists of most epithelial carcinomas, like those from the breast or prostate, where N-
cadherin was only found in the cancer cells. A second group called “Re-expression” has 
melanoma and leukaemia as its members: the embryonic cells were positive for N-cadherin 
but during adult phase N-cadherin was lost but came back in the cancer cells. Mesothelioma 
we classified in a third group named “Upregulation”, N-cadherin levels found in the cancer 
cells where higher than in the adult cells. In the last group “Downregulation”, we collected 
cancers where the expression remained the same or was downregulated, for example in 
osteosarcoma. Some new examples are presented in table 2.1. 
There is an important role for the tissue stroma in cancer cell invasion. N-cadherin is 
expressed by the invasive cancer cells but also by the host cells such as myofibroblast, 
neurons, smooth muscle cells, and endothelial cells. N-cadherin-dependent contacts may 
mediate matrix invasion, perineural invasion, muscular invasion and transendothelial 
migration (De Wever and Mareel 2003). Two examples of molecules regulating N-cadherin 
and influencing the cancer-stroma interaction are TGFβ and the non receptor tyrosine kinase 
Src. TGFβ upregulates N-cadherin in the cancer cells (Maeda et al. 2005), increases their 
motility and induces transdifferentiation of fibroblast cells to myofibroblasts (De Wever et al. 
2004). The Src family kinase is also implicated in the transendothelial migration of melanoma 
cells. Src becomes activated at the heterotypic contact and tyrosine phosphorylates N-
cadherin, as a result β-catenin then dissociates from the complex and translocates to the 
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nucleus of the transmigrating melanoma cells (Qi et al. 2006). Another kinase named Fer 
kinase physically associates with N-cadherin (Arregui et al. 2000, Xu et al. 2004) and 
regulates the mobility and clustering of N-cadherin. Fer does this by phosphorylation of N-
cadherin-associated cortactin (El Sayegh et al. 2005). Cortactin was originally discovered as a 
prominent substrate of the Src family tyrosine kinases (Wu et al. 1991) and is an organizer of 
cortical actin (Weaver et al. 2001). Not only kinases but also proteases can influence the 
strengthening and mobility of the cadherin/catenin complex. Proteases such as matrix 
metalloproteinases (MMP) are degrading the extracellular matrix, they do that by cleaving 
large insoluble ECM components and ECM associated molecules, liberate bioactive 
fragments and growth factors and by this change the extracellular matrix (Mott and Werb 
2004). For example, MMP’s are able to cleave cadherin protein and shed an extracellular 
fragment (see also part 3). These cadherin ectodomain are able to stimulate invasion (Noë et 
al. 2001, Ryniers et al. 2002), neurite outgrowth (Utton et al. 2001) and angiogenesis (part 4) 
and by this influencing the behaviour of cadherin expressing cancer cells. 
  23 
 
Table 2.1: Expression of N-cadherin in human cancer cell lines and biopsies and correlation with the expression in embryo and adult 
 
Tumour type Embryo Adult Cell line or biopsy % positiviy Observation Reference 
   DE NOVO EXPRESSION    
Breast 
carcinoma 
- - Biopsies 76 Invasive micropapillary CA Nagi et al. 2005 
Prostate 
carcinoma 
- - Biopsies 45 Correlates with increasing Gleason score Jaggi et al. 2006 
Bladder 
carcinoma 
- - Biopsies pT1: 14% 
pT2-3: 60% 
Correlation with invasive status of tumour Lascombe et al. 2006 
Colon 
carcinoma 
- - Cell lines and biopsies 44 No correlation with Twist Rosivatz et al. 2004 
Pancreatic 
carcinoma 
- - Biopsies 50 Correlation with neuronal invasion Nakajima et al. 2004 
Thyroid 
adenoma 
- - Biopsies  N-cadherin strongly upregulated and 
more interaction between thyrocytes and 
endothelial cells 
Wattel et al. 2005 
   RE-EXPRESSION    
Gastric 
carcinoma 
+ - Cell lines   Wang et al. 2006 
Melanoma + - Biopsies  Low expression in tumours but high 
expression in Spitz nevi 
Krengel et al. 2004 
Chordoma + - Biopsies 36 Diminished recurrence free survival Triana et al. 2005 
   DOWNREGULATION    
Renal cell 
carcinoma 
+ ± Biopsies  Associated with malignancy Shimazui et al. 2006 
Ovarian 
carcinoma 
+ + Biopsies  Only positivity in serous adenomas, 
carcinoma correlated with histological 
grade 
Marques et al. 2004 
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embryogenesis, invasion and signalling
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ABSTRACT Cell migration is a process which is essential during embryonic development, through-
out adult life and in some pathological conditions. Cadherins, and more specifically the neural cell
adhesion molecule N-cadherin, play an important role in migration. In embryogenesis, N-cadherin
is the key molecule during gastrulation and neural crest development. N-cadherin mediated
contacts activate several pathways like Rho GTPases and function in tyrosine kinase signalling (for
example via the fibroblast growth factor receptor). In cancer, cadherins control the balance between
suppression and promotion of invasion. E-cadherin functions as an invasion suppressor and is
downregulated in most carcinomas, while N-cadherin, as an invasion promoter, is frequently
upregulated. Expression of N-cadherin in epithelial cells induces changes in morphology to a
fibroblastic phenotype, rendering the cells more motile and invasive. However in some cancers, like
osteosarcoma, N-cadherin may behave as a tumour suppressor. N-cadherin can have multiple
functions: promoting adhesion or induction of migration dependent on the cellular context.
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Migration and invasion
Cell migration is a process that is essential during embryonic
development and throughout further life. In the adult, cell migration
is crucial for homeostatic processes, such as effective immune
responses and repair of injured tissues. To migrate, the individual
cell body must modify its shape to interact with the surrounding
tissue structures. The extracellular matrix (ECM) forms a sub-
strate, as well as a barrier for the advancing cell body. Cell
migration through tissues results from a continuous cycle of
interdependent steps. In general, there are five steps involved in
cell migration in the ECM. First comes the protrusion of the leading
edge, where growing actin filaments connect to adapter proteins
and push the cell membrane in an outward direction. In a second
step cell-matrix interactions and focal contacts are formed. After
that, surface proteases such as matrix metalloproteinases (MMP)
are recruited and focal proteolysis takes place. Then the cell
contracts by actomyosin activation, and finally the tail of the cell is
detached from its substrate (Friedl and Wolf, 2003).
Border cells of the Drosophila melanogaster ovary are nowa-
days used as a model for migration. There are three recently
discovered signalling pathways that control distinct aspects of
migration: a global steroid-hormone signal defines the timing of
migration, a highly localised cytokine signal that activates the
Janus kinase-signal transducer and activator of transcription is
both necessary and sufficient to induce migration, and finally, a
growth factor that is analogous to platelet-derived growth factor
(PDGF) and vascular endothelial growth factor (VEGF) contributes
to guiding the cells to their destination (Montell, 2003).
In embryonic morphogenesis two types of collective cell move-
ment can be observed. The first one involves mass migration
whereby a tissue moves in a coordinated manner. Gastrulation is
an example of mass migration. In the blastocyst large groups of
cells migrate collectively as sheets to form the three layers that will
eventually form the embryo. Cells within these layers migrate to
target locations and form various tissues and organs. The second
type of movement requires loss of cell-cell contacts for the migra-
tion of individual cells or small groups of cells through the ECM, as
seen in neural crest migration. Cells delaminate from the ectoder-
mal layer and acquire migratory properties as they undergo the
process of epithelial to mesenchymal transition (EMT). Another
example is the migration of muscle precursor cells from the somites
to the limbs (Locascio and Nieto, 2001; Horwitz and Webb, 2003).
The failure of cells to migrate to their appropriate locations can
result in developmental abnormalities and also in pathological
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processes, including vascular and inflammatory diseases, and
tumour invasion and metastasis (Lauffenberger and Horwitz, 1996).
Aberrant cell migration may play a role in cancer. Cancer is one of
the prime causes of human morbidity and mortality, and most of the
cancer deaths arise from metastases. Cancer cells have defects in
regulatory circuits that govern normal cell proliferation and homeo-
stasis. A cell becomes cancerous because of essential alterations
in its physiology: limitless replicative potential due to self-suffi-
ciency in growth signals, insensitivity to growth inhibitory signals or
escape from programmed cell death, induction of angiogenesis
and acquisition of invasive and metastasising potential (Hanahan
and Weinberg, 2000). Of all the processes involved in tumour
progression, local invasion and the formation of tumour me-
tastases are clinically the most relevant ones, but the least well
understood at the molecular level. They represent one of the great
challenges in experimental cancer research.
During the progression of cancer, primary tumour cells move
out, invade into adjacent tissues and travel to distant sites. Most
important, these processes allow cancer cells to enter the lym-
phatic and blood vessels for dissemination into the circulation.
Invasion is resumed when extravasation occurs in distant organs,
and when the secondary tumour contributes to the metastatic
cascade. Cancer cells use diverse patterns of migration. They can
disseminate as individual cells or expand as solid strands, sheets,
files or clusters. Leukemia, lymphoma and most sarcomas dis-
seminate as single cells, while epithelial cells commonly use
collective migration. In principle, the lower the differentiation state,
the higher the tendency of the tumour to disperse via individual
cells (Thiery, 2002; Friedl and Wolf, 2003).
Similarities between the three signalling pathways described for
the ovarian border cell migration, and the pathways that are
deregulated in human cancer cells indicate that signals that con-
tribute to aberrant proliferation and survival of the tumour cells, can
also promote motility, and hence invasion (Montell, 2003).
We will discuss in this review the impact of E- and N-cadherin on
migration in embryogenesis and tumour invasion. Epithelial or E-
cadherin plays a role in collective migration of epithelial cells. E-
cadherin is also an invasion suppressor molecule, and in tumours
this molecule can be downregulated in different ways (Mareel and
Leroy, 2003). Downregulation of E-cadherin is often correlated
with upregulation of neural or N-cadherin, an invasion promoter
molecule (Tomita et al., 2000; Li and Herlyn, 2000). However, both
the regulation of N-cadherin expression and its molecular contribu-
tion to invasion are incompletely understood.
Cadherins
In humans there are more than 80 members of the cadherin
superfamily. Sequencing the genome of C. elegans and Droso-
phila revealed the existence of 14 and 16 different genes, respec-
tively. Cadherins are composed of an extracellular part, that
mediates calcium-dependent homophilic interactions between
cadherin molecules, a transmembrane and a cytoplasmic part. The
extracellular part consists of several cadherin repeats (EC) of ±110
amino-acids, which are characterised by a number of conserved
amino acid sequences such as PE, LDRE, DXNDN and DXD.
These motifs can bind 3 calcium ions at each interdomain bound-
ary in a cooperative manner. Classification of cadherins into
subfamilies is based on domain layout of individual cadherins,
which include the number and sequence of EC repeats, and the
presence of other conserved domains and sequence motifs, like
tyrosine kinase and EGF domains. There are four cadherin sub-
families conserved between C. elegans, Drosophila and humans:
classic cadherins, fat-like cadherins, seven-pass transmembrane
cadherins and a new subfamily of cadherins that is related to
Drosophila Cad 102F. Classic cadherins consist of four subgroups:
vertebrate type I classic cadherins like E-, placental (P)-, N- and
retinal (R)-cadherin, with an HAV sequence in the first cadherin
repeat, vertebrate type II classic cadherins which have no HAV in the
first repeat, for example vascular endothelial (VE)-cadherin, ascidian
classic cadherins and the non-chordate classic cadherins for ex-
ample D (Drosophila) E- and D (Drosophila) N-cadherin (Tepass et
al., 2000). The molecular mechanism of type I cadherin interaction
has recently been unravelled. The model was proposed after eluci-
dation of the crystal structure of the C-cadherin ectodomain: the
trans-interaction is formed by a strand dimer (EC1-EC1) where
association is found between the side chain of Tryptophan 2 (Trp2)
in one molecule and a pocket in the hydrophobic core of another
molecule. The cis interaction occurs between EC1 of one molecule
and EC2 of another molecule, resulting in the formation of a lattice
of a supramolecular complex (Boggon et al., 2002).
It is now known that alterations in the expression and function of
cell-cell and cell-matrix adhesion molecules correlate with progres-
sion to malignancy. E-cadherin, a homotypic cell-cell adhesion
molecule is expressed on most epithelial cells and is an invasion
suppressor. E-cadherin expression or function is lost in most of the
carcinomas. This may be by mutational inactivation of the E-
cadherin gene, hypermethylation of the promoter, transcriptional
repression by SIP1 or snail, loss of transactivators like RB, Myc and
WT1, transactivation of other cadherins, phosphorylation of Arma-
dillo proteins by tyrosine kinases, sterical hindrance by mucin 1
(MUC-1) or by ectodomain shedding of E-cadherin by matrix
metalloproteinases (MMP) (Van Aken et al., 2001). The proof of
principle that the loss of E-cadherin is involved in the progression
of tumour malignancy came from a transgenic mouse model of
pancreatic β cell carcinogenesis (Rip1Tag2). In these mice, the
SV40 large T antigen was expressed under the control of the rat
insulin promoter, thus inducing neoplastic transformation from
differentiated adenoma to invasive carcinoma selectively in the β
cells of the islets of Langerhans. In these tumours E-cadherin was
downregulated. Forced expression of E-cadherin in the β cell
tumours resulted in an arrest in tumour development at the ad-
enoma stage. Conversely, expression of a dominant-negative form
of E-cadherin resulted in early invasion and metastasis (Perl et al.,
1998). These results show that E-cadherin suppresses tumour
invasion, and that loss of E-cadherin can actively participate in the
induction of tumour invasion (Cavallaro and Christofori, 2001).
N-cadherin
N-cadherin was first identified in 1982 (Grunwald et al., 1982) as
a 130 kD molecule in the chick neural retina that was protected by
calcium from proteolysis, and in 1984 A-CAM was identified (now
called N-cadherin) as a molecule that was localised at the adherens
junctions (Volk and Geiger, 1984). The N-cadherin gene in mice
was located on chromosome 18 (Miyatani et al., 1989). Via Yeast
Artificial Chromosome (YAC) analysis the structure of the human
N-cadherin gene was determined. The entire N-cadherin gene was
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Fig. 1. Schematic overview of the N-cadherin/catenin complex and the multiple proteins which associate and influence the complex. N-cadherin
associates via its HBM motif with the HAV sequence of the FGFR. N-cadherin also has a HAV sequence in the first extracellular domain (EC). Activation of
FGFR can lead to activation of MAPK and transcription of MMP9, inducing invasion and metastasis. In EC4, a domain is present which is responsible for N-
cadherin’s pro-migratory behaviour. However, in the cytoplasmic part there are also domains which can stimulate or inhibit migration. N-cadherin mediates
also survival of cells via the PI3K-AKT pathway. Many molecules associate directly with the complex, such as GalNacPtase, p120ctn, β-catenin, PTP1B, RPTPµ
and Gα12, or indirectly like FER (implicated in the cadherin/catenin complex, but also in the integrin complex) and α-catenin. Many molecules can change
the complex like proteases (MMP, caspase-3, PS 1) or the Robo-Abl kinase. When free cytoplasmic p120ctn is present, it changes the morphology of the
cell by blocking Rho in the GDP state or activating Rac1 and Cdc42. N-cadherin is already associated with the catenins in the ER and a microtubular kinesin-
driven mechanism is involved in the trafficking to the plasma membrane (Adapted from Van Aken et al., 2001 and Anastasiadis et al., 2001).
mapped to a 250-kb region on chromosome 18q11.2. The gene is
composed of 16 exons, and homology was found not only between
human and mouse, but also between N-cadherin and other
cadherins (Wallis et al., 1994). The protein exists of five extracel-
lular cadherin repeats (EC1 to EC5), a transmembrane and a
cytoplasmic part that are encoded by exons 4 to 13, 13 and 14, and
14 to 16, respectively. Eight sequence polymorphisms were iden-
tified in a Japanese population: three CCT or GCC-type trinucle-
otide repeat polymorphisms adjacent to the initiation codon and
five other novel single-nucleotide polymorphisms in the coding
region (Harada et al., 2002). The promoter of N-cadherin does not
contain CCATT or TATA boxes, but showed a high overall GC
content, high CpG dinucleotide content, and several consensus
Sp1 and Ap2 binding sequences (Li et al., 1997).
N-cadherin domains and associated proteins
In this part we will discuss the molecules associated with the
extracellular and intracellular part of N-cadherin, their influence on N-
cadherin function and the induction of signalling pathways (Fig. 1).
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Although N-cadherin typically forms homotypic homophilic interac-
tions, also heterotypic homophilic and heterophilic interactions
have been described. Examples include the interaction between
N-cadherin molecules of Sertoli cells and spermatides, and be-
tween N- and R-cadherin in transfected L cells and in neurons at
certain neural synapses (Shan et al., 2000).
The fibroblast growth factor receptor (FGFR) is implicated in N-
cadherin function. In the nervous system, N-cadherin function is
involved in a number of key events that range from the control of
axonal growth and guidance to synapse formation to synaptic
plasticity (Doherty and Walsh, 1996). Neurite outgrowth stimulated
by N-cadherin is inhibited by a wide variety of agents that block the
FGFR function, including the expression of a dominant negative
FGFR (Williams et al., 1994). In addition, N-cadherin can promote
contact-dependent survival of ovarian granulosa cells in an FGFR-
dependent manner (Trolice et al., 1997). More recently it has been
illustrated that both N-cadherin and the FGFR are necessary to
increase cell motility and induce metastasising capacity (Suyama
et al., 2002). N-cadherin and the FGFR interact directly: the HAV
sequence present in the FGFR associates with the IDPVNGQ
sequence present in EC4 of N-cadherin (Williams et al., 2001). This
motif was already previously described as a candidate for interac-
tion with FGFR, based on sequence homology of the motifs within
N-cadherin (INPISGQ in EC1) and R-cadherin (IDPVSGR in EC1)
that interact with the HAV region in N-cadherin (Doherty and
Walsh, 1996; Williams et al., 2000b). Peptides used to investigate
N-cadherin function were found to have opposite effects on neurite
outgrowth: whereas INP (Williams et al., 2000b) and a cyclic HAV
peptide (Williams et al., 2000a) antagonize its function, the cyclic
dimeric version of the HAV and the INPISG sequence have an
agonistic effect on neurite outgrowth (Williams et al., 2002). The
latter peptides act by binding to and clustering N-cadherin in the
cells, thereby activating the N-cadherin/FGFR signalling cascade.
After stimulation with FGF 2, invasion of breast carcinoma cells
was demonstrated in the same degree as in cells transfected with
N-cadherin, suggesting that N-cadherin and FGFR synergize to
generate signals that affect the invasive behaviour. As a conse-
quence of N-cadherin binding, internalisation of the FGFR is
inhibited. This is causing a sustained cell surface expression of
FGFR, leading to a persistent MAPK-ERK (mitogen activated
protein kinase-extracellular signal regulated kinase) activation,
MMP-9 expression and tumour invasion (Suyama et al., 2002).
Thus, N-cadherin may be involved in both ligand-dependent and
ligand-independent interactions with the FGFR (Wheelock and
Johnson, 2003).
Transfection of epithelial cells with N-cadherin influences the
morphology and the behaviour of these cells: it induces a “motile
phenotype” (Islam et al., 1996; Hazan et al., 1997). By transfection
of chimeras of E- and N-cadherin in squamous epithelial cells, a 69
amino acid portion of EC4 was identified that is necessary for
epithelial to mesenchymal transition and an increase in motility by
N-cadherin. The motile phenotype induced by N-cadherin is inde-
pendent of cell-cell adhesion because an antibody, recognizing the
69 amino acid sequence, inhibited cell motility without inhibiting
cell-cell aggregation, providing evidence that adhesion and motility
can be two separate features (Kim et al., 2000).
Recently, an S (suppression of movement) -domain (a C-
terminal domain: AA699-710 of E-cadherin) was identified in both
E- and N-cadherin, though N-cadherin lacked the capacity to
suppress motility, presumably because its domain is masked or
latent. This inability of N-cadherin to suppress movement required
the presence of the modulation-of-movement-domain (M-domain),
consisting of the juxtamembrane domain. The authors suggested
several ways in which diversity in cadherin function might arise in
different cell types. Variations could be expected if cells differ in
expression of molecules that interact with the S and M-domain
(Fedor-Chaiken et al., 2003). For example, N-cadherin has no
influence on the movement of MDA-MB-435, but the same mol-
ecule inhibits the migration of LM8 mouse osteosarcoma cells
(Kashima et al., 2003). So, the effect of cadherins can be cell type
specific.
The cytoplasmic part of N-cadherin is complexed with a multi-
tude of molecules, such as the catenins p120 catenin (p120ctn), β-
catenin and α-catenin, which are possible regulators of cadherin
function. p120ctn binds to the juxtamembrane domain and is a key
molecule in the regulation of the adhesive or motile phenotype.
When p120ctn is phosphorylated, its binding to N-cadherin is
increased, reducing the adhesive activity of the latter. Cadherin
adhesive activity is also subject to regulation by Rho GTPases.
Overexpression of p120ctn in fibroblasts or cadherin-deficient cells
causes a branching phenotype, whereas in epithelial cells an
increasing lamellipodia formation is observed. In fibroblast, this
cytoplasmic p120ctn inhibits RhoA, resulting in an increase in cell
motility and activation of Rac1 and Cdc42. In line with the direct
binding of RhoA and p120ctn in Drosophila (Magie et al., 2002), one
hypothesis says that a direct interaction of p120ctn with RhoA keeps
RhoA in the inactive GDP state. According to another hypothesis
the association of p120ctn with vav2, a Rho-GEF (guanine nucle-
otide exchange factor) explains the activation of Rac1 and Cdc42
(Anastasiadis et al., 2001).
Fer (fes –related protein; fes: feline sarcoma), a nonreceptor
tyrosine kinase, interacts via its coiled-coil domain with the coiled-
coil domain of p120ctn. Fer is implicated in the regulation of
adherens junctions and focal adhesions. Trojan peptides, recog-
nizing the juxtamembrane domain of N-cadherin, caused Fer to
dissociate from N-cadherin, rendering Fer available for complex
formation with FAK (Arregui et al., 2000). This correlated with
disruption of focal adhesion and reduced tyrosine phosphorylation
of the docking protein p130Cas. These observations indicate that
Fer has a role in the regulation of cell adhesion and migration
through effects on both adherens junctions and focal adhesions
(Greer, 2002). Fer and Fyn kinase phosphorylate Tyrosine 142 of
β-catenin, and this (unphosphorylated) tyrosine is necessary for
the association of β-catenin with α-catenin. In contrast, phospho-
rylation of tyrosine residues of p120ctn increases the binding of the
Fer/Fyn-p120ctn complex to cadherin (Piedra et al., 2003).
P120ctn not only modulates the function of cadherins but is also
important in the trafficking and maturation of the cadherin-catenin
complex. Wahl et al., have shown that p120ctn readily associates to
the cytoplasmic part of N-cadherin in the endoplasmatic reticulum
(ER). Later on, the cytoplasmic part is phosphorylated, leading to
additional binding of β- and α-catenin. The proregion is then
removed by furin protease and the complex is transported to the
plasma membrane (Wahl et al., 2003). N-cadherin trafficking is
mediated by a microtubular kinesin-driven mechanism (Mary et al.,
2002) and recent papers elucidated that p120ctn is the link with the
microtubule network by direct association of p120ctn with kinesin
(Chen et al., 2003; Yanagisawa et al., 2003). Presenilin 1 (PS1),
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playing a role in the pathogenesis of early onset familial Alzheimer
disease, also binds to the juxtamembrane domain and modulates
the adhesive capacity. When dominant negative PS1 is expressed,
cell-cell contacts are suppressed, and N-cadherin is localised
perinuclearly at the ER and Golgi apparatus. So, PS1 is essential
for the trafficking of N-cadherin to the plasma membrane (Uemura
et al., 2003).
Another point where the cadherin/catenin complex can be
regulated is at its interaction with β-catenin, which is responsible for
association with α-catenin and hence for linking the complete
complex to the actin network. The interaction of β-catenin with N-
cadherin is regulated by multiple proteins (Lilien et al., 2002). The
proteoglycan neurocan can inhibit N-cadherin- and β1-integrin–
mediated adhesion and neurite outgrowth. Neurocan interaction
with its receptor GalNAcPTase leads to tyrosine
hyperphosphorylation of β-catenin and uncoupling of β-catenin
from the complex (Lilien et al., 1999; Li et al., 2000).
Hyperphosphorylation of β-catenin has consistently been corre-
lated with loss of adhesive function. The nonreceptor protein
tyrosine phosphatase PTP1B regulates the phosphorylation of β-
catenin (Balsamo et al., 1998). PTP1B needs to be phosphorylated
on tyrosine-152 for its association with N-cadherin (Rhee et al.,
2001). PTP1B binds to the cytoplasmic part, specifically to the
amino acids 872-891 of N-cadherin, and this domain partially
overlaps with the β-catenin binding domain. Despite the partial
overlap of binding domains, β-catenin and PTP1B do not compete
with each other for binding (Xu et al., 2002). The interaction of N-
cadherin with PTP1B is essential for its association with β-catenin,
its stable expression at the cell surface, and consequently, its
function. Gα12/13, a Gα subunit of the heterodimeric G proteins,
associates with the cytoplasmic part of N-cadherin, overlapping
the binding site of PTP1B, so binding of Gα may displace PTP1B
and vice versa (Kaplan et al., 2001). The phosphatase PTPµ
directly interacts with the carboxy-terminal domain of the cadherins,
potentially dephosphorylating these. The absence of PTPµ is
correlated with increased phosphorylation of the cadherin itself,
but not of β-catenin (Brady-Kalnay et al., 1998). On its turn,
increased tyrosine phosphorylation of N-cadherin has been asso-
ciated with increased turnover of N-cadherin, releasing a 90 kD
extracellular fragment (Lee et al., 1997). N-cadherin phosphory-
lated by Src on tyrosine 851 and 883, associates with the SH2
domain of the adapter protein Shc (Xu and Carpenter, 1999),
opening the door to different signalling pathways.
N-cadherin function and signalling
N-cadherin promotes survival in melanoma and prostate carci-
noma cells. N-cadherin ligation recruits phosphatidylinositol 3-
kinase (PI3K) which activates Akt, resulting in inactivation of the
pro-apoptotic molecule Bad (Bcl2 antagonist of cell death, Bcl2 is
the acronym for B cell lymphoma) (Li et al., 2001; Tran et al., 2002).
However, N-cadherin can also have an inhibitory effect on cell
proliferation. Overexpression of N-cadherin in cells suppresses
cell proliferation by prolonging the G2/M phase and inducing β-
catenin dependent expression of p21 (inhibitor of cyclin dependent
kinase, cdk) which inhibit Cdc2 activity (Kamei et al., 2003). P27,
another cdk inhibitor is involved in N-cadherin mediated contact
inhibition of cell growth and cell cycle arrest in the G1 phase
(Levenberg et al., 1999).
N-cadherin stimulates migration and invasion of cells. Different
groups demonstrated that aberrant expression of N-cadherin in
cancer cells makes the cells more motile and invasive. Our
laboratory has demonstrated that retinal pigment epithelial cells
(RPE) are invasive in collagen type I. RPE cells have a polarised
epithelial phenotype in vivo but become rapidly fibroblastic and
invasive when explanted in vitro. In these conditions they undergo
a switch from E- to N-cadherin expression. Such a switch was
already seen in the epiblast cells of the chick embryo when the cells
where treated with hepatocyte growth factor (HGF) (Deluca et al.,
1999). We found indications for an autocrine HGF/c-Met loop
stimulating RPE cell invasion via focal adhesion kinase (FAK). N-
cadherin activates FAK in invasive RPE cells (Van Aken et al.,
2003).
In order to mimic and control the formation of cadherin mediated
cell-cell contacts, N-cad-Fc chimera, comprising the N-cadherin
ectodomain linked to an IgG Fc fragment, have been used. These
chimera form dimers by inter-chain disulfide bridges of the Fc
domains. Chimera-loaded beads bound specifically to various
cells expressing N-cadherin, inducing a rapid recruitment of
cadherin/catenin complexes, followed by a strong anchorage of
actin filaments, leading to cytoskeletal reorganisation and activa-
tion of intracellular signalling pathways (Lambert et al., 2000).
Rac1 is required for the anchoring of the cadherin/catenin complex
to the actin filaments in the myogenic C2 cells (Lambert et al.,
2002). Further studies demonstrated that for the formation of
lamellipodia a p120ctn-PI3K-Rac1 pathway is triggered, while for
the organisation of the cadherin complex and the actin cytoskel-
eton only p120ctn and Rac1 are needed (Gavard et al., 2004). In
addition, N-cadherin also controls crucial steps in myogenic differ-
entiation, and addition of N-cad-Fc beads triggered myogenesis in
isolated myoblasts. Here, inactivation of Rac1 and Cdc42 was
observed, while RhoA was activated. The RhoA GTPase activity is
important for myogenic differentiation since it controls the expres-
sion and the activity of the transcription factor SRF (serum re-
sponse factor) which binds to motifs present in the promoter of
muscle-specific genes. As a result the promoter of muscle-deter-
mining factor MyoD is stimulated by N-cadherin-dependent con-
tact formation (Charasse et al., 2002). A balance between Rac1-
Cdc42 and RhoA activity determines the cellular phenotype and
biological behaviour of various cell systems: actin cytoskeleton
organisation, formation of focal adhesions, neurite extension and
myogenesis. In fibroblasts the activation of RhoA leads to assem-
bly of stress fibers and focal contacts, which mediate adhesion to
ECM. Activation of Rac1 and Cdc42, however, results in the
formation of filopodia and lamellipodia. In mouse fibroblasts, Rac1
signalling is able to antagonize Rho activity. Activation of Rac1 by
the GEF Tiam1 in these cells induces an epithelial-like morphology
with functional cadherin-based adhesion and inhibition of migra-
tion (Sander et al., 1999; Yap and Kovacs, 2003).
Full length N-cadherin and its 90 kD N-terminal fragment have
been shown to promote cell-matrix adhesion and neurite outgrowth
when presented as a substratum (Paradies and Grunwald, 1993;
Bixby et al., 1994). Soluble N-cad-Fc can also stimulate FGFR
dependent neurite outgrowth (Utton et al., 2001).
N-cadherin is expressed in human endothelial cells, but its
function in angiogenesis is not fully elucidated. Literature data
demonstrated that N-cadherin is expressed during early neuro-
ectoderm vascularization where it probably establishes interactions
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between neuroectoderm and endothelium, followed by a
downregulation of N-cadherin in endothelia when the cells differenti-
ate to a blood-retina and blood-brain barrier (Gerhardt et al., 1999).
N-cadherin has also been indicated as an angiogenic factor in non-
small-cell lung cancer because biopsies positive for N-cadherin
were hypervascular (Nakashima et al., 2003). In our laboratory we
could find that plasmin cleaved a 90 kD ectodomain fragment from
N-cadherin, coined soluble N-cadherin. Soluble N-cadherin in-
duced angiogenesis in the chick chorioallantoic membrane and the
rabbit cornea. The 10-mer HAV peptide (LRAHAVDING) had the
same pro-angiogenic effect as soluble N-cadherin (our unpub-
lished data).
N-cadherin up- and downregulation
The N-cadherin/catenin functions are influenced by multiple
intracellular and extracellular factors (Table 1). We will discuss a
few factors more into detail. The upregulation of N-cadherin at the
transcription level has been explored. In Drosophila development
the transcription factor twist initiates DN-cadherin expression
during early mesoderm formation. Another transcription factor,
snail, is required for an increase in the level of N-cadherin (Oda et
al., 1998). In biopsies of gastric carcinoma, a correlation was
demonstrated between the expression of N-cadherin and twist
(Rosivatz et al., 2002). Growth factors as EGF and HGF are able
to induce a switch from E- to N-cadherin. An example is found in
breast carcinoma cells co-expressing E- and N-cadherin. When
treated with EGF they undergo epithelial-mesenchymal transition-
like changes, including upregulation of vimentin, downregulation of
E-cadherin and upregulation of N-cadherin (Ackland et al., 2003).
P120ctn is an important regulator of the turnover of cadherins.
Upon p120ctn knockdown with siRNA (small interfering RNA), the
cadherins are rapidly degraded, probably via ubiquitination (Davis
et al., 2003). Also, proteases like MMP (Paradies and Grunwald,
1993), caspase-3 (Hunter et al., 2001) and presenilin (Marambaud
et al., 2003) may cleave N-cadherin, giving rise to different frag-
ments. MMPs shed a 90 kD ectodomain fragment, soluble N-
cadherin, that is still functional while the role and the fate of the
TABLE 1
MECHANISMS OF REGULATION OF THE N-CADHERIN/CATENIN COMPLEX
Factor Context Properties Reference
UPREGULATION
twist and snail Drosophila correlation between twist and N-cadherin expression Oda et al., 1998
gastric cancer Rosivatz et al., 2002
GATA-4 heart binding to N-cadherin promoter Zang et al., 2003
SOX9 chondrocytes enhancing N-cadherin promoter activity Panda et al., 2001
Pax6 Lens placode induction of N-cadherin expression Van Raamsdonk et al., 2000
HOXD3 Lung cancer cells induction of N-cadherin expression Hamada et al., 2001
HGF epiblast cells when cells ingress the primitive streak Deluca et al., 1999
phorbol ester osteoblasts PKC dependent Delannoy et al., 2001
EGF breast carcinoma cells induction of EMT Ackland et al., 2003
gonadal steroids hippocampus mRNA levels increased Monks et al., 2001
testis Pötter et al., 1999
Sertoli cells mRNA levels increased MacCalman et al., 1997
Sertoli cells protein levels increased Perryman et al., 1996
granulosa cells Blaschuk and Farookhi, 1989
ovary mRNA levels increased MacCalman et al., 1995
DOWNREGULATION/ FUNCTIONAL INHIBITION
IL-6 melanoma mRNA and protein level decreased Gil et al., 2002
dexamethasone osteoblasts inhibition of expression Lecanda et al., 2000
caspase 3 osteoblasts Proteolysis at the juxtamembrane domain Hunter et al., 2001
plasmin producing a 90 kD ectodomain fragment Our unpublished data
MMP retina producing a 90 kD ectodomain fragment Paradies and Grunwald, 1993
presenilin neurons ε-cleavage produces an intracellular domain peptide CBP Marambaud et al., 2003
Porphyromonas gingivalis epithelial cells loss of cell-cell adhesion and apoptosis Chen et al., 2001
Bismuth/ cadmium proximal tubule epithelium nephrotoxicity Leussink et al., 2001
Prozialeck et al., 2003
siRNA of p120CTN rapid turnover of cadherin by proteasome/lysosome Davis et al., 2003
thalidomide binds to N-terminal domain mimicking a tryptophan residue Thiele et al., 2000
Robo axons activation of the receptor by Slit: complex formation of Rhee et al., 2002
Robo/Abl/N-cadherin resulting in β-catenin phosphoryaltion
Chlamydia trachomatis cervical epithelial cells Breakdown of the N-cadherin/β-catenin complex Prozialeck et al., 2002
N-acetylglucosaminyl neural retina cells loss of cell-cell adhesion and uncoupling of the N-cadherin Balsamo and Lilien, 1990
transferase V /transferase complex from actin Balsamo et al., 1991
Balsamo et al., 1995
Guo et al., 2003
Abbreviations used: GATA-4, zinc finger transcription factor recognizes the consensus motif (A/T)GATA(A/G); SOX9, DNA binding SRY box found in SOX family member; Pax6,
paired box protein 6; HOXD3, Homeobox D3; HGF, hepatocyte growth factor; EGF, epidermal growth factor; IL-6, interleukin 6; siRNA, small interfering RNA; TF, transcription
factor; PKC, protein kinase C; CBP, CREB binding protein; CREB, cyclic AMP response element binding protein.
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residual transmembrane/ intracellular part is not clear. Only for the
intracellular peptide fragment of N-cadherin, produced after PS1
cleavage, a role is described. It forms a complex with transcrip-
tional coactivator CBP (CREB binding protein) in the cytoplasm
and promotes the proteasomal degradation of CBP, via the ubiquitin-
proteasome pathway. N-cadherin has an important role during
embryogenesis. Thalidomide, a drug that causes teratogenicity,
affects mostly organs originating from neural crest cells. Thalido-
mide was found to bind at the N-terminal domain of N-cadherin,
mimicking a tryptophan residue which is critical for its
homodimerization, and thus functionally inhibiting homodimerisation
(Thiele et al., 2000). In axon trajectories, the Robo transmembrane
receptor forms a complex with N-cadherin. After activation with Slit,
a complex between Robo, Abl and N-cadherin is formed, followed
by tyrosine phosphorylation of β-catenin and resulting in loss of the
critical N-cadherin-actin connection (Rhee et al., 2002).
N-cadherin expression from embryo to adult
Members of the cadherin superfamily have distinct expression
patterns during embryonic development and in the adult. Changes
in cadherin expression are often associated with changes in
cellular morphology and tissue architecture. During gastrulation,
E-cadherin is downregulated in the primitive streak as cells un-
dergo an epithelial-mesenchymal transition and concomitantly
express N-cadherin in the mesoderm (Hatta and Takeichi, 1986).
This expression of N-cadherin is initiated by the transcription factor
twist in Drosophila (Oda et al., 1998). During neurulation, a similar
change in expression occurs in the developing neuroepithelium.
Different groups analysed the role of N-cadherin in embryogenesis
by using knockouts or an artifical system of cytodifferentiation, in
which either teratomas or cultured embryoid bodies from geneti-
cally manipulated embryonic stem (ES) cells are generated and
analysed. When N-cadherin was constitutively expressed in the E-
cadherin negative ES cells, the resulting teratomas formed neu-
roepithelia and cartilage (Larue et al., 1996). N-cadherin knockout
mice die at day 10 of gestation. The embryos display major heart
defects and malformed neural tubes and somites (Radice et al.,
1997). However, all tissues expected to be formed at this stage are
apparently present and seem to be normally differentiated. Re-
expression of N-cadherin using muscle-specific promoters (α- or β-
myosin heavy chain) partially rescues N-cadherin null embryos.
These embryos exhibit an increased number of somites, branchial
arches and the presence of forelimb buds, however, brain devel-
opment is still impaired (Luo et al., 2001).
N-cadherin is implicated in several aspects of cardiac develop-
ment including sorting out of the precardiac mesoderm, establish-
ment of left-right asymmetry, cardiac looping morphogenesis and
trabeculation of the myocardial wall. N-cadherin is one of the
earliest proteins to be asymmetrically expressed in the chicken
embryo and its activity is required during gastrulation for a proper
establisment of the left-right axis (Garcia-Castro et al., 2000). In the
early embryo N-cadherin is found in the mesoderm and the
notochord, while in the late embryo it is present in neural tissue,
lens and some other epithelial tissues, cardiac and skeletal muscles,
nephric primordial, some mesenchymal tissue, mesothelium and
primordial germ cells (Hatta et al., 1987; Takeichi, 1988).
N-cadherin is expressed in early hematopoietic cells
(CD34+CD19+) and is involved in the development and retention of
early hematopoietic cells in the bone marrow (Puch et al., 2001).
Cartilage formation in the developing vertebrate embryonic limb
consists of highly coordinated and orchestrated series of events
involving the commitment, condensation and chondrogenic differ-
entiation of mesenchymal cells and the production of cartilaginous
matrix. Here, N-cadherin has a role in the cellular condensation
(Tuan, 2003), being a direct target of SOX9, a transcription factor
that is essential for chondrocyte differentiation and cartilage forma-
tion (Panda et al.,2001). Misexpression of wnt7a (wingless/int, a
chondro-inhibitor in vitro) in mesenchymal chondrogenic cultures
directly led to prolonged expression of N-cadherin, stabilisation of
N-cadherin mediated cell-cell adhesion and eventual inhibition of
chondrogenesis (Tufan and Tuan, 2001; Tufan et al., 2002). N-
cadherin mRNA levels increase during osteogenic and myogenic
differentiation and decrease during adipogenic differentiation. N-
cadherin is expressed in all stages of osteoblast bone formation:
mRNA levels for example increase at the stages of nodule forma-
tion and mineralisation, and in vitro N-cadherin levels increase
concomitantly with osteoblast differentiation (Ferrari et al., 2000).
A lot of factors regulate the expression of N-cadherin in osteo-
blasts: BMP-2, FGF-2 and phorbol ester increase the level of N-
cadherin in a PKC-dependent way, while TNFα and IL-1 are
responsible for a decrease in expression. However, N-cadherin
expression is decreased in primary and metastatic osteosarcoma
(see also below) (Marie, 2002).
N-cadherin plays also an important role in skeletal muscle
differentiation. Cells with the potential to undergo skeletal
myogenesis are present in the epiblast layer. All cells express the
skeletal muscle-specific transcription factor MyoD but only the
epiblast cells that express N-cadherin but not E-cadherin will
differentiate into skeletal muscle (George-Weinstein et al., 1997).
So, N-cadherin is involved in myoblast migration and homing as
well as in muscle differentiation (Brand-Saberi et al., 1996).
Migratory cells play an important role in embryonic develop-
ment and disease. A migratory cell population known as neural
crest can be defined as a pluripotent population of cells that arise
from the dorsal part of the neural tube during or just before
closure. After an epithelial-mesenchymal transition (EMT), they
migrate over long distances along distinct pathways to many
different regions of the embryo and contribute to a diverse array
of tissues and cell types, such as the peripheral nervous system,
melanocytes, some endocrine cells, craniofacial cartilage and
bone. The transcription factor Slug is involved in both the forma-
tion of the neural crest precursors and in neural crest migration.
Slug downregulates cadherins, leading to a loss of cell-cell
contacts and allowing the cells to migrate. Indeed, when neural
crest cells are still associated with the neural tube, they express
N-cadherin but once they start migrating N-cadherin is
downregulated. At the end of the dorso-ventral migration N-
cadherin is re-expressed in aggregating cells, just before the
formation of the dorsal root and sympathic ganglia. After the
dorso-lateral migration only the dermal melanocytes express N-
cadherin and establish contacts with the fibroblasts in the dermis
(Nieto, 2001; Pla et al., 2001).
As is evident from the above, N-cadherin is expressed at
different time points and tissues in the embryo. In the adult, N-
cadherin is restricted to neural tissue, retina, endothelial cells,
fibroblasts, osteoblasts, mesothelium, myocytes, limb cartilage,
oocytes, spermatids and Sertoli cells.
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TABLE 2
EXPRESSION OF N-CADHERIN IN HUMAN CANCER CELL LINES AND BIOPSIES
AND CORRELATION WITH THE EXPRESSION FOUND IN EMBRYO AND ADULT
tumour type embryo adult cell line or biopsy % positivity observation /properties reference
DE NOVO EXPRESSION
Breast carcinoma - - BT549, MDA-MB-436, HS578T, HS578N invasive, fibroblastic, metastatic Hazan et al., 1997
SUM159PT motile, invasive Nieman et al., 1999
Biopsies + in sarcomatoid metaplastic carcinoma Han et al., 1999
Biopsies 48 no correlation with survival Peralta Soler et al., 1999
Ectopic expression in MCF-7 cells motile, invasive Hazan et al., 2000
Biopsies of ductal carcinoma in situ 12.3 no correlation with grade Paredes et al., 2002
Biopsies 30 + in invasive carcinomas Kovacs et al., 2003
Prostate carcinoma - - PC3N and JCA1 induction of epithelial-mesenchymal interactions Tran et al., 1999
TSU-pr1, PPC-1, ALVA-31, PC3, JCA-1 invasive, metastatic Bussemakers et al., 2000
Biopsies 60 when Gleason score above 7 Tomita et al., 2000
Bladder carcinoma - - 5637, Wmcub2, SW-780, SW-800,
SW-1710, J82, T24 fibroblastic Giroldi et al., 1999
T24, RT112, TCCSUP epithelioid/ fibroblastic Mialhe et al., 2000
Biopsies 39 + in invasive tumours Rieger-Christ et al., 2001
Thyroid carcinoma - - HTh7, C643, SW1736, HTh74 fibroblastic Husmark et al., 1999
Squamous cell carcinoma - - SCC1, UM-SSC-11A, UM-SCC-11B SCC9 fibroblastic Islam et al., 1996
Li et al., 1998
RE-EXPRESSION
Melanoma + - Biopsies / cell lines 75/ 90 Hsu et al., 1996
MeWo, A375 stronger adhesion, invasive, metastatic Matsuyoshi et al., 1997
Biopsies + in metastases Sanders et al., 1999
Biopsies 56 Laskin and Miettinen, 2002
Leukemia + - Oh13T, F6T, K3T, Molt-4F, CEM, Jurkat ATL and T-cell leukemia + Tsutsui et al., 1996
Hut102 50 ATL cell lines Matsuyoshi et al., 1998
Oh13T, F6T, K3T aggregation and co-aggregation with Kawamura-Kodoma et al., 1999
mesenchymal cells
Gastric carcinoma + - Biopsies of AFP producing carcinoma 100 Yanagimoto et al., 2001
Biopsies 21 correlation with twist Rosivatz et al., 2002
Chordomas + - Biopsies 100 Laskin and Miettinen, 2002
Biopsies 50 Horiguchi et al., 2004
Rhabdomyosarcoma + - RD, HS729 no correlation Soler et al., 1993
UPREGULATION
Leiomyoma + + Cells grow irregular compared to normal Kobayashi et al., 1996
Biopsies overexpression Tai et al., 2003
Mesothelioma + + Biopsies + in pleural mesothelia
− in lung adenocarcinoma Han et al., 1997
Biopsies 70 Laskin and Miettinen, 2002
Biopsies 70 to 100 Ordonèz, 2003
Adrenal tumours + + Biopsies up  in pheochromocytomas
down in adrenocortical carcinoma Khorram-Manesh et al., 2002
DOWNREGULATION
Osteosarcoma + + Biopsies − in metastasis Kashima et al., 1999
Dunn and LM8 migration and metastasis inhibited Kashima et al., 2003
Ovarian carcinoma + + Biopsies + in benign and borderline tumours
not in ovarian cancer Daraï et al.,1997
Biopsies − in mucinous cystadenoma Peralta Soler et al., 1997
Biopsies + in normal and metaplastic ovarian Wong et al., 1999
Biopsies aberrant P-cadherin expression Patel et al., 2003
Gliobastoma + + Biopsies no differences Shinoura et al., 1995
Biopsies down at time of recurrence Asano et al., 2000
Biopsies correlation with histological grade Utsuki et al., 2002
Renal cell carcinoma + +/- Caki-1, Caki-2, ACHN,A498 − in oncocytomas Tani et al., 1995
+ in renal cell carcinoma
OTHERS NOT CLASSIFIED
Small cell carcinoma in cervix Biopsies 0 no expression compared with 65 % in Zarka et al., 2003
other small cell carcinoma
Merkel cell carcinoma Biopsies (neuroendocrine) 63 Han et al., 2000
Abbreviations used: ‘+’, expression of N-cadherin;  ‘-’, no expression of N-cadherin; up, upregulation; down, downregulation; AFP, alpha-foetoprotein; ATL, adult T-cell leukemia; T cell leukemia, human
thymus derived cell line.
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N-cadherin and cancer
The process of EMT not only occurs under physiological condi-
tions during normal embryonic development, it also takes place in
pathological situations, such as the acquisition of an invasive
phenotype in tumour cell lines of epithelial origin. This goes
together with the first steps of the metastatic process. The EMT
associated with tumour progression frequently involves
downregulation of E-cadherin expression and the acquisition of
migratory properties. Snail is a strong and direct repressor of E-
cadherin (Cano et al., 2000), and influencing the levels of N-
cadherin expression, a pro-migratory factor. Indeed, in a number
of human cancer types which have lost E-cadherin, de novo
expression of N-cadherin is observed (Tomita et al., 2000).
The cadherins have been investigated in different areas of
tumour biology. In early neoplasia cadherins play a role in the
transformation of cells to an abnormal proliferative phenotype. E
and N-cadherin are normally involved in inducing cell cycle arrest.
However, N-cadherin also promotes survival in normal granulosa
cells (Makrigiannakis et al., 1999) and in melanoma cells (Tran et
al., 2002) by distinct mechanisms. In epithelial carcinomas E-
cadherin is downregulated in most cases, sometimes accompa-
nied by the upregulation of another cadherin, for example N-
cadherin, P-cadherin or cadherin –11. Here, we will focus on the
expression of N-cadherin in cancer. We reviewed the literature and
present an overview of N-cadherin expression in cancer cells and
looked whether this was also the case in their embryonic and adult
normal counterparts (Tabled 2). The table is divided into 4 groups:
in the first one (including breast, prostate, bladder, thyroid and
squamous cell carcinoma) N-cadherin is ‘DE NOVO EXPRESSED’
(Table 2) in the cancer cell and N-cadherin is never expressed in
the corresponding precursor or adult normal cells. In 1996 the
aberrant expression of N-cadherin in squamous cell carcinoma
was described. The inappropriate expression of N-cadherin in
these cells correlated with a scattered fibroblastic phenotype along
with decreased expression of E- and P-cadherin. Transfection with
antisense N-cadherin resulted in reversion to a normal appearing
squamous epithelial cell morphology, and increased expression of
E- and P-cadherin. In addition, transfection of a normal squamous
epithelial cell line with N-cadherin induced the scattered fibroblas-
tic phenotype (Islam et al., 1996). Aberrant N-cadherin expression
was also found in breast carcinoma cells and biopsies. Breast
carcinoma cells expressing N-cadherin are more motile and inva-
sive (Hazan et al., 1997 and 2000). In biopsies N-cadherin was
mostly found in invasive carcinoma, but no correlation could be
found with grade (Paredes et al., 2002) or patient survival (Peralta
Soler et al., 1999). De novo expression of N-cadherin was found
most frequently in prostate carcinoma: in one series, 60% was
positive in carcinomas with a Gleason score above 7 (Tomita et al.,
2000). In vitro studies show that the expression of N-cadherin
mediates an epithelial-mesenchymal transformation, possibly im-
proving the physical interaction with the surrounding stromal
fibroblasts and facilitating metastasis (Tran et al., 1999).
In the group ‘RE-EXPRESSION’ (Table 2) we classified tumours
that had embryonic precursor cells expressing N-cadherin. One of
the best examples are melanoma cells: melanocytes are derived
from neural crest cells, which are N-cadherin positive before they
start migrating. N-cadherin was found back in metastasising mela-
nomas (Matsuyoshi et al., 1997; Sanders et al., 1999). In gastric
carcinoma N-cadherin was found in all α-foetoprotein producing
tumours (Yanagimoto et al., 2001) and a correlation was found
between the expression of twist and N-cadherin expression
(Rosivatz et al., 2002). During early development N-cadherin is
found in some basal granulated epithelial cells of the stomach,
duodenum and jejunum (Gaidar et al., 1998). Another example is
the expression of N-cadherin in T-cell leukemia cell lines. Here, N-
cadherin is functionally active because it stimulates the co-aggre-
gation and adhesion with mesenchymal cells, which presumably
facilitates invasion in mesenchymal tissues of the skin and the
central nervous system (Kawamura-Kodama et al., 1999).
A third group, ‘UPREGULATION’ (Table 2), shows that cells
already expressing N-cadherin in embryonic and adult stages can
still increase their levels of expression in neoplastic stages. One
example is pleural mesothelioma, where a high and homogeneous
expression is characteristic (Han et al., 1997; Ordónez, 2003).
In the last group we collected cancers where N-cadherin levels
remain unaltered or are ‘DOWNREGULATED’ (Table 2). In os-
teosarcoma, N-cadherin inhibits cell migration and the formation of
metastasis (Kashima et al., 1999 and 2003). In gliobastoma no
differences were found in N-cadherin expression but at the time of
recurrence, decreased N-cadherin expression correlates with dis-
semination in malignant astrocytic tumours (Asano et al., 2000). In
ovarian carcinoma, N-cadherin is expressed in the different stages
but one report mentioned that mucinous cystadenomas were N-
cadherin negative (Peralta Soler et al., 1997). Recently it was
shown that probably P-cadherin is the important aberrantly ex-
pressed cadherin in ovarian cancer (Patel et al., 2003).
In summary, multiple in vitro and in vivo studies showed that
aberrant N-cadherin (re-) expression correlates in most cases with
a morphological change towards a more fibroblastic phenotype,
with cells becoming more motile, invasive and metastatic. There
are, however, invasive tumours where N-cadherin is downregulated
and where it may play the role of a tumour suppressor molecule.
Nowadays, loss of immunohistochemical E-cadherin expres-
sion is sometimes used in surgical pathology to characterize
gastric and breast carcinomas. It may be worthwhile to explore also
the cases where N-cadherin is aberrantly expressed, and chal-
lenge N-cadherin as a candidate prognostic marker. Another
ongoing project in our laboratory is the use of circulating soluble N-
cadherin, the 90 kD fragment that is released after MMP cleavage,
as a potential tumour marker of invasion. Soluble E-cadherin, a 80
kD ectodomain fragment, in the serum or urine of patients with
urothelial carcinoma (Griffiths et al., 1996), ovarian carcinoma
(Gadducci et al., 1999) and gastric carcinoma (Gofuku et al., 1998)
has already been launched as a circulating tumour marker. Yet, we
believe that soluble N-cadherin has better chances as a potential
circulating tumour marker than soluble E-cadherin, because in
general N-cadherin expression is upregulated in invasive tumours.
Conclusion
N-cadherin is associated with a lot of molecules that regulate its
function. It is involved in a lot of processes like cell-cell adhesion,
differentiation, embryogenesis, migration, invasion and signal trans-
duction. In embryogenesis, during gastrulation, cells undergo an
epithelial-mesenchymal transition leading to the expression of N-
cadherin and the downregulation of E-cadherin in the mesoderm.
This switch is regulated by multiple growth and transcription
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factors. A similar situation appears in carcinomas where loss of E-
cadherin is correlated with an upregulation of N-cadherin. The
aberrant expression (de novo or re-expression) of N-cadherin
attributes a more fibroblastic phenotype to the cancer cells, and
they become more motile and invasive. One of the transcription
factors responsible for upregulation is twist. Further research on
other possible factors that affect the N-cadherin switch, on the
signalling pathways initiated in N-cadherin mediated invasion and
on the perspective of N-cadherin as a potential marker of invasion
is needed.
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Part III Cadherins as circulating tumour markers 
3.1. Molecular Markers for Cancer 
 
The progression from preneoplasia to cancer is accompanied by genetic alterations. 
These lead to altered expression patterns and modifications in protein structure and function. 
Changes that occur exclusively or commonly in cancer cells are detectable in biopsies or body 
fluids and used as molecular markers for cancer. These markers are useful in detecting cancer 
at early stages, selection of therapy, monitoring disease progression and determining response 
to therapy (Sidransky et al. 2002). Molecular markers can add information to the traditional 
TNM (Tumour size, Lymph node spread, Metastases) staging system, because patients with a 
cancer of apparently equivalent type, stage and grade can give different outcomes. Those 
differences in outcome may relate in part to the time at which a single cancer cell happens to 
undergo all the steps necessary for successful metastasis or can relate to molecular factors that 
can be reasonably well understood at a deterministic level. The emerging use of molecular 
markers may herald an era in which physicians no longer make treatment choices that are 
based on population based statistics but rather on the specific characteristics of individual 
patients and their tumour (Dalton and Friend 2006). An example is the presence or not of the 
estrogen receptor (ER) and neu in breast carcinoma, they determine the prognosis and 
therapy. 
There is a whole range of markers nowadays, and some examples are DNA-based markers, 
RNA-based markers and protein markers. The DNA-based markers include single-nucleotide 
polymorphism, chromosomal aberrations, changes in DNA copy number, micro-satellite 
instability and differential promoter-region methylation. RNA-based markers are 
overexpressed or underexpressed transcripts, and regulatory RNA’s (microRNA). The protein 
markers include cell surface receptors such as CD20, tumour antigens such as prostate-
specific antigen (PSA), phosphorylation states, carbohydrate determination, and peptides 
released by tumours in serum, urine, sputum, nipple aspirates or other body fluids (Ludwig 
and Weinstein 2005). However, the lack of availability of biomarkers with high specificity 
and sensitivity limits the ability to screen for most cancers. Sensitivity refers to the percentage 
of individuals with disease who are marker positive, whereas specificity refers to the 
likelihood that a given marker will be elevated only in individuals with the disease. PSA for 
example is a very sensitive marker but has a low specificity for prostate cancer (Chatterjee 
and Zetter 2005). Therefore, new markers are still required for all cancers. Recently, 
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advancements in biomarker development using microarrays and proteomics have facilitated 
the discovery of new markers, and examples are survivin (Shariat et al. 2004) and calreticulin 
(Kageyama et al. 2004) for bladder cancer. However, the major difficulty in utilizing 
circulating tumour makers is that very small tumours, which need to be detected and removed 
prior to metastasis to other organs, may not produce sufficient amounts of the marker for 
detection in serum or urine.  
Cancer involves the transformation and proliferation of altered cell types that produce high 
levels of specific proteins and enzymes such as proteases. These proteinases not only modify 
the array of existing serum proteins (Anderson and Anderson 2002) but also their metabolic 
peptide products. The serum contains thousands of proteolytically derived peptides (Richter et 
al. 1999). Villanueva et al. (2006) reported that by correlating the proteolytic patterns with 
disease groups and controls, they could show that exoprotease activities superimposed on the 
ex vivo degradation pathways contribute to generation of not only cancer-specific but also 
cancer type-specific serum peptides. Their study provides a direct link between peptide 
marker profiles of disease and differential protease activity. In several tumours elevated levels 
of protease where observed, Riddick et al. (2005) detected significant more MMP15 and 
MMP26 in prostate cancer and the levels correlated with the Gleason score, whereas TIMP3 
and TIMP4 inversely correlated with the Gleason score. In addition, in intestinal carcinoma 
significant changes in the expression of matrix metalloproteinases were identified (Martinez 
et al. 2005). 
3.2. Soluble cadherins 
 
Damsky et al. (1983) reported for the first time that an 80 kD fragment is found in the 
conditioned medium of MCF-7 cells and this fragment had adhesion disrupting activities. 
This fragment was a cleaved form of human E-cadherin (Wheelock et al. 1987). Many 
proteases like matrilysin and stromelysin (Noë et al., 2001, Davies et al. 2001), plasmin 
(Ryniers et al. 2002, Hayashido et al. 2005) and ADAM10 (Maretzky et al. 2005) can cleave 
E-cadherin in vitro and shed the E-cadherin ectodomain (sE-CAD) (see figure 3.2.). Other 
enzymes like caspases (Steinhusen et al. 2001) and calpain (Rashid et al. 2001, Rios-Dora et 
al. 2002) cleave E-cadherin in its cytoplasmic part. E-cadherin, which is present on all 
epithelial cells and in some cancer cells in human can also be cleaved by present proteases. 
Many articles describe the detection of sE-CAD in different biological fluids (blood, urine 
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and cyst fluid) of healthy persons, cancer patients and patients suffering form other diseases. 
Table 3.2.: Overview of the literature detecting sE-CAD in human biological fluids 
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An overview of the literature is given in table 3.2. If we scroll through the data, we can 
conclude that:  
1) In serum of healthy persons ± 2,3 µg/ml of sE-CAD is present, while in serum of cancer 
patients ± 6,8 µg/ml of sE-CAD is present.  
2) No correlation is found with TNM staging. Only in gastric cancer sE-CAD is used as a 
marker for disease recurrence (Chan et al. 2005)  
3) Not only in cancer patients, elevated levels were observed also in patients suffering from 
any type of inflammatory process elevated levels of sE-CAD were found (Pittard et al. 1996).  
The P-cadherin ectodomain is also detected in several biological fluids: serum (Knudsen et 
al.2000), milk of lactating women (Soler et al. 2002) and semen (De Paul et al. 2005). VE-
cadherin can also be cleaved by MMP and caspases, to release a 90 kD fragment. sVE-CAD 
was found in blood of atherosclerosis patients (Soeki et al. 2004), but elevated levels were 
also found in sera of patients with colorectal cancer (Sulkowska et al. 2006). 
N-cadherin is cleaved by several enzymes: plasmin (see 4.2), ADAM10 (Reiss et al. 2005), 
MT1-MMP (Covington et al. 2006), MT5-MMP (Monea et al. 2006) which shed a 90 kD 
fragment in the medium and by Presenilin 1 (PS1)/γ-secretase which can cleave N-cadherin in 
the cytoplasmic part (see figure 3.2.). Recently ADAM10 and PS1 cleavage sites were 
characterised: ADAM10 cleaves between R714 and I715 in the extracellular domain and PS1 
between K747 and R748 located at the membrane-cytosol interface (Uemura et al. 2006). Up to 
now, sN-CAD was only detected in the embryonic vitreous humor. We could detect sN-CAD 
in serum of healthy persons and significant higher levels in serum of cancer patients. 
 
Figure 3.2. Sources of soluble-CAD in the tumour micro ecosystem  
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Classical cadherins such as E-, P- and N-
cadherin are transmembrane proteins that 
mediate cell-cell adhesion, and are important in 
embryogenesis, maintenance of tissue integrity 
and cancer. Proteolytic shedding of the 
extracellular domain results in the generation of 
soluble E-, P- or N-cadherin ectodomains. 
Circulating soluble E- and P-cadherin have been 
described in the serum, and elevated levels were 
detected in cancer patients as compared to 
healthy persons. Here we report the presence of 
soluble N-cadherin, a 90 kD protein fragment, in 
the serum of both healthy persons and cancer 
patients, using a direct ELISA and 
immunoprecipitation. A correlation was found 
between prostate specific antigen and soluble N-
cadherin, and significantly elevated levels were 
detected in prostate cancer follow-up patients. 
The N-cadherin protein is neo-expressed by 
carcinomas of the prostate, and is responsible 
for epithelial to fibroblastic transition. This is 
reflected in the higher concentrations of soluble 
N-cadherin in prostate cancer patients than in 
healthy persons. 
 
Keywords: soluble N-cadherin, serum and cancer 
 
Cell-cell adhesion molecules play an important 
role during embryogenesis, tumor invasion and 
metastasis. The cadherins, Ca2+-dependent cell-cell 
adhesion molecules, are essential for intercellular 
connections. E (epithelial)-cadherin is involved in 
normal epithelial cell-cell interactions but is often 
downregulated in epithelioid cancer cells. These 
cancer cells can switch cadherin expression from E- 
to N- (neural)1, E- to P- (placental)2 or E- to OB- 
(osteoblast)-cadherin.3 This coincides with the 
transition from an epithelioid to a fibroblastic 
phenotype, and is often correlated with 
invasiveness.4  
Proteolysis can contribute to the impairment of the 
cadherin function. Several enzymes have been 
shown to be responsible for the shedding of the 
extracellular domain. Cleavage of E-cadherin and 
shedding of an 80 kD fragment can be mediated by  
matrilysin, stromelysin-15,6; plasmin7 and a 
disintegrin and metalloproteinase 10 (ADAM10).8 
For N-cadherin, a 90 kD fragment can be released 
by the enzymes matrix metalloproteinase (MMP)9, 
plasmin10, ADAM10,11 Membrane Type 1 –MMP 
(MT1-MMP)12, MT5-MMP.13
Soluble E-cadherin (sE-CAD) has been described in 
the circulation of cancer patients.14 In that study, 
the mean sE-CAD level, detected by Enzyme 
Linked ImmunoSorbent Assay (ELISA), in serum 
was significantly higher in the studied cancer 
patients (3.8 ± 2.36 µg/ml) compared with the 
healthy controls (1.99 ± 0.5 µg/ml). In addition, sE-
CAD was detected in serum of patients with 
diabetes or hepatitis, but these values were not 
significantly different from the healthy controls. As 
a result, sE-CAD is now propagated as a marker for 
early prediction of tumor recurrence of gastric 
cancer.15 sE-CAD is also found in urine16 and the 
mean levels in the urine of patients with bladder 
cancer, are significantly higher than in the urine of 
healthy persons (1.6 versus 0.9 µg/ml).17 High 
levels of sE-CAD appear to be associated with 
positive cytology results and with bladder muscle 
invasion of transitional cell carcinoma.18
Soluble P-cadherin (sP-CAD) is found in serum19 of 
healthy persons as well as in patients with breast 
cancer, but no significant difference was found 
between these two populations. Remarkably, the 
sP-CAD levels are 20-fold lower than the sE-CAD 
levels in serum. In addition, sP-CAD is also 
detected in milk20 of lactating women (in the range 
100-400 µg/ml, while sE-CAD was not found in 
milk) and in semen of fertile and non-fertile men.21 
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Three major observations made us speculate that 
soluble N-cadherin (sN-CAD) might be present in 
extracellular fluids of cancer patients: its 
upregulation in epithelioid cancers, for example in 
breast, prostate and bladder carcinoma1,3,22,23, its 
reactive upregulation in stromal cells of malignant 
tumors24 and the presence of multiple extracellular 
proteases, like MMP26 that are reported to cleave 
the extracellular part of cadherins. Apart from its 
presence in the embryonic vitreous humor9, no 
reports of sN-CAD in biological fluids are 
available. Here we report the presence of sN-CAD 
in biological fluids. Moreover, we developed an 
ELISA method to quantify sN-CAD levels. We 
demonstrate the presence of sN-CAD in serum and 
found significantly higher levels in cancer patients 
compared with individuals without evidence of 
disease. sN-CAD was also present in seminal fluid, 
and urine but was undetectable in synovial fluid or 
spinal fluid. 
 
 
Material and methods 
 
Cell lines and preparation of medium containing 
soluble N-cadherin 
S180-N-cadherin (ARM), mouse sarcoma cells 
(a gift from R.M. Mège, INSERM, Paris, France)27 
were grown in D-MEM (Invitrogen, Merelbeke, 
Belgium) supplemented with 10% foetal bovine 
serum and penicillin, streptomycin and Fungizone 
(Invitrogen). The S180-NCAD cells, used as a 
source of sN-CAD, are S180 cells transfected with 
chicken cDNA encoding for N-cadherin. The cells 
were incubated in a 100% water-saturated 
atmosphere of 10% CO2. All cells were routinely 
tested for mycoplasma contamination by staining 
with 4’,6’-diamidino-2-phenylindole (DAPI) and 
were found to be negative.  
Subconfluent monolayers were washed 3 times with 
phosphate buffered saline (PBS) and were incubated 
with serum free medium for 24 hours, washed 
another 3 times with PBS and incubated for 48 hours 
with serum free medium. The medium containing 
sN-CAD was harvested and centrifuged for 5 
minutes at 250 g and for 15 minutes at 2,000 g. The 
supernatant was filtered through a 0.22 μm filter and 
was concentrated 10 times (Amicon Ultra 50 kD, 
Millipore Corp., Bedford, MA) before use in ELISA 
or Western blot. 
 
Reagents and antibodies 
Recombinant human N-cadherin/Fc chimera 
was purchased from R&D Systems (Abingdon, 
UK) and used to set up a standard curve with the 
ELISA method. Mouse GC-4 antibody (Sigma, St. 
Louis, Missouri, USA) against the extracellular part 
of N-cadherin was used for ELISA, 
immunoprecipitation and immunostaining of the 
Western blot. The secondary antibodies were goat 
anti-mouse linked to alkaline phosphatase (Sigma) 
for ELISA and anti-mouse linked to horseradish 
peroxidase (Amersham Pharmacia Biotech, 
Uppsala, Sweden) for Western blot.  
 
Collection of human biological fluids 
Serum samples were collected from 193 
healthy subjects (with no evidence of disease, 
N.E.D., and having C-reactive protein values below 
0.6 mg/dl) and 179 patients during follow-up of 
cancer. The selection of the cancer patients was 
based on the presence of high serum levels of an 
established tumor marker: prostate specific antigen 
(PSA) was above 50 ng/ml (prostate carcinoma, n = 
54 ), episialin (CA15-3) above 50 U/ml (breast 
carcinoma, n = 71), carcino embryonic antigen 
(CEA) above 100 ng/ml (various carcinoma, n = 
15), CA 125 above 50 U/ml (ovarium carcinoma, n 
= 12) or CA19-9 above 1000 U/ml (gastro-
intestinal carcinoma, n = 12). Also 8 sera samples 
from patients with Chronic Lymphocytic Leukemia 
(CLL) were included. Venous blood samples were 
collected and centrifuged (after clotting) at 1500 g 
for 10 minutes. All sera were stored at -20 °C until 
sN-CAD assessment. Sera were residual samples 
with an approval from the ethical committee of the 
Ghent University Hospital (nr. 2001/333). Other 
human biological fluids collected were urine (n = 
33), seminal fluid (n = 15), synovial fluid (n = 2) 
and spinal fluid (n = 18). After reception of these 
samples, they were centrifuged to remove cells and 
stored at -20 °C. 
 
Immunoenzymometric assay for soluble N-cadherin 
sN-CAD levels were measured with a home-
made ELISA. A dilution series of recombinant N-
cadherin from 1 to 1000 ng/ml was prepared. All 
serum samples were diluted 5 times in PBS 
containing 0.1% Bovine Serum Albumin (BSA). A 
96-well immunoplate (Nunc) was coated with 75 µl 
of the diluted sample overnight at 4°C. The wells 
were washed with PBS/0.05% Tween-20 and 
quenched at 37°C with PBS/1% BSA for 1 hour. 
Next, the plates were washed again (4 times) and 
incubated with the primary antibody (GC-4, 1/200 
in PBS/0.1% BSA) at 37°C for 2 hours. The plates 
were washed (4 times) and subsequently incubated 
with a mouse secondary antibody linked to alkaline 
phosphatase (Sigma, 1/3000). The substrate p-
nitrophenylphosphate (Sigma, St. Louis, Missouri, 
USA) was added to the plates and after 30 minutes 
the optical density of each well was determined 
with a microplate reader (Molecular Devices, 
Wokingham, UK) at 405 nm. In control 
experiments we omitted the primary antibody. 
Measurements were done at least in duplicate for 
each sample, and the mean value was calculated. 
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Immunoprecipitation and Western blotting 
Serum samples were depleted from albumin 
and immunoglobulins using the AurumTM Serum 
Protein Mini kit (Bio-RAD, Hercules, USA). The 
eluted fractions were used to start the 
immunoprecipitations. For the immunoprecipi-
tation, equal amounts of serum samples were 
incubated with Dynabeads Protein G (Dynal 
Biotech, Oslon, Norway) for 30 minutes. After 
discarding the beads, the supernatant was incubated 
with primary antibody for 3 hours at 4°C, followed 
by incubation with Dynabeads Protein G for 1 hour. 
Next, sample buffer (Laemmli) with 5% 2-
mercaptoethanol and 0.012% bromophenol blue 
was Serum samples were depleted from albumin 
and immunoglobulins using the AurumTM Serum 
Protein Mini kit (Bio-RAD, Hercules, USA). The 
eluted fractions were used to start the 
immunoprecipitations. For the immunoprecipi-
tation, equal amounts of serum samples were 
incubated with Dynabeads Protein G (Dynal 
Biotech, Oslon, Norway) for 30 minutes. After 
discarding the beads, the supernatant was incubated 
with primary antibody for 3 hours at 4°C, followed 
by incubation with Dynabeads Protein added and 
supernatant was separated on 8% SDS-PAGE and 
blotted onto a nitrocellulose membrane (Amersham 
Pharmacia Biotech). Quenching and immuno-
staining were done in 5% non-fat dry milk in PBS 
containing 0.5% Tween-20. The membranes were 
quenched for 30 minutes, incubated with primary 
antibody (1/1000) for 1 hour, washed four times for 
10 minutes, incubated with horseradish peroxidase-
conjugated secondary antibody (1/3000) for 45 
minutes, and washed 6 times for 5 minutes. 
Detection was carried out using enhanced 
chemiluminescence reagent (ECL) (Amersham 
Pharmacia Biotech) as a substrate.  
 
Statistical Analysis 
Data were collected and analysed with SPSS 
(SPSS Inc, Chicago, USA). Comparisons were 
performed with the non-parametric Mann-Whitney 
U-test because the populations were not normally 
distributed. Differences were considered significant 
at p values < 0.001. Spearman correlation 
coefficients were used to examine the correlation 
between sN-CAD and the tumor markers like PSA, 
CA15-3 and CEA. 
 
Results 
 
ELISA for the detection of soluble N-cadherin in 
serum samples and other biological fluids 
A recombinant N-cadherin chimera (RECN), 
which consists of amino acids 1 to 724 of human N-
cadherin fused to the carboxyterminal end of the Fc 
region of human IgG1, migrated at 135 kD in SDS-
PAGE, and was reactive with the GC-4 antibody in 
ELISA and immunostaining of Western blot. This 
recombinant protein was used as an assay standard 
for quantification of antigen levels in several 
biological fluids. A dilution series of RECN was 
made from 1 to 1000 ng/ml and 75 µl of each 
dilution was incubated at 4°C overnight in an 
immunoplate in order to coat the wells. On the next 
day the immunoplate was quenched with 1% BSA, 
followed by incubation at 37°C with the primary 
antibody GC-4 for 2 hours. Next, the immunoplate 
was incubated with the goat anti-mouse antibody 
linked to alkaline phosphatase, and finally the 
chromogen p-nitrophenylphosphate was added to 
the plate. After 30 minutes the optical density was 
read at 405 nm (Fig. 1).  
 
 
Figure 1: Standard curve used to measure the sN-CAD 
concentrations 
A dilutions series from 1 to 1000 ng/ml of recombinant human 
N-cadherin/Fc chimera was prepared with 0.1% BSA in PBS, 
and coated on a immunoplate overnight at 4°C. After washing 
with PBS/ 0.05% Tween-20 followed by an incubation with 1% 
BSA during 1 hour, plates were washed and incubated with GC-
4 antibody for 2 hours at 37°C. Plates were washed again and 
incubated with an anti-mouse antibody linked to alkaline 
phophatase. After 1 hour the substrate p-nitrophenylphospate 
was added for 30 minutes, and the optical density of each well 
was read at 405 nm. 
 
Dilution curves from two serum samples were 
linear, suggesting that the same immuno-reactive 
substance is measured at the different dilutions 
(Fig. 2). We found that a dilution factor of 5 of all 
samples gave the best read out compared with the 
standard curve. The precision of the ELISA was 
tested assaying 8 times serum samples from 5 
healthy donors, with a mean sN-CAD value 
between 50 and 300 ng/ml. Intra-assay and inter-
assay coefficients of variation were 6% and 9% 
respectively. 
 
 
Figure 2: Dilution curve of 2 serum samples: one from the 
N.E.D. group (squares) and one from the cancer follow-up 
patients group (stars). 
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Serum samples from 193 people with no evidence 
of disease (N.E.D.) were collected and tested in the 
ELISA. sN-CAD concentrations had a median 
value of 99 ng/ml (range 0-1130 ng/ml). 179 serum 
samples from cancer follow-up patients were 
selected on the basis of elevated tumor maker 
concentration of CA15-3, CEA, PSA, CA19-9 and 
CA 125 and CLL patients. The results are shown in 
a box plot, and compared with the N.E.D 
population (Fig. 3a). 
 
Significantly elevated levels were observed in the 
cancer patient group with a median value of 584 
ng/ml (range 0-2713 ng/ml) (Mann Witney U-test, 
p < 0.001). Neither the frequency distribution curve 
of the N.E.D population (Fig. 3b) nor that of the 
cancer patients group (Fig. 3c) showed a normal 
distribution as assessed by the Kolmogorov –
Smirnov test. 
 
Figure 3: (a) Box plots representing the levels of sN-CAD in 
sera of 193 people with no evidence of disease (N.E.D.) and 179 
follow-up cancer patients. *Significant difference was 
determined using the Man-Whitney U-test (p < 0.001). Serum N-
cadherin levels were determined by a direct ELISA (b-c) 
Histograms representing the distribution of the sN-CAD 
concentrations in the N.E.D. and cancer population 
 
Using the nonparametric Spearman correlation 
coefficient, the sN-CAD serum concentrations 
showed no correlation with the tumor markers 
CA15-3 (r = -0.086) and CEA (r = -0.273). A 
significant, but weak correlation was found 
between PSA and sN-CAD levels (r = 0.254, p < 
0.05) (Fig. 4a). The PSA positive population (n = 
54) had significant higher sN-CAD values (range 0-
1445 ng/ml, median 675 ng/ml) compared with the 
N.E.D. population (range 0-1130 ng/ml, median 99 
ng/ml) (p < 0.001) (Fig. 4b).  
 
 
Figure 4: (a) Significant correlation (p < 0.05) between PSA and 
sN-CAD in sera from prostate cancer patients (PSA > 3,6 ng/ml) 
(b) Box plots representing the sN-CAD values found in the 
N.E.D. population compared to those in sera from prostate 
cancer patients (* Man Whitney U-test, p<0.001). 
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Other biological fluids where also tested for the 
presence of sN-CAD: we found sN-CAD in seminal 
fluid samples (range 1063-2553 ng/ml) and in urine 
(range 0-655 ng/ml), but none in synovial fluid or 
spinal fluid (data not shown). 
 
Immunoblot analysis of serum soluble N-cadherin 
In immunoblot analysis after 8% SDS-PAGE, 
we separated the immuno-isolated proteins, reactive 
with the GC-4 antibody, from serum samples of 3 
subjects with no evidence of disease and 4 cancer 
patients (2 breast cancer patients and 2 prostate 
cancer patients). Serum samples were first depleted 
for albumin and immuno-globulins. As positive 
control we used medium containing sN-CAD, 
which was harvested from S180 cells transfected 
with cDNA of N-cadherin (S180-NCAD). Various 
amounts of the 90 kD N-cadherin fragment (sN-
CAD) were detected in the serum samples by the 
GC-4 antibody (Fig. 5). Moreover, these could be 
correlated with the concentrations measured by 
ELISA. The molecular weight of the soluble N-
cadherin was in all samples identical. The upper 
band in lane 6 is an aspecific band, recognised by 
the secondary antibody (anti-mouse linked to HRP) 
alone. 
 
 
 
 
Figure 5: Immunoblot of a 90 kD fragment (sN-CAD) present in 
serum. Serum samples from 3 healthy individuals and 4 cancer 
patients are shown after depletion for albumin and immuno-
globulins. Serum samples were immunoprecipitated with the 
GC-4 antibody and loaded on a SDS-PAGE, transferred onto 
nitrocellulose membrane and immunostaining with the same 
antibody. As a positive control we used medium containing sN-
CAD harvested from S180-NCAD cells. sN-CAD concentrations 
of each serum sample tested, was also measured by ELISA 
(result mentioned under each lane). The upper band in lane 6 is 
immuno-reactive with the secondary antibody (anti-mouse 
linked to HRP). 
 
Stability of the soluble N-cadherin in serum 
To investigate the role of calcium in the 
stabilization of sN-CAD, S180-NCAD cells were 
treated with EDTA (0.125 to 3 mM) for 24 hours. 
The release of soluble N-cadherin remained the 
same as with untreated cells up to a concentration 
of 0.5 mM of EDTA in the culture medium (Fig. 
6a). Treatment with higher concentrations of EDTA 
made sN-CAD less detectable in the culture 
medium. Concentrations of EDTA higher than 0.75 
mM are known to chelate all divalent cations (for 
example Ca2+) in the medium. Adding EDTA to 
serum samples at a final concentration of 1 mM 
dramatically reduced the amount of sN-CAD to 
50%. So, this shows that we detect the cadherin 
protein. This effect was also observed when blood 
from the same individual was collected in tubes 
containing (EDTA K2 or EDTA K3, 8%) or citrate 
(3.2% sodium citrate). The plasma concentrations 
of sN-CAD were reduced to 30% and 45% 
respectively (Fig. 6b) compared with serum 
concentrations. For this reason we used serum from 
clotted blood to measure sN-CAD. 
 
Figure 6: (a) Detection of sN-CAD in the culture medium of 
S180-NCAD cells in presence of several concentrations of 
EDTA. Subconfluent monolayers of S180-NCAD cells were 
serum starved and followed by a treatment with serum free 
DMEM with or without EDTA at several final concentrations 
(0.125 to 3 mM). Culture medium was harvested after 24 hours 
and centrifuged to remove cells. The medium containing sN-
CAD was concentrated 10 times and loaded on SDS-PAGE. 
Immunoblot was stained with GC-4. (b) Detection of sN-CAD in 
serum (white), serum plus 1mmol/l EDTA added (grey), plasma 
from blood collected in a tube containing 8% EDTA (dark grey) 
or plasma from blood collected in a tube containing 3.2% 
sodium citrate (black) using the direct ELISA. Results were 
compared with the amount of sN-CAD in serum from the same 
vena puncture. (c) Stability of sN-CAD at different conditions 
tested with the ELISA: serum (white), serum 5 times frozen and 
thawed (grey) and serum left at room temperature for 2 days 
(dark grey). 
 
Serum with a known concentration of sN-CAD was 
mixed (1:1) with serum containing high 
concentrations of hemoglobin (± 15 g/dl), bilirubin 
(± 10 mg/dl) or triglycerides (± 1500 mg/l), 
affecting the aspect of the serum. These factors did 
not interfere with the detection of sN-CAD (data 
not shown). Repeated freezing and thawing (5 
times) of the biological fluids did not affect the 
stability of sN-CAD in serum samples. Storage of 
the samples at 4 °C did not change the amount of 
sN-CAD. However, storage of the samples for 2 
days at room temperature diminished the 
concentration of sN-CAD (49% to control) (Fig. 
6c).  
 
Discussion 
 
Tumor invasion is characterised in part by the 
ability of cancer cells to downregulate cell-cell 
adhesion and to invade into the surrounding tissues. 
In this respect the progression of a carcinoma is 
 56
III. CADHERINS AS CIRCULATING TUMOUR MARKER 
often characterised by a switch from E- to N-
cadherin. This switch in cadherin type expression 
has been observed in different malignant tissues, 
like breast, prostate, bladder, skin and colon 
carcinoma.1,3,22,23 This switch also coincides with 
the transition of the cells from an epithelial to a 
fibroblastic phenotype, and invasiveness of the 
cancer cells. By extension in the tumor micro-
environment, N-cadherin expression is not 
exclusively found on the cancer cells, but is also 
reactively overexpressed on the surface of 
surrounding fibroblasts and endothelial cells.24 
During cancer progression a multitude of 
extracellular proteinases are present and are now 
known as the cancer degradome.25,28 These 
proteinases are responsible for the shedding of 
several transmembrane protein ectodomains, 
including cadherins and tyrosine kinase receptors.29
In the eighties Damsky et al.30 reported the 
cleavage of E-cadherin in cell culture experiments, 
with the release of an 80 kD extracellular fragment 
(sE-CAD). Later, this fragment was also found in 
different biological fluids, like serum14 and urine17, 
and elevated concentrations were described in the 
serum of gastric carcinoma patients.14,31,32 In recent 
studies the serum sE-CAD concentration was 
considered as an independent predictive factor for 
long term survival33 and can predict tumor 
recurrency after cancer resection.15  
sP-CAD, also an 80 kD fragment, was measurable 
in different biological fluids like semen, milk and 
serum. The concentrations observed in serum were 
approximately 20-fold lower than those of sE-CAD. 
However, no correlation was found with the sE-
CAD levels or the occurrence of breast cancer. 
Paradies and Grunwald9 reported the finding of a 90 
kD fragment of N-cadherin during retinal 
development of the chick, but until now no data 
were reported on sN-CAD in other biological 
fluids. Here we describe the presence of sN-CAD in 
serum by using a direct ELISA or via 
immunoprecipitation and Western blot. sN-CAD is 
a relatively stable molecule, and repeated freezing 
and thawing of the samples does not affect the 
levels. However, EDTA at concentrations higher 
then 0.5 mM reduces the serum concentration of 
sN-CAD dramatically, which confirms the cadherin 
nature of the measured protein. Measuring sN-CAD 
in a population with no evidence of disease resulted 
in a median value of 99 ng/ml which is 
approximately 10 times lower than the levels of sE-
CAD and in the same range as the sP-CAD value 
reported for a similar population.19 This could be 
explained by the number of cells expressing either 
E-, N- or P-cadherin, E-cadherin being the more 
abundant protein. It is no surprise that low levels of 
soluble cadherins are found in the control 
population, as the normal turn over of the cells will 
be responsible for the shedding of these soluble 
cadherins. However when people are suffering from 
a disease, like diabetes or liver cirrhosis, higher 
amounts of sN-CAD are measured (data not 
shown), probably because more protease is shed. 
The same has been observed for sE-CAD.34  
In a population of cancer follow-up patients 
selected for elevated serum concentration of 
different tumor markers, we could find an almost 6-
fold higher median concentration. In our population 
various types of cancers at different stages were 
included. In the future a more stratified study along 
tumor types, grades and stages is mandatory to 
elucidate the clinical performance of sN-CAD as a 
potential tumor marker. Therefore, we have started 
collecting documented serum samples from cancer 
patients. Prostate cancer patients are of particular 
interest, because we found a correlation between 
PSA and sN-CAD, and a recent report 
demonstrated that N-cadherin expression occurs in 
high grade prostate cancer and correlates 
significantly with increasing Gleason patterns.1  
It is currently not clear whether the circulating sN-
CAD possesses a biological function. We found 
recently that sN-CAD stimulates angiogenesis in 
the chorioallantoic membrane assay and in the 
rabbit cornea assay.10 Moreover, it exerts a 
motogenic action on cancer cells in vitro, and we 
found evidence that the fibroblast growth factor 
receptor is involved in both signalling processes. 
Our results indicate that sN-CAD is present in 
human serum, and that significantly higher amounts 
are present in cancer patients than in persons with 
no evidence of disease. Further clinical studies are 
needed to evaluate whether this finding can be the 
basis for the development of potentially useful 
tumor marker for cancer follow-up. 
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Part IV Cadherins and Angiogenesis 
4.1. Introduction to angiogenesis 
 
Blood vessels form a complex network of tubes that carry oxygen and nutrients 
throughout our organism. Vasculogenesis is the assembly of vessels through in situ 
differentiation from endothelial precursors in an embryo, while angiogenesis is the expansion 
of this network by sprouting from pre-existing vessels (Carmeliet and Jain 2000). 
Angiogenesis is regulated by a very sensitive interplay of growth factors and inhibitors, and 
their imbalance can lead to disease. In cancer, diabetic eye disease and rheumatoid arthritis, 
excessive angiogenesis feeds diseased tissue and destroys normal tissue. Conversely, 
insufficient angiogenesis underlies conditions such as coronary heart disease, stroke and 
delayed wound healing, where inadequate blood vessel growth leads to poor circulation and 
tissue death.  
We could demonstrate a novel proangiogenic molecule, named soluble N-cadherin (article: 
“soluble N-cadherin promotes angiogenesis”), by using in vivo assays as a model for 
angiogenesis. The chorioallantoic membrane (CAM)-assay was used as a first screening test 
(Jain et al. 1997). The CAM is a critical component of the oxygen exchange system of the 
developing chick embryo. The membrane is normally highly vascular and transparent, 
allowing any alteration in blood vessel growth to be easily seen. The second test we used was 
the rabbit corneal micropocket assay. The accessibility and the transparency of the cornea 
make it an ideal site for the study of experimental neovascularization (Gimbrone et al. 1974). 
The role of other adhesion molecules during angiogenesis are well described, like PECAM1 
or CD31 (Wright et al. 2002) and Vascular Endothelial (VE)- cadherin (Carmeliet 1999, 
Cavallaro et al. 2006). Endothelial cells express both cadherins, N- and VE-cadherin, but 
have a differential localisation: VE-cadherin is localised at the cell contacts whereas N-
cadherin is dispersed over the whole cell membrane (Dejana 2004). VE-cadherin promotes the 
homotypic interaction between endothelial cells while N-cadherin may be responsible for the 
anchorage of the endothelium with the surrounding cell types expressing N-cadherin such as 
vascular smooth muscle or pericytes (Navarro et al.. 1998; Gerhardt et al.. 2000). These 
mural cells are important for the vascular stabilisation. The stabilisation is regulated by the 
activation of the sphingosine 1-phosphate receptor, which regulates the trafficking of N-
cadherin and strengthening of N-cadherin dependent cell-cell adhesion with mural cells (Paik 
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et al., 2004). The platelet-derived growth factor (PDGF) – PDGF-receptor pathway plays a 
critical role in the recruitment of pericytes to newly formed vessels. The endothelial cells 
secrete PDGF, which signals through PDGF-receptor expressed by the mural cells, resulting 
in proliferation and migration of the pericytes during vessel maturation (Armulik et al. 2005). 
The matrix metalloproteinases are also involved in the recruitment of pericytes by direct 
activation of pericyte invasion, stimulation of proliferation and releasing growth factors from 
the extracellular environment (Chantrain et al. 2006).  
Recent work from the Luo and Radice describes knockdown experiments of N-cadherin in the 
endothelial cells in vivo and in vitro. Loss of N-cadherin caused a significant decrease in VE-
cadherin and p120ctn, and N-cadherin seemed to be important for the proliferation and 
motility of the endothelial cells (Luo and Radice 2005). This opens new perspectives for the 
role of N-cadherin in regulating angiogenesis. Cyclic N-cadherin peptides are known to work 
as antagonists and induce apoptosis in endothelial cells (Erez et al. 2004), while the dimeric 
N-cadherin-peptides, agonists, are able to stimulate neurite outgrowth (Utton et al. 2001). 
Both events are FGF-receptor dependent. Interestingly, the FGF-receptor is known to interact 
with N-cadherin via the HAV binding region in extracellular domain 4 (Williams et al. 2001), 
by this, the FGF-receptor is not internalized and maintains on the membrane, and induces a 
state of continuous cell activation (Suyama et al. 2002). We could speculate that N-cadherin, 
which is present at sites where endothelial cells meet pericytes, engagement to FGF-receptor 
would promote endothelial motility and vessel elongation.  
In the process of angiogenesis, the FGF/FGF-receptor system plays an important role 
(Gerwins et al. 2000). The process of angiogenesis exists out of 3 steps (figure 4.1), namely 
proteolysis, migration/proliferation and maturation and differentiation in new vascular tubes. 
External signals involved in these processes are mainly secreted paracrine factors. Tyrosine 
kinase, G-coupled receptor and serine-threonine receptors are able to evoke an angiogenic 
signal. In this part, some signalling pathways involved in the degradation of the extracellular 
matrix and migration of the endothelial cells are described (see figure 4.1). FGF induces 
proliferation, extracellular matrix degradation, endothelial cell migration and modulation of 
the integrins. Extracellular matrix degradation represents an important step during the first 
phases of the angiogenic process: the plasmin-plasminogen system and matrix 
metalloproteinases cooperate in the degradation of the matrix. FGF upregulates uPA and 
MMPs production in endothelial cells and regulates the expression of the uPA receptor 
(uPAR) on the endothelial cell surface, thus allowing the localisation of the proteolytic 
activity at the migration front (Presta et al. 2005). Association of uPAR with Jak1 and Tyk2, 
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transforms uPAR in a tyrosine kinase receptor and transduce signals via the STAT proteins to 
the nucleus of the endothelial cells (Dumler et al. 1999). Also, the zinc finger transcription 
factor Ets-1 seems to play a key role in the activation of the proteolytic system (Chen et. al 
1997). This transcription factor is upregulated by activation of the VEGF-receptor 2 and FGF-
receptor (Sato et al. 2000). CD44 might also be involved in the upregulation of proteolytic 
enzymes. CD44 lacks kinase activity but associates with Rho GTPases and members of the 
Src family, which leads to the upregulation of uPA and uPAR (Thorne et al. 2004). Multiple 
signalling pathways also stimulate migration: the integrins (for example α5β1 or αv integrins) 
can be activated when they bind to specific substrates like fibronectin (Friedlander et al. 1995, 
Urbich et al., 2002). Angiopoietin, a ligand of the Tie2 receptor is substrate for the α5 
integrins and playing by this a role in endothelial cell migration (Carlson et al. 2001). Binding 
of VEGF to VEGF-receptor 2, induces the phosphorylation of MAPK which modulates actin 
polymerisation (Landry and Huot 1999), but VEGF-receptor 2 can also activate FAK, and this 
non-receptor tyrosine kinase regulates the organisation of the actin cytoskeleton via the 
MAPK pathway or via the PI3K pathway (Abedi and Zachary 1997). The phospholipid 
sphingosine-1-phosphate stimulates the G-coupled receptor EDG1 (endothelial differentiation 
gene 1, also called S1P1) leading to activation of PI3K and can activate Rac. In this way, 
S1P1 is involved in the assembly of the actin cortex and in endothelial chemotaxis (Morales-
Ruiz et al. 2001). PECAM1 or CD31 was recently being found involved in mechanosignal 
transduction, and tyrosine phosphorylation of PECAM1 leads to activation MAPK signalling 
cascade (Fujiwara 2006). Other important signalling molecules involved in angiogenesis are 
wnt, Frizzled, β-catenin, TGFβ, NFκB, G-coupled receptors like Endothelin B receptor, IL-8 
and CXCR1, hypoxia and ROS (Munoz-Chápuli et al. 2004). 
 
 
 
 
 
Legend figure 4.1: Angiogenesis and its signalling pathways 
A. Schematic outline of angiogenesis. Angiogenesis can be divided into a series of temporally 
regulated responses, including protease induction, migration, proliferation and differentiation. VEGF, 
FGF and sN-CAD are important factors involved in angiogenesis (adapted from Gerwins et al. 2000). 
B. Schematic overview of factors and signalling pathways involved in migration and matrix 
degradation by endothelial cells, and recruitment and interaction with the surrounding pericytes. The 
VEGF-VEGFR, FGF-FGFR, PDGF-PDGFR, S1P-S1P1 pathway are involved in the different 
processes of angiogenesis. VE-cadherin and CD31 (or PECAM1) are responsible for the adhesion 
between endothelial cells, while N-cadherin mediate the interaction of the endothelial cell with the 
pericytes. The integrins mediate the interaction with the substrate and has important signalling 
function during migration. The uPA receptor and the CD44 receptor contribute to the upregulation of 
proteases necessary for matrix degradation. 
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Abstract Endothelial cells express two dependent 
intercellular adhesion molecules: VE-cadherin, specific 
for endothelial cells, and N-cadherin, also present in 
neuronal, lens, skeletal and heart muscle cells, 
osteoblasts, pericytes and fibroblasts. While there exists 
a vast amount of evidence that VE-cadherin promotes 
angiogenesis, the role of N-cadherin still remains to be 
elucidated. We found that a soluble 90 kD fragment N-
cadherin promotes angiogenesis in the rabbit cornea 
assay and in the chorioallantoic assay when cleaved 
enzymatically from the extracellular domain of N-
cadherin. Soluble N-cadherin stimulates migration of 
endothelial cells in the wound healing assay and 
stimulates phosphorylation of extracellular regulated 
kinase. In vitro experiments with PD173074 and knock-
down of N-cadherin and fibroblast growth factor 
receptor, showed that the pro-angiogenic effect of 
soluble N-cadherin is N-cadherin and fibroblast growth 
factor receptor dependent. Our results suggest that 
soluble N-cadherin stimulates migration of endothelial 
cells through the fibroblast growth factor receptor. 
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Introduction  
 
Angiogenesis is the process of endothelial cells 
detaching from the vascular wall, invading the 
underlying tissues, and forming tubes that branch and 
organise into anastomotic networks [1]. Angiogenesis 
occurs in physiological (embryology, ovulation, wound 
healing) and in pathological situations (neoplasia, 
diabetic retinopathy, rheumatoid arthritis) [2]. The 
process is regulated by a balance between pro- and anti-
angiogenic molecules, emanating from endothelial, 
stromal and epithelial cells [3], by comprising growth 
factors [4], proteinases [5] and their respective inhibitors 
[6], extracellular matrix molecules [7], and also by cell-
cell and cell-substratum adhesion molecules [8]. 
In vivo angiogenesis in cornea or chorioallantoic 
membrane models, induced by fibroblast growth factor 
(FGF)-2 depends on αvβ3 integrin, whereas 
angiogenesis induced by Vascular Endothelial Growth 
Factor type A (VEGF-A) depends on αvβ5 integrin. 
Antibody to αvβ3 and αvβ5 receptor for vitronectin 
blocked angiogenesis in the chick chorioallantoic 
membrane induced by FGF-2 and VEGF-A respectively 
[9, 10, 11]. Vitronectin not only binds to integrins, but 
also to urokinase plasminogen activator receptor 
(uPAR) [12], both localized at focal adhesion sites. 
uPAR can stimulate endothelial migration in two ways: 
first by plasmin formation and subsequent proteolytic 
degradation of the extracellular matrix [13], and second, 
by direct interaction with vitronectin. Vascular 
Endothelial (VE)-cadherin, a cell-cell adhesion 
molecule specific for endothelial cells serves 
interendothelial cell-cell adhesion and prevents 
endothelial apoptosis [2]. Neural (N)-cadherin is a cell 
adhesion molecule expressed by various cells, like 
neurons, fibroblasts, oocytes, spermatides, Sertoli cells, 
lens cells, osteoblasts and also by endothelial cells. 
Homophilic homotypic N-cadherin interaction in non-
endothelial cells, like in cardiomyocytes serves 
stabilisation of the adherens junction [14]. Heterotypic 
N-cadherin interactions on the other hand stimulate 
migration. Various cancer cells invade the surrounding 
stroma by expressing N-cadherin aberrantly [15], and 
neural cells migrate on oligodendrocytes, expressing N-
cadherin as well [16]. The function of N-cadherin in 
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angiogenesis remains to be elucidated. Homophilic 
heterotypic interactions exists between endothelial and 
stromal cells [17], specifically between endothelial cells 
and pericytes [18, 19]. Also homotypic N-cadherin 
interactions were found at the intercellular junctions in 
endothelial cells. Luo and Radice [20] concluded that N-
cadherin controls vasculogenesis upstream of VE-
cadherin, because loss of N-cadherin in endothelial cells 
results in embryonic lethality at mid-gestation due to 
severe vascular defects. The knock-down of N-cadherin 
caused a significant decrease in VE-cadherin 
expression. 
Our laboratory has provided evidence that an 80 kD 
Epithelial (E)-cadherin fragment (sE-CAD), released by 
plasmin, matrilysin or stromelysin-1, affects epithelial 
tissue integrity, causing loss of cell-cell adhesion and 
gain of invasion [21, 22]. Similar soluble fragments are 
released from cells expressing N-cadherin (sN-CAD), 
and they also exert regulatory functions, such as during 
neurite outgrowth in the retina of the chick embryo [23]. 
The aim of the present study was to identify a possible 
effect of sN-CAD on angiogenesis. We found that sN-
CAD mediated the invasion of endothelial cells into the 
extracellular matrix during angiogenesis, like sE-CAD 
mediated the invasion of cancer cells. Therefore, we 
used N-cadherin expressing mouse sarcoma cells as a 
source of sN-CAD. We found that sN-CAD stimulated 
angiogenesis in vivo. In vitro studies revealed that sN-
CAD is able to stimulate migration of endothelial cells 
through activation of the fibroblast growth factor (FGF)-
receptor. 
 
 
Material and Methods 
 
Cell lines 
 
Human endothelial cells, PSV1, derived from umbilical 
veins (a gift from Véronique Fafeur, Institut Pasteur de 
Lille) [24]. These cells were checked after thawing for 
endothelial cell markers VE-cadherin, N-cadherin and 
factor VIII. All experiments were done with cells 
between passage 3 and 10. Cells were grown on 0,1% 
gelatin-coated dishes in RPMI 1640 (Invitrogen, 
Merelbeke, Belgium) supplemented with 20% foetal 
bovine serum, 100 IU/ml penicillin (Invitrogen), 100 
µg/ml streptomycin (Invitrogen) and 2.5 µg/ml 
Fungizone® (Bristol-Meyers Squibb, Brussels, 
Belgium). S180-NCAD and S180 cells, mouse sarcoma 
cells (a gift from R.M. Mège, INSERM, Paris, France) 
[25] were grown in D-MEM (Invitrogen) supplemented 
with 10% foetal bovine serum and penicillin, 
streptomycin and Fungizone® (see above). The S180-
NCAD cells, used as a source of sN-CAD, are S180 
cells transfected with chicken cDNA encoding for N-
cadherin. The cells were incubated in an 100% water-
saturated atmosphere of 5% CO2 for PSV1 and 10% 
CO2 for S180-NCAD and S180 cells. All cells were 
routinely tested for mycoplasma contamination by 
staining with 4’,6-diamidino-2-phenylindole (DAPI) 
and found negative. 
 
Reagents and antibodies 
 
A 10-mer histidine-alanine-valine (HAV)-comprising 
peptide, identical to amino acids 235-244 in the first 
extracellular domain of N-cadherin (hu N-CAD10, 
LRAHAVDING) [26] served as a peptidomimetic for 
the first extracellular domain (ECD1) of N-cadherin. 
As a control, a scrambled 10-mer peptide (scrambled 
N-CAD10, LHDANVGRIA) (Eurogentec, Seraing, 
Belgium) was included. Recombinant human N-
cadherin/Fc chimera was purchased from R&D 
Systems (Abingdon, UK). Recombinant human basic 
Fibroblast Growth factor (FGF-2) (Sigma, St. Louis, 
Missouri, USA) and recombinant human Vascular 
Edothelial Growth Factor (VEGF-A) (R&D Systems, 
Abingdon, UK) were used as positive control. 
Cortisone Acetate (Sigma) was used to block the 
process of inflammation in the chorioallantoic assay. 
PD173074, a selective inhibitor of the fibroblast 
growth factor receptor [27] was a gift from P. Doherty 
(King’s College London, UK). 
The antibodies used for immunoprecipitation were 
rabbit polyclonal anti-human β-catenin (Sigma), rabbit 
polyclonal anti-human FGF receptor (FGFR1) (Santa 
Cruz Biotechnology, California, USA), mouse 
monoclonal anti-pan cadherin (CH19) (Sigma) and 
mouse IgG isotype control (eBiosciences). The rat 
monoclonal antibody NCD-2 (a gift from C. Redies, 
University Hospital Essen, Germany) [28] was used for 
immunodepletion of sN-CAD out of the medium 
containing sN-CAD. The primary antibodies for 
Western blot were: mouse monoclonal antibody GC-4, 
CH-19 (Sigma) and 13A9 (kindly provided by M.J. 
Wheelock, Department of Biology, University of 
Toledo, Toledo, USA) against N-cadherin, mouse 
monoclonal antibody anti-α-tubulin (Sigma), rabbit 
polyclonal antibody anti-phospho-ERK kinase and 
rabbit polyclonal antibody anti-ERK kinase (Cell 
Signaling technology, Beverly, USA). The secondary 
antibodies were anti-mouse or anti-rabbit antibody 
linked to horseradish peroxidase (Amersham 
Pharmacia Biotech).  
 
Electroporation 
 
PSV1 cells were seeded and, at 70-80% confluency, 
were trypsinized and collected in a NucleofectorTM 
certified cuvette (Amaxa GmBH, Cologne, Germany). 
A mixture of 100 µl Nucleofector Solution and 3 µg of 
short interference RNA (siRNA) was added. The cells 
were electroporated in the Nucleofector electroporator 
with the A34 specific Nucleofector program. siRNAs 
targeting N-cadherin (GenBank/EMBL/DDBJ 
accession number NM-001792) were designed by 
Qiagen (Leusden, The Netherlands). Inhibition of N-
cadherin expression was achieved by RNA interference 
using the following double-stranded oligoribo-
nucleotides: siN-cad2 5’-AGUGGCAAGUGGCAGUA 
AA-3’ and siN-cad3 5’-GGAGUCAGCAGAAGUUG 
AA-3’ [29]. siRNA targeting FGFR1 (GenBank/EMBL 
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/DDBJ accession number NM-000604) were designed 
by DHARMACOM (Lafayette, Co). The FGFR1 
siRNA represented mixtures of four distinct RNA 
duplexes (SmartPool). To verify specificity of the 
knock-down effect, we used an oligonucleotide 
sequence with no known mammalian target (con 5’-
UUCUCCGAACGUGUCACGU) as a control. 
 
Preparation of medium containing sN-CAD 
 
Confluent monolayers were washed 3 times with 
phosphate buffered saline (PBS) and incubated for 2 
hours at 37°C with serum free DMEM to which plasmin 
1 μg/ml (Sigma) was added. Our recombinant N-
cadherin could also be cleaved by plasmin and releasing 
a 90kD fragment. sN-CAD was also spontaneously 
released by the cells: for this subconfluent monolayers 
were washed 3 times with PBS and put on serum free 
medium for 24 hours, washed another 3 times with PBS 
and incubated for 48 hours with serum free medium. 
The medium containing sN-CAD was harvested, 
centrifuged at 250 g for 5 minutes followed by a 
centrifugation step at 2,000 g for 15 minutes and filtered 
through a 0.22 μm filter. The medium containing sN-
cad after plasmin treatment or the medium after 48 
hours contact with the cells was always checked by 
western blot for the presence of the 90 kD N-cadherin 
fragment before use in functional assays (see also Figure 
2). sN-CAD was removed from the medium by 
immunoadsorption as follows. Medium containing sN-
CAD was incubated four times for 1 hour with protein G 
Sepharose 4 fast flow beads (Amersham, Pharmacia 
Biotech) coated with NCD-2 antibody against N-
cadherin. Beads and supernatants were separated and the 
remaining supernatant was finally filtered through a 
0.22 μm filter. Medium without sN-CAD (serum-free 
DMEM) was also incubated for 2 hours at 37°C with 1 
μg/ml plasmin for evaluation of the effect of plasmin on 
angiogenesis. Media with or without sN-CAD were 
concentrated twice (Amicon Ultra 50 kD, Millipore 
Corp., Bedford, MA) before use in angiogenesis assays 
in vivo and in vitro assays. 
 
Rabbit cornea assay 
 
In vivo angiogenesis was studied in the cornea of New 
Zealand rabbits (Charles River, Calco, Como, Italy) 
since this is an avascular and transparent tissue, where 
inflammatory reactions and growing capillaries can be 
easily monitored and changes quantitated by 
stereomicroscopic examination. Slow-release pellets 
were prepared under sterile conditions, incorporating 
the test substances into a casting solution of an ethynil-
vinyl copolymer (Elvax-40, DuPont-De Nemours, 
Wilmington, DE). Rabbits were anaesthetized by 
sodium pentothal (30 mg/kg) and in the lower half of 
the eyes, one or two micropockets were surgically 
made using an iris spatula. The pellets were implanted 
in the micropockets. Pellets impregnated with 
recombinant growth factor FGF-2 (R&D Systems) 
were used as positive control [30]. Subsequent 
daily observations of the implants were made with 
a slit lamp stereomicroscope by two independent 
operators. Angiogenic activity is indicated by the 
number of implants exhibiting neovascularization over 
the total implants studied, and by the angiogenic score. 
The angiogenic score was considered positive when 
budding of vessels from the limbal plexus occurred 
after 3-4 days and capillaries progressed to reach the 
implanted pellet. The angiogenic score is calculated by 
the number of newly formed vessels and by their 
growth rate (number of vessels x distance from the 
limbus) [31]. A density value of 1 corresponded to 0-
25 vessels per cornea, 2 from 25-50, 3 from 50-75, 4 
from 75-100 and 5 for > 100 vessels. The distance from 
the limbus was graded with the aid of an ocular grid. 
The Student’s t-test for unpaired data was used for 
statistics (p < 0.05). 
 
Chorioallantoic membrane (CAM) assay  
 
The CAM assay was performed as described by 
Maragoudakis et al.[32] with some modifications. 
Briefly, fertilized eggs were incubated for 3 days at 
37°C. On day 3, albumen was removed to detach the 
shell from the developing CAM. On day 4, a window 
was made in the eggshell, exposing the CAM, and 
covered with cellophane tape. The eggs were returned to 
the incubator until day 9, prior to application of the test 
compounds. Test compounds and control compound 
(PBS) were poured onto separate sterile discs (11 mm 
diameter), which were allowed to dry under sterile 
conditions. A solution of cortisone acetate (100 μg/disc) 
was poured onto all discs to prevent an inflammatory 
response. Test discs probed with the 165 amino acid 
isoform of VEGF-A served as positive control. On each 
CAM, the disc containing control compound and the 
disc containing test compound were placed at a distance 
of 1 cm. The windows were covered and the eggs were 
incubated until day 11, before assessment of 
angiogenesis. Therefore, the eggs were flooded with 
10% buffered formalin, the discs were removed, and the 
eggs were kept at room temperature for at least 2 hours. 
A large area around the discs was cut out and placed on 
a glass slide, and the vascular density index was 
measured by the method of Harris-Hooker et al. [33]. 
Briefly, a grid containing three concentric circles of 6-, 
8- and 10-mm diameter was positioned on the surface of 
the CAM previously covered by the disc. All vessels 
intersecting the circles were counted. The angiogenic 
index = (t-c)/c, with t the number of intersections in the 
area covered by the test disc and c the number of 
intersections in the area covered by the control disc in 
the same egg. All experiments were performed at least 
twice, and the Mann Whitney U-test was used for 
statistics (p < 0.05). 
 
Wound healing migration assay 
 
Cells were grown in 6-well tissue culture dishes until 
confluent. Medium was removed and the monolayers 
were wounded with a plastic tip. Wounded monolayers 
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were washed 3 times with Ca2+- and Mg2+-containing 
PBS pH 7.4 to remove dead cells. Cell migration 
occurred in 1 ml serum free medium. Wounds were 
marked and measured at time points zero and 16 hours 
with an inverted microscope. The migration distance of 
the untreated cells was put at 100% and compared to 
the treated cultures. The Student’s t-test was used for 
statistics (p < 0.05).  
 
F-actin staining 
 
Cells were grown on glass coverslips in 24 well culture 
dishes until islands of cells were formed. Cells were 
washed with PBS and serum-starved overnight, 
followed by treatment or left untreated for 6 hours in 
serum free medium. Cells were fixed in 3% 
paraformaldehyde, blocked in 50 mM NH4Cl in PBS, 
permeabilized in 0.2% Triton-X-100 in PBS and 
stained with Phalloidin–FITC (Sigma).  
 
Immunoprecipitation and Western blotting 
 
All cell lysates were made from cell cultures at 
approximately 70% confluence. All cells were washed 
three times with PBS, serum-starved overnight, washed 
again three times and treated for the indicated times. 
Cells were lysed with PBS containing 1% Triton X-100 
and 1% Nonidet P-40 and the following protease- and 
phosphatase inhibitors: aprotinin (10 µg/ml), leupeptin 
(10 µg/ml), phenylmethylsulphonyl fluoride (1.72 
mM), NaF (10 mM), NaVO3 (1 mM) and Na4P2O7 (1 
mM) (Sigma). For the co-immunoprecipitation of FGF-
receptor and N-cadherin the following lysis buffer was 
used: 50 mM Tris-HCl pH of 7.5, 150 mM NaCl, 1% 
Nonidet P-40 and the same protease- and phosphatase 
inhibitors as described above. The protein 
concentration was measured using Rc Dc protein assay 
(Bio-Rad), and samples were prepared at equal protein 
concentrations. For immunoprecipitation, equal 
amounts of proteins were first incubated with protein A 
or G Sepharose beads (Amersham Pharmacia Biotech) 
for 30 minutes. After discarding the beads, the 
supernatant was incubated with primary antibody for 3 
hours at 4 °C, followed by incubation with protein A or 
G-Sepharose beads for 1 hour. Sample buffer 
(Laemmli) with 5% 2-mercaptoethanol and 0.012% 
Bromophenolblue was added, followed by boiling for 5 
minutes and separated on 8% SDS-PAGE and 
transferred on a nitrocellulose membrane (Amersham 
Pharmacia Biotech.). Quenching and immunostaining 
were done in 5% non-fat dry milk in PBS containing 
0.5% Tween 20, except for anti-phospho-ERK 
antibody, where 4% bovine serum albumin in PBS 
containing 0.2% Tween 20 was used instead. The 
membranes were quenched for 1 hour, incubated with 
primary antibody for 1 hour, washed four times for 10 
minutes, incubated with horseradish peroxidase-
conjugated secondary antibody for 45 minutes, and 
washed six times for 10 minutes. Detection was carried 
out using enhanced chemiluminescence reagent 
(Amersham Pharmacia Biotech) as a substrate. To 
control for equal loading of total lysates, 
immunostaining with anti-tubulin antibody was 
performed. Quantification of the bands was done using 
Quantity-One software (Bio-Rad). 
 
 
Results  
 
HAV-comprising N-CAD10 peptide promotes 
angiogenesis in vivo  
 
The effect of hu N-CAD10 peptide, comprising the HAV 
motif of the first extracellular domain of N-cadherin, 
was examined in the CAM (chorioallantoic assay) 
(Figure 1a).VEGF-A (1µg/ml), serum free medium 
without and with hu N-CAD10 peptide(2 µg/µl) or with 
scrambled peptide (2 µg/µl) were tested. VEGF-A and 
hu N-CAD10 peptide induced angiogenesis, 45% and 
27,7% respectively, with angiogenic indices that were 
statistically different from the angiogenic index of the 
scrambled peptide. Serum free medium with or without 
scrambled peptide did not induce angiogenesis. 
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Fig.1 Hu N-CAD10 peptide induces angiogenesis. (a) hu N-CAD10 
peptide induces angiogenesis in the CAM. Bars indicate angiogenic 
indices of CAM probed with VEGF-A (1 µg/ml), serum free medium 
without or with hu N-CAD10 peptide 2 µg/µl, or with a scrambled N-
CAD10 peptide 2 µg/µl. Each value (mean + standard deviation) is the 
result of three experiments. In each experiment, 5 eggs were tested per 
condition. * Statistically different from the mean angiogenic index of 
CAMs probed with scrambled peptide (Mann-Whitney U-test, p < 
0.05). (b) Hu N-CAD10 peptide induces angiogenesis in the rabbit 
cornea. Angiogenic scores of rabbit corneas probed with pellets 
impregnated with hu N-CAD10 peptide 200 ng (closed diamonds, 
n=4), hu N-CAD10 peptide 500 ng (closed squares, n=4), hu N-CAD10 
peptide 10 μg (closed triangles, n=3), hu N-CAD10 peptide 50 μg 
(closed circles, n=3), scrambled N-CAD10 peptide 10 μg (open 
triangles, n=3), and scrambled N-CAD10 peptide 50 μg (open circles, 
n=3). Symbols represent the mean + standard deviation of angiogenic 
scores of n number of rabbit corneas tested. *Statistically different 
from the mean angiogenic score of rabbit corneas probed with 
scrambled peptide 10 μg (Student’s t-test, p < 0.05). 
 
Different concentrations of hu N-CAD10 peptide and 
scrambled peptide were tested in the rabbit cornea assay 
(Figure 1b). Mean angiogenic scores of hu N-CAD10 
peptide were concentration dependent. Low doses of hu 
N-CAD10 peptide (200 ng/pellet and 500 ng/pellet) were 
devoid of any angiogenic capacity (0/4 rabbit corneas 
were positive for both concentrations). Pellets 
impregnated with 10 μg or with 50 μg hu N-CAD10 
peptide induced angiogenesis in respectively 2/3 and 3/3 
rabbit corneas. Pellets impregnated with 10 μg or 50 μg 
scrambled N-CAD10 peptide induced angiogenesis in 
only 1 rabbit cornea (1/3 rabbit corneas positive for both 
concentrations). The mean angiogenic score of 
rabbitcorneas probed with pellets impregnated with hu 
N- CAD10 peptide in any concentrations was statistically 
different from the angiogenic score of rabbit corneas 
probed with pellets impregnated with scrambled 
peptide. No inflammatory effect was microscopically 
observed at any of the concentrations tested.  
In these in vivo experiments we could prove that the 
HAV comprising N-cadherin peptide induced 
angiogenesis. 
 
sN-CAD promotes angiogenesis in vivo 
 
To approach the physiological situation, we used for all 
further experiments soluble N-cadherin, which is 
released from the mature N-cadherin after enzymatical 
cleavage. Different enzymes, like MMP, plasmin, 
ADAM10, are able to shed the 90 kD N-cadherin 
fragment. sN-CAD is also present in different body 
fluids of the patients, like the serum [34]. 
 
Fig. 2 Detection of sN-CAD and induction of angiogenesis. (a) 
Immunodepletion of medium containing sN-CAD is performed by 
immunoadsorption with NCD-2 antibody-coated beads removing sN-
CAD. Lanes represent medium containing sN-CAD, immunodepleted 
medium, and sN-CAD linked to NCD-2 antibody-coated beads used 
for immunodepletion of medium containing sN-CAD. As a control for 
sN-CAD containing medium, spontaneously released sN-CAD was 
used. For this purpose, S180-NCAD cells were incubated with serum-
free medium and medium was harvested after 48 hours. As control for 
the sN-CAD depletion we used an isotype control antibody. Media and 
beads were separately dissolved in sample buffer, and proteins were 
separated by SDS-PAGE, blotted and immunostained with NCD-2 
antibody. (b) Bars indicate angiogenic indices of CAMs probed with  
 
 
 
VEGF-A 1 μg/ml, serum free medium, serum free medium with 
plasmin1 μg/ml, medium containing sN-CAD or sN-CAD 
immunodepleted medium. Each value (mean + standard deviation) is 
the result of three experiments. In each experiment, 5 eggs were tested 
per condition. *Statistically different from the mean angiogenic index 
of CAMs probed with serum free medium (Mann-Whitney U-test, p < 
0.05). (c) Angiogenic scores of rabbit corneas, probed with pellets 
impregnated with serum free medium (diamonds, n=4), serum free 
medium with plasmin (triangles, n=5), medium containing sN-CAD 
(squares, n=6), or sN-CAD immunodepleted medium (circles, n=3). 
Symbols represent the mean of angiogenic scores of n number of 
rabbit corneas tested. Flags represent standard deviations. * 
Statistically different from the mean angiogenic score of rabbit 
corneas probed with pellets impregnated with serum free medium 
(Student’s t-test, p < 0,05). 
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Medium from S180-NCAD cells treated with 1 µg/ml of 
plasmin was collected after 2 hours (MsN pl). This 
medium was used in the CAM assay because we 
presumed it contained less growth factors than the 48 
hours medium containing sN-CAD. Medium harvested 
from S180-NCAD cells after a 48 hours incubation-
period with serum-free medium contained 
spontaneously released sN-CAD (MsN) (Figure 2a). 
The immunosignal for sN-CAD was present at 90 kD in 
medium containing sN-CAD, but not when sN-CAD 
was immunodepleted by immunoadsorption. NCD-2 
antibody-treated beads, used for immunoadsorption of 
sN-CAD, also showed an immunosignal for sN-CAD. 
When the medium containing sN-CAD was 
immunodepleted with an isotype control antibody, there 
was no change in MsN and no immunosignal appeared 
in isotype antibody-treated beads. 
The effect of sN-CAD on angiogenesis was examined in 
the chorioallantoic membrane assay (CAM) (Figure 2b). 
VEGF-A, serum free medium, plasmin, medium 
containing sN-CAD and sN-CAD immunodepleted 
medium were tested. Only VEGF-A and medium 
containing sN-CAD induced angiogenesis statistically 
different from serum free medium (p < 0.05). Results 
with plasmin alone were not statistically different from 
those with serum free medium. sN-CAD 
immunodepleted medium did not induce angiogenesis 
compared to serum free medium while sN-CAD 
medium depleted with isotype control antibody gave the 
same angiogenesis response as the non-depleted 
medium.  
Medium containing sN-CAD, sN-CAD immunodepleted 
medium, and serum free medium with and without 
plasmin were also tested in the rabbit cornea assay 
(Figure 2c). The mean angiogenic score of rabbit 
corneas probed with pellets impregnated with medium 
containing sN-CAD, was 7 and statistically different 
from the mean angiogenic score of rabbit corneas 
probed with pellets impregnated with serum free 
medium. 6/6 rabbit corneas probed with pellets 
impregnated with medium containing sN-CAD were 
positive. Pellets impregnated with sN-CAD immuno-
depleted medium or with serum free medium with 
plasmin induced angiogenesis in respectively 1/3 and 
1/5 rabbit corneas. The mean angiogenic score of rabbit 
corneas probed with pellets impregnated with sN-CAD 
immunodepleted medium or with serum free medium 
with plasmin did not differ statistically from the mean 
angiogenic score of rabbit corneas probed with pellets 
impregnated with serum free medium.  
sN-CAD induced angiogenesis the CAM and in the 
rabbit cornea assay. 
 
sN-CAD-stimulated migration in vitro is N-cadherin 
dependent 
 
Since angiogenesis is dependent on migration of 
endothelial cells we were interested whether sN-CAD 
modulates the migration of endothelial cells in the 
wound healing migration assay in vitro. Confluent PSV1 
cultures were serum-starved for a minimum of 24 hours 
to establish quiescence such that the presence of cells in 
the wounded area was owed to cell motility rather than 
cell proliferation. After wounding the monolayer, PSV1 
cells were treated with different concentrations (0,5 to 2 
mg/ml) of the hu N-CAD10 peptide (Figure 3a). 
Endothelial cells migrated perpendicularly to the wound 
in a irregular shaped front and there was a statistically 
difference in migration between hu N-CAD10 peptide 
treated cells (144%) and serum free treated cells (100%) 
 
 
Fig. 3. sN-CAD stimulates migration (a) Confluent monolayers of 
S180-NCAD (white bars) and PSV1 (grey bars) cells were wounded 
with a plastic tip, and treated with hu NCAD10 peptide in a 
concentration range of 0,5 to 2 mg/ml or with serum free medium 
(SFM). The distance of migration of SFM treated cultures was set at 
100%. Each value (mean + standard deviation) is the result of two 
experiments. * Statistically different from the mean relative distance 
of SFM treated cultures (Student’s t-test, p < 0.05) (b) Confluent 
monolayers of S180 (dotted bars), S180-NCAD (white bars) and 
PSV1 (grey bars) cells were wounded with a plastic tip, and treated 
with medium containing sN-CAD (MsN) or serum free medium 
(SFM). Each value (mean + standard deviation) is the result of three 
experiments. * Statistically different from the mean relative distance 
of SFM treated cultures (Student’s t-test, p < 0.05) (c) Confluent 
monolayers of PSV1 cells were wounded with a plastic tip, and treated 
with different concentrations of recombinant N-cadherin (RECN, 1 to 
10 µg/ml). Wounds were marked and measured at time points zero and 
after 16 hours. Bars represent mean values of at least three 
independent experiments and flags indicate standard deviation. * 
Statistically different from the mean migration of SFM treated cultures 
(Student‘s t-test, p < 0.05). (d) Confluent monolayers of siRNA 
transfected PSV1 cells were wounded after 48 hours with a plastic tip 
and subsequently treated with serum free medium (SFM) (white bars) 
or RECN (5 µg/ml) (grey bars). Wounds were marked and scored at 
time zero and after 16 hours. Bars represent mean value of one 
experiment performed in triplet. 
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Next, we treated wounded PSV1 monolayers with serum 
free medium containing sN-CAD (MsN) or with serum 
free medium (SFM) (Figure 3b). Medium containing 
sN-CAD induced migration that was significantly faster 
(228%) than cells treated with SFM (100%). Medium 
from S180, not expressing N-cadherin, was also tested 
in the wound healing assay but had no stimulatory effect 
on the PSV1, S180-NCAD or S180 cells. Moreover, 
recombinant N-cadherin (RECN), which consist of the 
extracellular domain of N-cadherin linked to the Fc 
fragment of human IgG1, stimulated migration of PSV1 
cells in a dose response manner (0 to 10 µg/ml) (Figure 
3c). Untreated PSV1 cells migrated slower compared to 
PSV1 cells treated with 10 µg/ml of RECN (100% 
versus 201%). Other recombinant cadherins like E- or 
P-cadherin did not stimulate the migration of the 
endothelial cells. For all migration assays, knock-down 
and immunocytochemistry experiments we used RECN 
at a concentration of 5 µg/ml. Furthermore, we use this 
in vitro assay to analyse the molecular mechanism of 
sN-CAD stimulated migration. 
We found the presence of full-length N-cadherin to be a 
prerequisite for the stimulatory effect of sN-CAD. 
Migration of S180-NCAD cells, transfected with full-
length N-cadherin, and their parental S180 cells devoid 
of N-cadherin, were compared (Figure 3b). S180-NCAD 
cells treated with their own medium containing sN-CAD 
(MsN) migrated significantly faster then S180-NCAD 
cells treated with SFM (144% and 100% respectively). 
Migration of S180 cells (100%) was not stimulated by 
adding MsN (95%). To confirm the role of N-cadherin 
in sN-CAD-stimulated migration, we used the siRNA 
knock-down approach. N-cadherin expression was 
silenced using siRNA. For this, endothelial cells were 
electroporated with two double stranded 
oligonucleotides derived from different regions of N-
cadherin cDNA. PSV1 cells electroporated either with 
control oligonucleotide or without were used as 
controls. As revealed by Western blot analysis 72 hours 
after transfection, siN-cadherin supresses N-cadherin 
protein expression by 93% (see Figure 5). After 48 
hours, confluent monolayers of electroporated PSV1 
cells were wounded and treated with or without RECN 
(5 µg/ml) (Figure 3d). Control cells were stimulated by 
RECN (5 µg/ml) in the wound healing assay (not: SFM: 
100 and RECN 119% and scramble: SFM 104% and 
RECN 127%). RECN-stimulated migration of N-
cadherin silenced cells was hampered in comparison 
with not or control transfected cells (siNCAD2 SFM 
92% and RECN 95% and siNCAD3 SFM 113% and 
RECN 103%).  
The promigratory effect of sN-cad on PSV1 cells in the 
wound healing assay was dependent on N-cadherin. 
 
 
sN-CAD-stimulated migration in vitro is FGF-receptor 
dependent 
 
We investigated a possible association between full-
length N-cadherin and the FGF-receptor (Figure 4a). 
S180-NCAD cells of approximately 70% confluency 
were lysed and co-immunoprecipitation was performed 
using an antibody against the C-terminus of N-cadherin 
or the C-terminus of the FGF-receptor. After gel 
electrophoresis, proteins were blotted and immuno- 
stained using an antibody against N-cadherin and the 
FGF-receptor. N-cadherin co-immunoprecipitated with 
the FGF-receptor in both cell lines, suggesting a direct 
or indirect interaction between both molecules (as has 
been demonstrated before in cell lines by Suyama et al. 
[35]). 
 
 
 
Fig. 4 sN-cad activates the FGF-receptor. (a) Subconfluent 
monolayers of S180-NCAD were solubilized in low detergent lysis 
buffer and immunoprecipitation was performed with an antibody 
against N-cadherin or the FGF-receptor. The precipitated proteins 
were resolved by SDS-PAGE, and immunoblots were stained with 
antibody against N-cadherin. (b) sN-CAD dissociates the N-
cadherin/FGF-receptor interaction. Serum starved S180-NCAD cells 
were treated 30 minutes with serum free medium (without sN-CAD), 
medium containing sN-CAD (MsN) or RECN (5 µg/ml), followed by 
solubilisation in low detergent lysis buffer. Equal amounts of protein 
were immunoprecipitated with an antibody against the FGF-receptor, 
the precipitated proteins were resolved by SDS-PAGE. Immunoblots 
were stained for N-cadherin. The bands in the immunoblot stained 
with anti-FGFR remained the same. All imunoblots were quantified 
with the Quantity One Software and the relative intensity of the N-
cadherin / FGFR bands are showed in the figure and this figure is 
representative for at least 3 independent experiments performed. (c) 
Confluent monolayers of S180-NCAD (white bars) and PSV1 (grey 
bars) cells were wounded with a plastic tip and subsequently treated 
with serum free medium (SFM), PD173074 (PD, 500nM), RECN (5 
µg/ml), RECN with PD, FGF-2 (12.5 ng/ml) or FGF-2 with PD. 
Wounds were marked and measured at time points zero and after 16 
hours. Bars represent mean values of at least three independent 
experiments and flags indicate standard deviation. * Statistically 
different from the mean migration of SFM treated cultures (Student‘s 
t-test, p < 0.05).  
 
We then examined the effect of sN-CAD on the N-
cadherin/FGF-receptor complex. S180-NCAD cells 
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were used at 70% confluency, followed by serum 
starvation overnight. Cells were treated for 30 minutes 
with serum free medium (SFM), medium containing sN-
CAD (MsN) or RECN. Cells were lysed and co-
immunoprecipitation was performed. In SFM treated 
cells N-cadherin still interacted with the FGF-receptor. 
In sN-CAD treated cells however, N-cadherin was 
dissociated from the FGF-receptor (MsN: 71% and 
RECN 50%)(Figure 4b). 
We then examined the effect of PD173074, a specific 
FGF-receptor inhibitor (Mohammadi et al.,1998 [27]), 
on the migration of PSV1 and S180N-CAD cells. 
Wounded monolayers were stimulated to migrate by 
treatment with RECN or FGF-2 (12.5 ng/ml +heparin 5 
µg/ml) (Figure 4c). PSV1 and S180-N-CAD cells that 
were treated with SFM migrated slower then treatment 
with RECN stimulated migration up to 134% and 127%. 
Addition of 500nM PD173074 to RECN-treated cultures 
counteracted the pro-migratory effect of sN-CAD both 
in PSV1 and in S180-NCAD cells. By contrast, 
PD173074 alone had no effect on migration of cells. 
Next, the FGF-receptor was knocked-down in PSV1 
cells using siRNA. For this, endothelial cells were 
electroporated with a pool of 4 double stranded 
oligonucleotides derived from different regions of FGF-
receptor cDNA. PSV1 cells electroporated either with 
control oligonucleotide or without were used as 
controls. As revealed by Western blot analysis 72 hours 
after transfection, siFGF-receptor supresses FGF-
receptor protein expression by 74% (Figure 5b). After 
48 hours, confluent monolayers of electroporated PSV1 
cells were wounded and treated with or without RECN 
(5 µg/ml) (Figure 3d). Control cells were stimulated by 
RECN (5 µg/ml) in the wound healing assay (not: SFM: 
100% and RECN 199% and scramble: SFM 104% and 
127%). RECN-stimulated migration of FGF-receptor 
silenced cells was hampered in comparison with control 
(siFGFR SFM 76% and RECN 83%). We conclude that 
FGF-receptor expression and activity is necessary to 
observe the pro-migratory effect of sN-CAD in the 
wound healing assay.  
 
 
sN-CAD phosphorylates ERK 
 
The FGF-receptor signals through the ERK pathway to 
stimulate migration (Presta et al., 2005 [11]). We 
therefore examined the possible contribution of ERK as 
signalling component in sN-CAD-stimulated migration 
of endothelial cells. As shown in figure 5a, PSV1 and 
S180-NCAD cells were grown until 70% confluency, 
followed by serum starvation overnight. Cells were 
treated for 30 minutes with SFM, medium containing 
sN-CAD (MsN), RECN (5 μg/ml) or FGF-2 (12.5 
ng/ml), as a positive control, in the presence or absence 
of PD173074. ERK was hardly phosphorylated when 
cultures of the three cell lines were treated with serum 
free medium, but ERK was strongly phosphorylated in 
PSV1 and S180-NCAD cell lines treated with MsN, 
RECN or FGF-2 (Figure 5a). Staining with the anti-
ERK1/2 antibody and anti-tubulin was used as control 
and remained the same in all conditions. The relative 
intensity was calculated by measuring the intensity of 
the p-ERK bands compared to intensity of the total ERK 
bands.  
 
 
 
 
Fig. 5 sN-CAD stimulates ERK phosphorylation (a) sN-CAD induces 
ERK phosphorylation. PSV1 and S180-NCAD were serum starved 
and treated for 30 minutes with serum free medium (SFM), medium 
containing sN-CAD (MsN), RECN (5 µg/ml) or FGF-2 (12.5 ng/ml) 
without or with PD173074 (PD). Equal amounts of protein were 
loaded on SDS-PAGE and stained with an antibody against phospho-
ERK and with an antibody for total ERK. Immunoblots from phospho-
ERK and total ERK were quantified with a Quantity One Software and 
the relative intensity is the value of pERK corrected for the amount of 
total ERK present. This result is representative for at least 3 
independent experiments performed. (b) PSV1 cells, knocked-down 
with oligonucleotides against N-cadherin, the FGF-receptor or a non-
mammalian target, were serum starved after 60 hours and after 72 
hours treated with serum free medium (SFM) or RECN (5 µg/ml) 
during 30 minutes. Cells were lysed and equal amounts of protein 
were loaded on SDS-PAGE. Western blot was stained for N-cadherin, 
the FGF-receptor, phospho-ERK and total ERK and tubulin. All 
imunoblots were quantified with the Quantity One Software. This 
experiment was done twice and gave the same result. 
 
 
PSV1 cells were knocked-down for N-cadherin and 
FGFR, using oligonucleotides, and were serum starved 
after 60 hours and treated for 30 minutes in absence or 
presence of RECN. As revealed by Western blot 
analysis, siRNA efficiently reduced N-cadherin and 
FGF-receptor expression (Figure 5b). Tubulin 
expression was used as control for equal protein 
loading. Again, phosphorylation of ERK was checked. 
(Figure 5b). By knocking-down the expression of N-
cadherin and FGF-receptor phosphorylation of ERK was 
strongly diminished in RECN-treated cell cultures. As 
control these cells were also treated with FGF-2, in the 
FGF- receptor silenced cells ERK could not be 
phosphorylated (data not shown). 
Our experiments suggest that sN-CAD-stimulated ERK 
activation is dependent on expression of N-cadherin 
and FGF-receptor, and FGF-receptor activity. 
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sN-CAD induces cytoskeleton reorganisation  
 
PSV1 and S180-NCAD were seeded at low density on 
glass coverslips. Cells were put on serum free medium 
and cells were treated further with serum free medium, 
or with medium containing sN-CAD (MsN), RECN, 
RECN with PD173074 or PD173074 alone for 6 hours 
(Figure 6). MsN and RECN treatment of PSV1 and 
S180-NCAD cells induced cytoskeleton reorganisation 
of cells: loss of stress fibers, and more filopodia-like 
extensions were formed and cells were more elongated, 
compared to cells treated with SFM. Cytoskeleton 
reorganisation induced by sN-CAD was counteracted by 
adding PD173074. 
 
 
 
Fig 6 sN-CAD induces filopodia formation. PSV1 and S180-NCAD 
were sparsely seeded on glass coverslips and grown until islands of 
cells were formed. Cells were put on serum-free medium overnight 
and treated with serum free medium, medium containing sN-CAD 
(MsN), RECN (5 µg/ml), RECN with PD173074 or PD173074 (500 
nM) alone for 6 hours. Actin filaments were visualised with FITC-
phalloidin. Scale bar, 50µm. 
 
Discussion 
We present here evidence that a hu HAV N-
CAD10 peptide (LRAHAVDING) induces angiogenesis 
in the chorioallantoic membrane and in the rabbit 
cornea assay dose-dependently. Several experiments 
have been published with substratum bound N-
cadherin peptides containing HAV-sequence dimeric 
versions of the N-CAD peptides promote neuronal cell 
survival and neurite outgrowth, while cyclic peptides 
containing the HAV-sequence of extracellular domain 
1 induce FGF-receptor–mediated apoptosis in 
endothelial cells [36] and inhibit neurite outgrowth 
[37]. When presented as soluble molecules, dimeric 
peptides stimulate neurite outgrowth in a manner 
similar to native N-cadherin [38, 39].  
As a better approach of the physiological situation we 
tested the complete ectodomain of N-cadherin (90 kD 
extracellular N-cadherin fragment, sN-CAD) in two 
angiogenesis models in vivo, where sN-CAD 
stimulated angiogenesis in both assays. Different 
proteases have already been described which are able 
to cleave N-cadherin extracellularly, like MMP (matrix 
metallo-proteinases) [23] and ADAM10 (protein with a 
disintegrin and a metalloprotease domain) [40], giving 
rise to a 90 kD sN-CAD fragment. Other proteases like 
presenilin/γ-secretase [41] and caspase-3 [42] are able 
to cleave N-cadherin intracellularly. In tumours sN-cad 
can originate from different cell types, like endothelial, 
fibroblast, cancer cells,…because N-cadherin on the 
cell membrane can be cleaved by multiple proteases 
present in the micro-environment We used plasmin, a 
serine protease, to cleave N-cadherin in its extracellular 
domain, in order to release a 90 kD sN-CAD in culture 
medium of the cells.  
To elucidate the possible working mechanism we 
tested both the medium containing sN-CAD and the 
dimeric recombinant N-cadherin/Fc chimera (termed 
both as sN-CAD) in vitro, which consist of the 
extracellular part of N-cadherin linked to the Fc 
fragment of the human IgG1 antibody. N-cadherin is 
known as a cell-cell adhesion molecule, but it is also a 
pro-migratory factor, since transfection of epithelial 
cells with N-cadherin induces the motile phenotype 
[43, 44]. The domain implicated in migration was 
restricted to 69 amino acids in extracellular domain 4 
[45]. Although the role of N-cadherin in endothelial 
cells is not yet completely clear, it is important for its 
interaction with surrounding pericytes in the micro-
environment [19]. Recent knockdown experiments of 
N-cadherin in endothelial cells showed a role of N-
cadherin during vasculogenesis [20]. Furthermore, 
recom-binant N-cadherin/Fc chimera was shown to 
stimulate neurite outgrowth in an FGF-receptor 
dependent manner [46], but nothing has been reported 
to date about its function in migration and invasion of 
endothelial cells. We found that sN-CAD stimulates 
the migration of endothelial cells and this event 
requires the presence of N-cadherin on the acceptor 
cells, because silencing of N-cadherin by siRNA in the 
endothelial cells strongly reduced the sN-CAD 
promigratory effect and S180 (N-cadherin negative, 
parent) cells cannot be stimulated by sN-CAD 
containing medium nor by recombinant N-cadherin. 
We observed no differences in the cell-cell adhesion of 
endothelial cells when they were treated with sN-CAD 
or HAV N-CAD10 peptide (data not shown). So, the 
sN-CAD mediated migration is not due to alterations in 
cell-cell adhesion. 
We also investigated the role of the FGF-receptor in the 
pro-migratory effect of sN-CAD, because we could 
demonstrate that N-cadherin co-immunoprecipitates 
with the FGF-receptor. It was shown in literature that in 
neuronal cells N-cadherin interacts directly with the 
FGF-receptor via the HAV-binding region present in 
extracellular domain 4 of N-cadherin [48], and by this 
prolongs the activation of the FGF-receptor by 
stabilisation of the receptor on the membrane [35]. In 
pancreatic tumour cells as well as in neurons N-cadherin 
can trigger FGF-receptor signalling independently from 
FGF [48, 49]. Indeed we were able to reduce sN-CAD 
mediated migration of endothelial cells in two ways. 
First, by using a specific inhibitor PD173074, which 
binds to the ATP pocket of the FGF-receptor [27], and 
second by knocking down the FGF-receptor by siRNA. 
FGF stimulated chemotaxis and/or chemokinesis in 
endothelial cells requires the activation of the ERK 
signalling pathway [11]. We confirmed that both sN-
CAD containing medium and recombinant N-cadherin 
stimulated phosphorylation of ERK, and this was 
abolished by addition of the FGF-receptor inhibitor, 
PD173074. However, the stimulated phosphorylation of 
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ERK induced by sN-CAD containing medium could not 
be blocked by the PD173074, presumably because of 
the presence of other growth factors. 
 
 
 
Fig. 7. Hypothetical model of the sN-cadherin-mediated angiogenesis 
pathway. N-cadherin (N-CAD) contains an HAV (Histidine-Alanine-
Valine)-sequence in its first extracellular domain and an HAV-
binding motif in extracellular domain 4. In quiescent endothelial 
cells, N-cadherin is directly linked to the HAV-sequence present on 
the FGF-receptor (FGFR). In the presence of proteases, endothelial 
cells are activated by soluble N-cadherin (sN-CAD). sN-CAD, a 90 
kD fragment, is directly released by proteases. sN-CAD can directly 
or indirectly interact with the FGF-receptor. sN-CAD stimulates the 
migration of the endothelial cells, sN-CAD phosphorylates 
extracellular regulated kinase (p-ERK), which can be blocked by 
adding PD173074, it stimulates the formation of filopodia and 
activates Cdc42. All these cell activities promote sN-CAD or the 10-
mer HAV peptide (LRAHAVDING) mediated angiogenesis. 
 
Cytoskeletal reorganisation is essential for migration of 
endothelial cells and therefore the formation of new 
vessels. sN-CAD stimulates the loss of stress fibers and 
the formation of filopodia and cells become elongated. 
Again these effects are N-cadherin- and FGF-receptor-
dependent as evidenced by using siRNA in endothelial 
cells and N-cadherin deficient S180 cells. It is 
noteworthy that sN-CAD stimulates the activation of 
Cdc42 which usually held responsible for the formation 
of filopodia, and diminishes the activation of RhoA 
(data not shown).  
Comparable results were published with another neural 
cell adhesion molecule, L1. Plasmin is responsible for 
the posttranslational cleavage of L1 in fibronectin 
domain 3 of the molecule with the release of a 150 kD 
fragment in the medium [51], and ADAM10 can also 
cleave L1 extracellularly with the shedding of a 200 kD 
fragment. Both L1 extracellular fragments can 
stimulate cell migration [52]. Furthermore, pro-
migratory effects were observed also with other soluble 
cadherins, like sE-cadherin [22].  
In “quiescent” endothelial cells N-cadherin is 
responsible for the adhesion with other endothelial 
cells and with stromal cells like pericytes (Figure 7). 
However in the micro-environment of tumours and in 
inflammatory processes, numerous proteases activate 
endothelial cells to form new blood vessels. We 
hypothesize that sN-CAD plays an important role in 
this process. Proteases cleave the extracellular 
fragment of N-cadherin from stromal cells, endothelial 
cells or N-cadherin expressing tumour cells. sN-CAD 
will on its turn interact with the N-cadherin/FGF-
receptor complex present on endothelial cells and 
stimulate the migration of endothelial cells in an FGF-
receptor-dependent manner. sN-CAD activates the 
ERK pathway, leading to upregulation of protease 
expression, like plasmin and MMP, via the zinc-finger 
transcription factor Ets-1 [52], which has indeed been 
shown to induce angiogenesis [53]. By this an 
autocrine loop is formed: newly expressed proteases on 
their turn are responsible for the formation of sN-CAD 
which again induces migration of the endothelial cells. 
Our results indicate that sN-CAD stimulates 
angiogenesis in vivo and migration of endothelial cells 
in vitro through an N-cadherin/ FGF-receptor complex. 
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Part V Cadherins as targets for (anti-) invasive agents 
5.1. Overview of factors influencing the cadherins 
 
E-cadherin can be (down) regulated at various levels: several inactivating mutations 
were already found in lobular breast carcinoma (Berx et al. 1996), gastric cancer (Suriano et 
al. 2003a and b; Suriano et al. 2005), thyroid carcinoma (Rocha et al. 2004) and gynaecologic 
cancer (Risinger et al. 1994). Not only genomic mutations but also abnormal epigenetic 
methylation can significantly contribute to gene silencing and carcinogenesis. Methylation is 
particularly often observed in the CpG islands of the promoter regions. However, there are 
considerable differences between genes in the incidence of methylation. Examples of 
methylated tumour suppressor genes are APC, Rb and E-cadherin (Curtis and Goggins 2005, 
Graff et al. 1995). Promoter methylation of the E-cadherin gene is related to EMT transition 
in breast carcinoma cell lines, while the E-cadherin inactivating mutation is not involved 
(Lombaerts et al. 2006). Another way to deregulate the E-cadherin expression is at the level 
of transcription. In the promoter of E-cadherin, specific regulatory elements are present: 
CCAAT box, GC Box and CANNTG (E-) box, where different repressors bind. Some 
examples of transcriptional repressors are SNAIL (Battle et al. 2000), SIP1 (Comijn et al. 
2001), SLUG (Hajra et al. 2002), E12/E47 (Perez-Moreno et al. 2001), Twist1 (Yang et al. 
2004) and DeltaEF1 (Eger et al. 2005). Others, like p300, AML1, SP1, HNF3 (Liu et al. 
2005) and SMAD4 (Muller et al. 2002) are positive regulators of E-cadherin. Furthermore, 
the transactivation of other cadherins like N-, P- or OB-cadherin can also deregulate the E-
cadherin/catenin complex. The function of the E-cadherin/catenin complex can also be 
influenced by phosphorylation of the associated catenins via cytokines like EGF (Shiozaki et 
al. 1995), IGF-1 (André et al. 1999) or heregulinβ1 (Stove et al. 2005, Stove et al.) or by 
proteolysis and ectodomain shedding via for example MMP’s (Noë et al. 2001), ADAM10 
(Maretzsky et la 2005) or plasmin (Ryniers et al. 2002). Environmental factors also influence 
the E-cadherin/catenin complex: xanthohumol, present in hop, is able to stimulate the function 
of the complex (Vanhoecke et al. 2005, see article 5.3), hypotonic stress (Kippenberger et al. 
2005) and other factors are extensively reviewed by Van Aken et al.. 
Not only E-cadherin but also P-cadherin is regulated at different levels: two mutations are 
described, one missense mutation (R503H) is altering the Ca-binding domain (Indelman et al. 
2002) and the other one is a nonsense mutation (Y615X) resulting in blocking of the P-
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cadherin translation (Indelman et al. 2005). Both mutations cause hypothrichosis with 
juvenile macular dystrophy in human. P-cadherin is expressed aberrantly in different 
carcinomas, for example, P-cadherin is expressed in high-grade ductal carcinoma in situ 
which lacks the estrogen receptor (Paredes et al. 2002). When the antiestrogen, ICI182780, 
was added to P-cadherin negative and ER positive breast carcinoma cells this resulted in 
upregulation of P-cadherin (Paredes et al. 2004, see article 5.4). Not only the estrogen 
receptor has seemed to play role in the aberrant expression of P-cadherin but also the 
methylation status of the promoter. The P-cadherin expression in breast cancer might be 
regulated by promoter hypomethylation (Paredes et al. 2005). 
Furthermore, N-cadherin is also influenced by multiple intracellular and extracellular factors 
(see section 2.2 and Table 5.1., Derycke and Bracke 2004). So far, there were no data about 
any mutation in N-cadherin. At the epigenetic level, the transcription factor NFκB is 
enhancing the N-cadherin promoter activity in melanoma cells (Kuphal and Bosserhof 2006). 
Furthermore, the growth factor TGFβ (Maeda et al. 2005) and the extracellular matrix 
molecule collagen type 1 (Shintani et al. 2006) induce N-cadherin expression at the mRNA 
and the protein level, and this results in EMT. While the nuclear protein HMGN1 (high-
mobility group nucleosome binding domain 1) downregulates the N-cadherin expression 
(Rubinstein et al. 2005). Finally, the protease ADAM10 downregulates the function of the N-
cadherin/catenin complex by ectodomain shedding and alters by this the N-cadherin mediated 
cell-cell adhesion (Reiss et al. 2005).  
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Table 5.1.: Mechanisms of regulation of the N-cadherin/catenin complex 
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exander et al. 2006 
Notch1 Melanoma Enhancing cell-cell adhesion Liu et al. 2006 
NFκB Melanoma Enhancing N-cadherin promoter activity Kuphal and Bosserhoff 
2006 
Gelsolin Mammary cells Knockdown of gelsolin, induction of EMT Tanaka et al. 2006  
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The Heregulin/Human Epidermal Growth Factor Receptor as a
New Growth Factor System in Melanoma with MultipleWays of
Deregulation
Christophe Stove,Veronique Stove, Lara Derycke,Veerle Van Marck, Marc Mareel, and Marc Bracke
Laboratory of Experimental Cancerology, Department of Radiotherapy and Nuclear Medicine and the Department of Clinical Chemistry, Microbiology
and Immunology, Ghent University Hospital, Ghent, Belgium
In a screening for new growth factors released by mela-
noma cells, we found that the p185-phosphorylating ca-
pacity of a medium conditioned by a melanoma cell
line was due to the secretion of heregulin, a ligand for
the human epidermal growth factor receptor (HER)
family of receptor tyrosine kinases. Expression of
heregulin, including a new isoform, and secretion
of functionally active protein was found in several cell
lines. Receptor activation by heregulin, either autocrine
or paracrine, resulted in a potent growth stimulation
of both melanocytes and melanoma cells. Heregulin
receptor HER3 and coreceptor HER2 were the main
receptors expressed by these cells. Nevertheless, none
of the cell lines in our panel overexpressed HER2 or
HER3. In contrast, loss of HER3 was found in two cell
lines, whereas one cell line showed loss of functional
HER2, both types of deregulations resulting in unre-
sponsiveness to heregulin. This implies the heregulin/
HER system as a possible important physiologic growth
regulatory system in melanocytes in which multiple
deregulations may occur during progression toward
melanoma, all resulting in, or indicating, growth
factor independence. Key words: heregulin-neuregulin-1/
autocrine-paracrine communication/receptor tyrosine kinases.
J Invest Dermatol 121:802 ^812, 2003
G
rowth of melanocytes and their malignant counter-
parts is regulated by a variety of cytokines and other
polypeptides (LaŁ zaŁ r-MolnaŁ r et al, 2000; Payne and
Cornelius, 2002). Under physiologic conditions,
melanocytes depend for their survival on paracrine
stimulatory factors provided by the surrounding keratinocytes
(Meier et al, 1998). Transformed melanocytes have a decreased de-
pendence on paracrine stimulation, which facilitates their survival
outside their natural environment, the epidermis. Changes in sev-
eral growth factor systems contribute to this decreased depen-
dence. Whereas overexpression of receptor tyrosine kinases
(RTK) may lead to increased growth factor sensitivity and con-
stitutive signaling, loss of expression may result in insensitivity to
inhibitory factors or indicate growth factor independence (Easty
and Bennett, 2000). Also, the pro¢le of growth factors secreted
by melanoma cells is frequently altered, compared to melano-
cytes.Whereas de novo expression of some growth factors by mel-
anoma cells may stimulate proliferation of these cells in an
autocrine loop, these factors may act on the surrounding cells as
well, stimulating or inhibiting these cells in a paracrine way
(Halaban, 2000; LaŁ zaŁ r-MolnaŁ r et al, 2000; Ruiter et al, 2002).
The human epidermal growth factor receptor (HER) family
of RTK consists of four members, epidermal growth factor
receptor (EGFR)/erbB1/HER1, neu/erbB2/HER2, erbB3/HER3,
and erbB4/HER4 (Olayioye et al, 2000; Yarden and Sliwkowski,
2001). Although constitutive activation of these receptors, owing
to overexpression, frequently occurs in various types of cancers
(ReŁ villion et al, 1998), this does not seem to be common in mela-
noma (Natali et al, 1994; Korabiowska et al, 1996; Persons et al,
2000; Fink-Puches et al, 2001). Constitutive RTK signaling may
also be the result of truncation, mutation, association with other
cell-surface proteins, transactivation via other receptors, or the
presence of autocrine loops (Blume-Jensen and Hunter, 2001;
Gullick, 2001). The latter may result from the aberrant expression
of HER ligands.
Neuregulin-1 is the term for a family of proteins derived by
alternative splicing from a single gene, functioning as ligand for
HER3 and HER4 (Holmes et al, 1992; Yarden and Sliwkowski,
2001). At present, at least 24 splice variants have been identi¢ed
in di¡erent species, of which 10 were found in humans. Alterna-
tive splicing at the N-terminus results in three types of proteins:
heregulins (HRG, type I) (Holmes et al, 1992), glial growth factors
(type II) (Marchionni et al, 1993), and sensory- and motor-neu-
ron-derived factors (type III) (Ho et al, 1995). Further alternative
splicing of HRG at the EGF-like domain (a or b), the C-terminal
part of the EGF-like domain (1, 2, or 3) (Fig 1), and/or at the
intracellular tail (a, b, or c) gives rise to closely related proteins,
di¡ering in size and cellular localization and having distinct
receptor activation potentials and functions (Wen et al, 1994;
Pinkas-Kramarski et al, 1996; Meyer et al, 1997). Transmembrane
Reprint requests to: Marc Bracke, Laboratory of Experimental Cancer-
ology; Department of Radiotherapy and Nuclear Medicine, De Pintelaan
185, Ghent University Hospital, B-9000 Ghent, Belgium. Email: brackemarc
@hotmail.com
Abbreviations: bFGF, basic ¢broblast growth factor; CM, conditioned
medium; EGF, epidermal growth factor; HER, human EGF receptor;
HRG, heregulin; MAPK, mitogen-activated protein kinase; PBS, phos-
phate-bu¡ered saline; rHRG-b1, 7-kDa recombinant EGF-like domain of
heregulin isoform b1; RTK, receptor tyrosine kinase.
Manuscript received March 24, 2003; accepted for publication May 6,
2003
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HRG typically function as precursor molecules that are subject to
the action of metalloproteinases. This results in the release of the
extracellular domain that may subsequently bind to nearby re-
ceptors (autocrine/paracrine action) (Montero et al, 2000; Shira-
kabe et al, 2001). Necessary and su⁄cient for receptor binding is
the EGF-like domain; the roles of the various other domains have
not been fully elucidated yet. Some regulation may be exerted by
the cytoplasmic tail (Liu et al, 1998a, b; Han and Fischbach, 1999)
or by interaction of the N-terminal heparin-binding motif with
other molecules such as cell surface heparan sulfate proteoglycans
(Li and Loeb, 2001). A recently proposed model for ligand-
mediated HER activation proposes receptor conformational
changes as the driving force for receptor activation (Cho and Lea-
hy, 2002; Garrett et al, 2002; Ogiso et al, 2002). For HRG, this
would mean that binding of its EGF-like domain to HER3 or
HER4 leads to an altered receptor conformation, thus promoting
dimerization with another HER, preferentially HER2. Hetero- or
homodimerization of the receptors leads to trans- and autopho-
sphorylation, creating speci¢c docking sites for signal transduc-
tion molecules (Dankort et al, 2001; Hellyer et al, 2001) and
initiating further downstream signaling.When only HER2 and
HER3 are present, this model of HRG-induced receptor activa-
tion implies that HER3, which lacks catalytic activity (Guy et al,
1994; Sierke et al, 1997), can only become phosphorylated in trans
by heterodimerization with HER2 (Kim et al, 1998). Conversely,
HER2, for which no direct ligand has been identi¢ed yet, only
becomes activated after ligand binding to HER3.
Based on the initial observation that conditioned medium
(CM) from a melanoma cell line induced a strong phosphoryla-
tion of HERs in MCF-7 mammary cancer cells, we decided to
dissect the role of this putative ligand^receptor system in mela-
nocytes and a panel of melanoma cell lines. Here, in 4 of a panel
of 13 melanoma cell lines, we describe a number of deregulations
in the HRG/HER system. Production and release of functionally
active HRG in the medium were found in three cell lines and
resulted in an autocrine loop in one case. Whereas exogenous
HRG-stimulated growth of the majority of melanoma cell lines
and melanocytes, three cell lines did not respond to HRG, owing
to the absence of HER3 or owing to a functionally incompetent
HER2.
MATERIALS ANDMETHODS
Cell lines The cell lines were obtained as follows: 530 and BLM
melanoma cell lines from L. Van Kempen (University of Nijmegen, the
Netherlands); A375 melanoma cell line from J. Hilkens (NKI, the
Netherlands); Bowes melanoma from G. Opdenakker (Rega Institute,
Belgium); DX3 and DX3azaLT5.1 melanoma cell lines from J. Ormerod
(Imperial Cancer Research Fund, UK); FM3/D, FM3/p, FM45, and FM87
melanoma cell lines from J. Zeuthen (Danish Cancer Society, Denmark);
HMB2, MeWo, and MJM melanoma cell lines from D. Rutherford
(Rayne Institute, St Thomas Hospital, UK); MCF-7/6 mammary carci-
noma cell line (further called MCF-7) from H. Rochefort (University
of Montpellier, France); COLO-16 squamous skin carcinoma cell line and
SK-BR-3 mammary carcinoma cell line from C. De Potter (Ghent Univer-
sity Hospital, Belgium); and MDA-MB-231 breast cancer cell line from
American Type Culture Collection (Manassas, VA). Cell lines were
routinely maintained in the following media (Gibco BRL, Belgium):
RPMI 1640 (FM and COLO-16 cell lines), L15 (MDA-MB-231), 50% Dul-
becco’s modi¢ed Eagle’s medium/50% Ham’s F12 (MCF-7), or Dulbecco’s
modi¢ed Eagle’s medium (all other cell lines). All media for rou-
tine culture contained 10% heat-inactivated fetal bovine serum (Greiner
Bio-One, Belgium), 100 IU per mL penicillin, 100 mg per mL strepto-
mycin, and 2.5 mg per mL amphotericin B. Epidermal melanocyte primary
cultures were obtained from neonatal foreskins and established in M199
medium (Gibco BRL), supplemented with 2% fetal bovine serum, 10^9 M
cholera toxin, 10 ng per mL basic ¢broblast growth factor (bFGF), 10 mg
per mL insulin, 1.4 mM hydrocortisone, and 10 mg per mL transferrin (all
from Sigma, Belgium). Postprimary cultures were maintained in low-
calcium (0.03 mM) M199 medium, supplemented with the same factors
and 10% fetal bovine serum. The melanocytic origin of all melanoma cell
lines was checked by immunocytochemistry using two antibodies against
melanoma-speci¢c proteins, HMB45 (Enzo Diagnostics, Farmingdale,
NY) and NKI/C3 (Biogenex, San Ramon, CA). All melanoma cell lines
were positive for at least one of these markers (data not shown). Because
most of the experiments were carried out with Bowes melanoma cells,
which were only positive for NKI/C3, additional electron microscopy was
performed to con¢rm the presence of premelanosome-like structures in
this nonpigmented cell line (data not shown).
Antibodies and reagents Primary antibodies used were: rabbit
polyclonal anti-HER1, -2, -3, and -4 and anti-HRG precursor antibodies
(Santa Cruz Biotechnology, Santa Cruz, CA), mouse monoclonal
antitubulin (Sigma), mouse antiphospho-mitogen-activated protein kinase
(MAPK; Westburg, the Netherlands), and antiphosphotyrosine antibody
RC20 conjugated to horseradish peroxidase (Transduction Laboratories,
Lexington, KY). Goat anti-HRG-a and recombinant HRG-b1, consisting
of the EGF-like domain of HRG (rHRG-b1, used at 10 ng/mL unless
indicated otherwise), was purchased from R & D Systems (Abingdon,
UK). Full-length recombinant HRG-b1 was obtained from Laboratory
Vision (Fremont, CA), whereas heparin, PD168393 (used at 2 mM, unless
indicated otherwise), and PD98059 were from Calbiochem (Darmstadt,
Germany).
Preparation of CM Subcon£uent monolayers were washed three times
with phosphate-bu¡ered saline (PBS), incubated for 24 h with serum-free
medium, and washed again three times with PBS, followed by a 48-h
incubation with serum-free medium. The latter medium was cleared from
cells by 5 min centrifugation at 250 g. The resulting supernatant was
centrifuged for an additional 20 min at 2000 g to remove cell debris,
¢ltered through a 0.2-mm ¢lter, and stored at ^201C until use. To isolate
the heparin-binding fraction from the CM, the latter was depleted from
heparin-binding factors by triple precipitations with heparin beads (Bio-
Rad, Hercules, CA). Elution of the heparin-binding fraction was done
with 1 M NaCl, followed by desalting and dilution in fresh serum-free
medium.
Figure1. Neuregulin-1 splicing variation in the EGF-like domain.
The scheme depicts the genomic organization of the exons encoding
the region surrounding the variable part of the EGF-like domain of the
NRG-1 gene. The locations of the sequences that are complementary to
the primers used for RT-PCR are indicated with S and AS for the sense
and antisense primers, respectively. The table indicates all possible splicing
variants within this domain with their expected ampli¢cation product
lengths in base pairs (bp), when using the indicated primer pair. NA, not
ampli¢ed; EGFc, sequence common in the EGF-like domain of all HRG;
hatched, coding sequence for the HRG transmembrane domain; asterisk, lo-
cation of the stop codon in case of the (a)^(b) combination; ?, putative
isoform not yet characterized.
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Western blotting and (immuno)precipitation All lysates were
made of cells of approximately 90% con£uence. For phosphorylation
experiments, cells were washed three times with PBS, serum-starved
overnight, washed again three times with PBS, and treated with serum-
free medium for the indicated times. Before making all lysates, the cells
were washed three times with PBS. Cells were lyzed with PBS containing
1% Triton X-100, 1% Nonidet P-40 (Sigma), and the following protease
inhibitors: aprotinin (10 mg/mL), leupeptin (10 mg/mL) (ICN Biomedicals,
Costa Mesa, CA), phenylmethylsulfonyl £uoride (1.72 mM), NaF (100 mM),
NaVO3 (500 mM), and Na4P2O7 (500 mg/mL) (Sigma). After clearing the
lysates, protein concentration was determined using Rc Dc protein assay
(Bio-Rad), and samples were prepared such that equal amounts of protein
were to be loaded. For immunoprecipitation, equal amounts of protein
were ¢rst incubated with protein A^Sepharose (Amersham Pharmacia
Biotech, UK) for 30 min. After discarding the beads, the supernatant was
incubated with primary antibody for 3 h at 41C, followed by incubation
with the added protein A^Sepharose beads for 1 h. For heparin and
streptavidin precipitations, cell lysates were incubated with heparin
beads (Bio-Rad) or streptavidin beads (Sigma). Sample bu¡er (Laemmli)
with 5% 2-mercaptoethanol and 0.012% bromophenol blue was added,
followed by boiling for 5 min and separation of proteins by gel
electrophoresis on a 8 or 12% polyacrylamide precast gel (Invitrogen, San
Diego, CA) and transfer onto a nitrocellulose membrane (Amersham
Pharmacia Biotech). Quenching and immunostaining of the blots were
done in 5% nonfat dry milk in PBS containing 0.5% Tween 20, except
for RC-20 and antiphospho-MAPK antibodies, where 4% bovine serum
albumin in PBS containing 0.2% Tween 20 was used instead. The
membranes were quenched for 1 h, incubated with primary antibody for 1
h, washed four times for 10 min, incubated with horseradish peroxidase-
conjugated secondary antibody for 45 min, and washed six times for 10
min. Detection was done using enhanced chemiluminescence reagent
(Amersham Pharmacia Biotech) as a substrate. To control for equal
loading of total lysates, immunostaining with antitubulin antibody was
performed routinely (not shown). Quanti¢cation of bands was done using
Quantity-One software (Bio-Rad).
RT-PCR, cloning, and sequencing Total RNA was extracted from
approximately 5106 cells using the Qiagen RNeasy kit (Qiagen,
Chatsworth, CA). One microgram of total RNA was reverse transcribed
with oligo(dT) primers using the Qiagen RT kit (Qiagen) according to
the manufacturer’s instructions. HRG cDNA encoding all transmembrane
isoforms was ampli¢ed using the sense primer 50 -CTGTGTGAATGGAG-
GGGAGTGC-30 (complementary to a sequence encoding a conserved
part of the EGF-like domain) and the antisense primer 50 -GACCACAAG-
GAGGGCGATGC (complementary to a sequence encoding part of the
transmembrane domain) (Fig 1). As a control (not shown), b2-microglobulin
cDNA was ampli¢ed using the sense primer 50 -CATCCAGCGTACTC-
CAAAGA-30 and the antisense primer 50 -GACAAGTCTGAATGCTC-
CAC-30 to generate a 165-bp product. PCR was performed on 250 ng
template cDNA using the QiagenTaq PCR kit (Qiagen) according to the
manufacturer’s instructions. Reactions were done in a Minicycler (Biozym,
the Netherlands) with an initial denaturation at 941C for 3 min, 35 cycles
of 941C for 50 s (denaturation), 611C for 50 s (annealing), and 721C for 1
min (elongation), followed by a ¢nal extension at 721C for 10 min. For
cloning of the HRG ampli¢cation products, the HRG sense and antisense
primers were extended at the 50 end with GCCGGATCCG, creating a
BamHI restriction site, and with TCCGAATTC, creating a EcoRI
restriction site, respectively. The resulting ampli¢cation products were
either separated by agarose gel electrophoresis, followed by gel extraction
using Qiagen gel extraction kit (Qiagen), or used directly for digestion
with BamHI and EcoRI restriction enzymes (Roche Diagnostics,
Germany). Digested products were ligated into dephosphorylated BamHI/
EcoRI-digested pIRES2-EGFP vector (Clontech, Palo Alto, CA). After
transformation of competent DH5a bacteria with the ligated product, the
kanamycin-resistant clones were screened by PCR using primers com-
plementary to sequences of the pIRES2-EGFP vector surrounding the
insert. This resulted in PCR products of di¡erent lengths, corresponding
to di¡erent HRG isoforms, which were subjected to sequencing (Applied
Biosystems, Foster City, CA). The sequence of the a4-isoform was
submitted to GenBank (Accession Number AY207002).
Scattering assay MCF-7 cells were seeded until small islands were
formed. The cells were washed three times with PBS and were serum-
starved overnight. The following day, the cells were washed again three
times with PBS, after which the treatments (all in serum-free medium)
were applied for 2 h. Pictures were taken with an Axiovert 200M
microscope (Carl Zeiss Vision, Germany) on living cultures or after the
cultures had been ¢xed with crystal violet (0.5% in 4% formaldehyde,
30% ethanol and 0.17% NaCl) for 15 min.
Cell proliferation assays A total of 12,500 melanocytes were seeded in
the wells of a 96-well plate in 100 mL of Dulbecco’s modi¢ed Eagle’s
medium/Ham’s F12 medium containing 10% fetal bovine serum. After
attachment, 100 mL of medium, supplemented with growth factors as
indicated, was added. After 5 days, metabolic activity was measured with
a colorimetric assay. Brie£y, 100 mL of medium was taken o¡, followed by
the addition of 20 mL of 5 mg per mL 3-(4,5-dimethyl-thiazol-2-yl)-2,5-
diphenyltetrazolium bromide (Sigma) in PBS. After a 2-h incubation and
removal of all £uid, the colored formazan formed was dissolved in 100 mL
of dimethyl sulfoxide and absorption was measured with an ELISA reader
at 490 nm. Proliferation of melanoma and MCF-7 cells was measured with
the sulforhodamine B colorimetric assay. A total of 5000 cells were seeded
in 96-well plates, allowed to attach, and treated as indicated. After 5 days,
50 mL of 50% trichloroacetic acid was added to the culture medium,
followed by an incubation of 1 h at 41C. The wells were rinsed with
water, dried, incubated with 100 mL of sulforhodamine B (0.4% in 1%
acetic acid) for 30 min, rinsed with 1% glacial acetic acid, and dried
again. Bound dye was dissolved in 200 mL of 10 mM Tris bu¡er, pH 10.5,
and absorption was measured with an ELISA reader at 490 nm.
Annexin V staining Melanocytes were seeded on a collagen type I
gel for 4 days. After taking photographs, adherent cells were detached
with a swab and brought together with £oating cells. Annexin V staining
was performed with Annexin V^PE (Becton Dickinson Biosciences,
Mountain View, CA), according to the manufacturer’s instructions.
The cells were analyzed on a FACSCalibur £ow cytometer (Becton
Dickinson) with an argon^ion laser tuned at 488 nm and a helium^neon
diode laser at 635 nm. Forward light scattering, orthogonal scattering, and
two £uorescence signals were stored in list-mode data ¢les. Data
acquisition and analysis were done using the CellQuest software (Becton
Dickinson). Additional propidium iodide (PI) staining was performed to
rule out cells that were necrotic (AnnexinVþ and PIþ ).
Statistics Di¡erences between means were considered signi¢cant when
the p value was less than 0.01, using Student’s t test.
RESULTS
Expression of HERs in a panel of melanoma cell
lines Expression of HERs by melanocytes and melanoma cell
lines was examined by Western blotting and immunostaining
with anti-HER1, -2, -3, and -4 antibodies. Neither melanocytes
nor any of the melanoma cell lines showed expression of full-
length HER1 or HER4, compared with the respective posi-
tive controls A431 and T47D (data not shown). Nevertheless,
this does not necessarily mean that these receptors are comple-
tely absent. All melanoma cell lines, as well as melanocytes,
expressed HER2 (Fig 2). HER2 levels in melanocytes and in all
Figure 2. Analysis of HER2/HER3 expression in melanocytes and
melanoma cell lines.Whole-cell lysates were analyzed by immunoblot-
ting (I.B.) with anti-HER2 and anti-HER3 antibodies, as described under
Materials and Methods. Quanti¢cation of the resulting bands was done re-
latively to the level of HERs in MCF-7 mammary carcinoma cells, set at 1.
Open and ¢lled bars, HER2 and HER3 expression, respectively.
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melanoma cell lines were far below the level found in the
HER2-overexpressing SK-BR-3 mammary carcinoma cell line
(Press et al, 1993). Moreover, quanti¢cation showed that none of
the melanoma cell lines had HER2 levels that were more than
two times higher than that seen in MCF-7 mammary carcinoma
cells, often used as a control for normal expression (Press et al,
1993; Aguilar et al, 1999). Comparable levels of HER3 were
expressed by melanocytes and 11 of the melanoma cell lines.
Two melanoma cell lines (BLM and FM45) did not show
expression of HER3 protein (Fig 2). The absence of HER3
protein was due to a strongly reduced level of HER3 mRNA
in these cell lines, compared with the other cell lines (data not
shown).
Expression of HRG by melanoma cell lines Western
blotting, followed by immunostaining of total lysates using an
anti-HRG antibody directed against a cytoplasmic sequence
conserved in all transmembrane HRG isoforms, revealed the
presence of a7105-kDa band in Bowes melanoma, BLM, and
MJM, the ¢rst two having the stronger expression (Fig 3A,
top panel). This band was also present in the positive controls
MDA-MB-231 (although very faint) and COLO-16, previously
described to secrete HRG (Holmes et al, 1992) or HRG-like
activity (De Corte et al, 1994), respectively, and was not found in
the MCF-7-negative control (Aguilar et al, 1999; Aguilar and
Slamon, 2001). The size of this band indicates that it corresponds
to the full-length HRG precursor (Burgess et al, 1995; Aguilar and
Slamon, 2001). The 50-kDa band, also seen by others using this
antibody (Aguilar and Slamon, 2001), probably represents an
artifact, because it could also be found in the MCF-7 HRG-
negative cells. Also two other bands (at785 and 75 kDa), seen
in some melanoma cell lines, are likely due to cross-reactivity of
the antibody with other proteins. Because these bands were not
consistently found in cell lines expressing HRG mRNA, and
CM of these cells had no HRG-like activity (see below), they
are unlikely to represent cleavage products of transmembrane
HRG. The localization of the 105-kDa immunoreactive band at
the plasma membrane was con¢rmed for Bowes melanoma
cells by biotinylation (Fig 3B, lane 4) and by precipitation us-
ing heparin beads (Fig 3B, lane 3), which is consistent with
the presence of a heparin-binding motif at the extracellular
N-terminus of HRG.
RT-PCR analysis was carried out to verify the results obtained
by western blotting and to detect which isoforms were expressed
by the HRG-positive melanoma cell lines. Because alternative
splicing of the HRG-encoding gene leads to multiple isoforms,
with most variation in the EGF-like domain, primers were
chosen so that di¡erent lengths of ampli¢cation products were
obtained, depending on the isoform expressed. The sense and
antisense primers chosen were complementary to the mRNA
encoding a conserved part of the EGF-like domain and a
sequence conserved in all transmembrane isoforms, respectively
(Fig 1). RT-PCR using this primer set, with MDA-MB-231 and
COLO-16 as positive controls and MCF-7 as a negative control,
con¢rmed the results obtained by western blotting for Bowes
melanoma, BLM, and MJM cells (Fig 3A, bottom panel). In
addition, lower levels of mRNA were found in some other
melanoma cell lines, possibly resulting in HRG protein levels
that were below the detection level in western blotting.
Melanocytes had amounts of mRNA that were comparable to
those found in MJM cells. Because we initially did not detect
HRG protein in these cells (Fig 3A), we loaded more protein
and overexposed the ¢lm, which eventually resulted in the
appearance of a weak band at 7105 kDa (Fig 3C). The pattern
of PCR ampli¢cation products that was obtained from Bowes
melanoma suggested the presence of multiple isoforms. Cloning
and sequencing of these products revealed that a2, b1, and b2
isoforms were the most abundant transmembrane isoforms in
this cell line (Fig 3D). In addition, a new isoform, designated
a4, was identi¢ed. This isoform combines the sequences from
both the exon leading to the a isoforms and the exons leading to
the b1 isoform (Figs 1, 3D). Two bands (indicated with an open
circle) did not correspond to a speci¢c isoform because they were
the result from cross-annealing of PCR products coming from
b1^b2 or a2^b2 isoforms, presumably resulting in an imperfect
double strand with slower migration on agarose gel (Fig 3D).
Melanoma cells release functionally active HRG in the
culture medium Following cleavage in the juxtamembrane
Figure 3. Presence of HRG protein and mRNA in melanocytes and
melanoma cell lines. (a, top panel; c) HRG precursor expression was ana-
lyzed by immunoblotting (I.B.) of whole-cell lysates with an anti-HRG
antibody. (b) Total lysates of MCF-7 and Bowes melanoma (T), a heparin
precipitate (H), streptavidin precipitate (S), or control protein G^Sepharose
precipitates of Bowes melanoma cells or biotinylated Bowes melanoma
cells (bio) were analyzed by immunoblotting with an anti-HRG antibody.
(c) Prolonged exposure after immunoblotting of total lysates of melano-
cytes and Bowes melanoma cells reveals a weak band in the former. Aster-
isk, the band of full-length HRG at 105 kDa. (a, bottom panel) RT-PCR
analysis of HRG mRNA in the indicated cell lines using the primer panel
indicated in the legend to Fig 1. (d) The ¢rst lane depicts HRG mRNA
expression in Bowes melanoma as assessed by RT-PCR, using the primer
panel indicated in the legend to Fig 1. Lanes 2^5, PCR analyses of clones
derived from Bowes melanoma, representing the indicated HRG isoforms.
Open circle, bands corresponding to PCR products formed by cross-anneal-
ing of two related isoforms and thus considered as aspeci¢c.
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extracellular region, HRG are released into the culture medium
as 40- to 45-kDa proteins, depending on the isoform and glyco-
sylation level (Holmes et al, 1992; Lu et al, 1995a, b).Western blotting
of 50 concentrated CM, using an antibody directed against the
HRG extracellular domain, revealed the presence of a broad band
at the expected molecular weight (Fig 4A, lane 1). This band was
absent upon depletion of the concentrated CM from heparin-
binding factors (Fig 4A, lane 2).
To test whether the released HRG was functional, we veri-
¢ed whether CM from the melanoma cell lines was capable
of activating HERs in MCF-7 cells. Prominent tyrosine
phosphorylation of a 185-kDa protein was evident upon
treatment with the positive controls recombinant HRG-b1
(rHRG-b1) and COLO-16 CM and was further restricted to
CM from HRG-positive melanoma cell lines (Fig 4B). This
phosphorylation could be blocked by pretreating the MCF-7
cells for 30 min with the HER-speci¢c irreversible inhibitor
PD168393 (Fry et al, 1998) or by adding heparin to the CM (Fig
4C,D). Heparin treatment did not interfere as such with the
capability of HERs in MCF-7 cells to become activated, because
the combination with rHRG-b1 (lacking a heparin-binding
domain) still resulted in full phosphorylation of HERs in these
cells (data not shown). To quantify the phosphorylating capacity
of the Bowes melanoma CM, we made a comparison with the
phosphorylation of MCF-7 cells that had been treated with
di¡erent concentrations of rHRG-b1. As also shown by others
(Aguilar and Slamon, 2001), phosphorylation of a 185-kDa
protein could readily be detected using 0.5 ng per mL rHRG-b1
(Fig 4E). Treatment with CM of Bowes melanoma cells resulted
in a phosphorylation at 185-kDa equivalent to 75 ng per mL
(700 pM) rHRG-b1, correlating with a concentration of 7100
pM 45-kDa HRG in the CM. Also the kinetics of this
phosphorylation were similar, with phosphorylation occurring
already after 1 min of treatment, suggesting a similar mechanism
of direct receptor activation (Fig 4F).
One of the well-described biologic e¡ects of HRG is the rapid
induction of spreading/scattering of epithelial islands (Spencer et
al, 2000), which led us to test the e¡ect of the CM of the HRG-
positive melanoma cell lines in this assay. We found that a 2-h
treatment of serum-starved MCF-7 islands with melanoma cell
line CM resulted in a disruption of epithelial islands similar to
that of treatment with rHRG-b1. This scattering was blocked by
pretreating the cells for 30 min with PD168393 (Fig 5A).
Based on the fact that HRG contains an extracellular heparin-
binding domain, we performed precipitations using heparin
beads on 50 concentrated CM. Three consecutive precipi-
tations completely abolished the ability of the CM to induce
phosphorylation (Fig 5B, lane 4) or spreading/scattering of
epithelial MCF-7 islands (Fig 5C). In contrast, after
eluting the heparin-binding factors from the heparin beads,
desalting, and dilution of these factors in serum-free medium,
used for treating MCF-7 cells, the phosphorylation of a 185-kDa
band (Fig 5B, lane 3) as well as the induction of spreading/
scattering (Fig 5C) were evident. Both e¡ects could be blocked
by pretreating the cells for 30 min with PD168393 (Fig 5C,B,
lane 6).
An autocrine loop in Bowes melanoma cells leads to
constitutive HER phosphorylation, MAPK activation, and
increased growth Total lysates from di¡erent melanoma cell
lines were immunostained for tyrosine-phosphorylated proteins.
This revealed the presence of a highly phosphorylated protein at
185 kDa, possibly re£ecting activated HER2 and HER3, in
Bowes melanoma cells, but not in the other melanoma cell lines
tested (Fig 6A). This band was also found in the HRG-positive
COLO-16 cells, but not in the weaker HRG-positive MDA-
MB-231 cells. By precipitating HER2 and HER3 from Bowes
melanoma cells and staining for tyrosine phosphorylated pro-
teins, we could show constitutive phosphorylation of HER2
and HER3 (Fig 6B, middle panel). Treating the cells for 30 min
with PD168393 resulted in a complete block of this phospho-
rylation (Fig 6B, left and middle panels). This was not due to
alterations in receptor levels, as immunostaining for HER2 and
HER3 showed no di¡erences between untreated cells and cells
treated with PD168393 (Fig 6B, right panel). In line with this,
when tested in a 5-day growth assay, PD168393 gave a signi¢-
cant (po0.01) and concentration-dependent growth inhibition
of Bowes melanoma cells (Fig 6C). This e¡ect was not due to
general cytotoxicity because virtually no growth inhibition was
seen of MCF-7 cells (HER2/3-positive and HRG-negative) or
BLM cells (HER2/HRG-positive and HER3-negative).
Figure 4. Melanoma cells release receptor activating HRG in the
medium. (a) Immunoblotting (I.B.), using an anti-HRG antibody directed
against the EGF-like domain, of concentrated CM of Bowes melanoma,
before (lane 1) and after (lane 2) depletion of heparin-binding factors reveals
the presence of a 45-kDa protein only in lane 1. Full-length recombinant
HRG-b1 (rHRG-b1), produced in Escherichia coli (lane 3)migrates at 33 kDa
owing to di¡erences in glycosylation. (b^e) Analysis of tyrosine-phos-
phorylated proteins in serum-starved MCF-7 cells. (b) Cells treated for 30
min with serum-free medium (Untr), with rHRG-b1, or with CM from
the indicated cell lines. (c) Cells pretreated or not for 30 min with 2 mM
PD168393 (PD) and treated for an additional 30 min with serum-free med-
ium or CM from the indicated cell lines. (d) Cells pretreated or not for 30
min with 2 mM PD168393 (PD) and treated with serum-free medium or
with CM of Bowes melanoma to which heparin was added in the indi-
cated concentrations. (e) Quanti¢cation of tyrosine phosphorylation, in-
duced by treating MCF-7 cells with Bowes melanoma CM or by treating
these cells with increasing concentrations of rHRG-b1. The arrow indicates
that, by extrapolation, the phosphorylating capacity of Bowes melanoma
CM is equivalent to that of 7 5 ng per mL rHRG-b1. (f) MCF-7 cells
treated with 5 ng per mL rHRG-b1 or CM Bowes melanoma for the in-
dicated periods of time. Arrowheads, 7185-kDa tyrosine-phosphorylated
bands.
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Constitutive receptor activation in Bowes melanoma cells
could be inhibited not only by directly blocking its kinase
activity, but also the interference with ligand binding resulted
in this e¡ect. This was evident from the rapid, concentration-
dependent inhibition of HER phosphorylation and the con-
sequent growth inhibition seen upon treatment with heparin
(Fig 6D,E). The MAPK pathway is a major pathway implicated
in uncontrolled growth of melanomas (Govindarajan et al, 2003;
Satyamoorthy et al, 2003). Because it is also a well known
signaling pathway activated by HRG (Pinkas-Kramarski et al,
1998), we checked its activation status in Bowes melanoma cells
by western blotting using a phospho-MAPK-speci¢c antibody.
Constitutive HER phosphorylation of Bowes melanoma cells
was accompanied by a constitutively active MAPK pathway (Fig
6F, lane 1). Blocking HER phosphorylation with PD168393
rapidly led to a block of MAPK activation (Fig 6F, lanes 2,3),
showing that continuous HER activation is the main cause of
the constitutively activated MAPK pathway in these cells. The
importance of the continuous activation of this pathway for the
growth of Bowes melanoma cells was shown in experiments in
which we used PD98059, a MAPK inhibitor. Bowes melanoma
cells were particularly sensitive to this inhibitor and showed
signi¢cant growth inhibition at concentrations that did not have
any e¡ect on growth of control BLM or MCF-7 cells (Fig 6G).
In conclusion, constitutive HER activation by autocrine HRG
supports growth of Bowes melanoma cells via continuous
MAPK activation.
Exogenous HRG stimulates growth of melanoma cells and
melanocytes but does not protect melanocytes against
apoptosis Melanocytes depend for their survival in vitro
strongly upon the addition of extracellular stimuli. A prominent
growth factor promoting growth and survival of these cells is
bFGF (Halaban, 2000). To test whether HRG could have similar
e¡ects, we treated melanocytes with di¡erent concentrations of
rHRG-b1, bFGF, or the combination of both. As is evident
from Fig 7A, rHRG-b1 stimulated HER phosphorylation of
melanocytes and a variety of melanoma cell lines. rHRG-b1
concentration-dependently stimulated growth of melanocytes
and could even provide an additive stimulus over bFGF (Fig
7B). A signi¢cant growth stimulation was also seen when, e.g.,
MCF-7, MeWo, and A375 cells were treated with rHRG-b1
(data not shown). Because bFGF is also a potent antiapoptotic
factor for melanocytes (Alanko et al, 1999), we next tested
whether HRG might have a similar e¡ect. Upon seeding of
melanocytes on a collagen gel, these cells undergo apoptosis,
round up, and become annexin V-positive owing to the
exposure of phosphatidylserine at the outer surface of the cells.
This can be inhibited by adding bFGF to the medium (Alanko
et al, 1999) (Fig 7C,D). Although a small decrease in the
percentage of apoptotic cells was reproducibly seen upon treat-
ment with rHRG-b1, this e¡ect was negligible compared to the
antiapoptotic e¡ect of bFGF (Fig 7C,D). Overall, the results
from these assays show that HRG potently stimulates growth
of melanoma cells and melanocytes, but does not protect
melanocytes against collagen-induced apoptosis.
Defective HRG/HER system in various melanoma cell
lines As shown in Fig 8A, phosphorylation in Bowes mela-
noma cells was already maximal, because treatment with
Figure 5. Scattering of MCF-7
epithelial islands by rHRG-b1 and
by CM of HRG-positive cell lines.
Serum-starved MCF-7 cells pretreated
or not for 30 min with 2 mM PD168393,
followed by an additional 30-min treat-
ment and preparation of lysates (b) or
followed by additional 2-h treatments
before taking pictures of living cultures
(a) or crystal-violet-¢xed cultures (c). (b)
Antiphosphotyrosine immunoblotting
(I.B.) of whole-cell lysates of MCF-7
cells that were treated for 30 min with
serum-free medium, CM of Bowes mel-
anoma (CM Bowes), the heparin-binding
fraction from CM Bowes (eluate) or CM
Bowes depleted from heparin-binding
factors. Arrowhead,7185-kDa phosphory-
lated band. (c) Indicated conditions as in
(b). Bars, 50 mm.
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rHRG-b1 did not result in an increase of phosphorylation.
Consistent with this, no additional growth stimulation could be
seen upon treatment with rHRG-b1 (data not shown). The
observation that the HRG-positive BLM cells lack constitutive
receptor activation (Fig 6A) and cannot be activated upon
addition of rHRG-b1 (Fig 8A) is in agreement with the absence
of the HRG-receptor HER3 (Fig 2A) in these cells. The lack
of HER3 also accounts for the unresponsiveness of FM45 cells
to rHRG-b1 (Fig 8A). MJM cells seem to have a defective
HER-system as well: although HER2 and HER3 were present
(Fig 2A), treatment with rHRG-b1 led only to a minor
phosphorylation, compared with treated MCF-7 cells (Fig 8A).
This minor phosphorylation was due to a small increase in
phosphorylation of HER3, but not of HER2 (Fig 8B, lane 2).
To check whether HER2 can be activated in MJM cells, we
treated them for 10 min with pervanadate, a phosphatase
inhibitor. This led to phosphorylation of multiple proteins,
including HER2 and HER3 (Fig 8B, lane 3). Cotreatment with
rHRG-b1 and pervanadate led to an additional increase in
phosphorylation of only HER3 (Fig 8B, lane 4), compared to
treatment with pervanadate only. To verify whether mutations
in HER2 could be responsible for the lack of activation in
response to signaling from outside the cell, we sequenced all
exons of the HER2 gene. Apart from described polymorphisms
in the sequences encoding the transmembrane domain (Ile655 to
Val655) (Ehsani et al, 1993) and the C-terminal tail (Pro to Ala),
no mutations were found. Furthermore, biotinylation revealed
that full-length HER2 was present at the plasma membrane of
MJM cells (data not shown). So, despite the lack of mutations
of HER2 and its localization at the plasma membrane in MJM
cells, this receptor lacks the potential to become activated via
stimulation with ligands.
DISCUSSION
In this report, we investigated the expression and function of the
HRG/HER ligand^receptor system in 13 melanoma cell lines,
compared to normal melanocytes. HER2 and HER3 were found
to be the main members of the EGFR family expressed in these
cells. Nevertheless, these receptors were not overexpressed, which
is consistent with the analysis of both nevi and melanoma tumor
material by others (Natali et al, 1994; Korabiowska et al, 1996;
Persons et al, 2000; Fink-Puches et al, 2001). Similar amounts of
HER3 protein were present in melanocytes and in 11 of the
13 cell lines. The fact that two melanoma cell lines (BLM and
FM45) showed only low HER3 mRNA levels and even no de-
tectable HER3 protein is a ¢rst example of how the HRG/HER
system may be deregulated in melanoma (Fig 9). Loss of HER3
may imply that transformed melanocytes no longer depend on
HRG, normally provided by the surrounding keratinocytes
(Schelfhout et al, 2000), for their survival. Downregulation or loss
of other melanocytic RTK (e.g., c-Kit, protein-tyrosine kinase 4,
ephrin receptor EphA4) during melanoma progression has been
Figure 6. Correlation between constitutive HER activation in
Bowes melanoma, continuous MAPK activation, and increased
growth. (a) Whole lysates from 48-h serum-starved cell lines analyzed
by immunoblotting (I.B.) using an antiphosphotyrosine antibody. (b,d)
Immunoblotting of tyrosine-phosphorylated proteins in serum-starved
Bowes melanoma cells, treated or not with 2 mM PD168393 for 30 min
(b) or with di¡erent concentrations of heparin for 10 min before making
cell lysates (d). (b) The left panel indicates whole-cell lysates. Middle and right
panels, equal amounts of protein were immunoprecipitated (I.p.) using anti-
HER2 or anti-HER3 antibodies, before immunoblotting with anti-phos-
photyrosine, anti-HER2, or anti-HER-3 antibodies. (f) Bowes melanoma
cells treated with 1 mM PD168393 for di¡erent periods of time.Whole-cell
lysates were analyzed by immunoblotting using antiphosphotyrosine (top
panel) or antiphospho-MAPK antibodies (bottom panel). Arrowheads, 7185-
kDa phosphorylated bands. (c,e,g) Growth, relative to vehicle-treated cells,
as measured by sulforhodamine B assay. Cells were treated for 5 days with
the indicated concentrations of PD168393 (c,e) or heparin (e) or with 5 mM
PD98059 (g). Asterisks, di¡ers signi¢cantly (po0.01) from controls.
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described before (Easty and Bennett, 2000). Their loss may un-
couple the melanocytes from certain physiologic regulatory me-
chanisms or may indicate an independence from the growth
factor system involved. In the latter case, other systems (auto-
crine/paracrine) and/or activating mutations of other (intracellu-
lar) proteins may have substituted for the loss. In this context, it
is noteworthy that we found a mutated N-ras allele in BLM, and
also in MJM cells (see further), resulting in a constitutively active
N-ras (data not shown), whereas FM45 cells have a mutation in
the tumor suppressor PTEN (Guldberg et al, 1997), resulting in
constitutive phosphoinositide 3-kinase signaling. We have evi-
dence (unpublished data) that the absence of HER3 in BLM
and FM45 cells is accompanied by the loss of microphtalmia
transcription factor M, a melanocyte-speci¢c transcription factor
necessary for melanocyte development. Interestingly, expression
of both HER3 and microphtalmia transcription factor M has
been described to be under the control of SOX-10, a transcription
factor necessary for melanocyte development, thus making this
protein a putative regulatory candidate (Verastegui et al, 2000;
Britsch et al, 2001).
The MJM cell line represents a second example of a deregu-
lated HRG/HER system in melanoma (Fig 9). Although it ex-
presses HRG, HER2, and HER3, surprisingly, it cannot use the
secreted HRG in an autocrine loop. Following treatment of
MJM cells with exogenous HRG, HER2 is not activated at all,
whereas HER3 becomes only weakly phosphorylated. The fact
that a minute phosphorylation of HER3 still occurs is surprising,
because HER3 lacks catalytic activity and needs HER2 for its
phosphorylation in the absence of other HERs. We cannot ex-
clude that HER1 or HER4, whose levels were below the detec-
tion limit of our western blotting experiments, account for this
e¡ect.We can exclude the possible (lack of) regulatory action of
heparan sulfate proteoglycans to be responsible for the impaired
response, because the used rHRG-b1 only consists of the EGF-
like domain. Also the interference by circulating soluble HER2
Figure 8. Deregulated HRG/HER system in several melanoma cell
lines. (a) Serum-starved cells, treated with rHRG-b1 or not before the
preparation of whole-cell lysates and analysis by immunoblotting (I.B.)
using an antiphosphotyrosine antibody. (b) Equal amounts of protein from
cell lysates of MJM cells that had been treated for 10 min with rHRG-b1
and/or pervanadate were subjected to immunoprecipitation (I.p.) with anti-
HER2 or anti-HER3 antibodies before immunoblotting using an anti-
phosphotyrosine antibody. Arrowhead,7185-kDa phosphorylated band.
Figure 7. Receptor-activating and growth-promoting, but no anti-
apoptotic e¡ects of exogenous HRG on melanoma cells and mela-
nocytes. (a) Immunoblotting (I.B.), using an antiphosphotyrosine
antibody, of lysates from serum-starved cells, treated or not with rHRG-
b1. Arrowhead, 7185-kDa phosphorylated band. (b) Growth, relative to
untreated cells, as measured by 3-(4,5-dimethyl-thiazol-2-yl)-2,5-diphenylte-
trazolium bromide assay. Melanocytes were treated for 5 days with the
indicated concentrations of growth factors. Asterisks, di¡ers signi¢cantly (p
o 0.01) from control. (c) Phase contrast photographs of melanocytes cul-
tured on a collagen gel for 4 days with the treatments indicated. Arrows,
rounded cells in melanocyte cultures that were left untreated or were trea-
ted with rHRG-b1. These rounded cells were not found in bFGF-treated
cultures. Bar, 50 mm (d) Histogram, showing the pro¢le of annexinV posi-
tivity in melanocytes that were cultured on a collagen gel in the absence of
added growth factors (solid line) or in the presence of 5 ng per mL bFGF
(broken line) or 50 ng per mL rHRG-b1 (dotted line). The percentage of
annexinV-positive cells is indicated.
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or HER3 ectodomains (Doherty et al, 1999; Aigner et al, 2001;
Lee et al, 2001; Justman and Clinton, 2002) is unlikely, because
CM from the HRG-positive MJM cells still induced activation
of HERs in MCF-7 cells. Biotinylation experiments suggested a
transmembrane localization of HER2 in MJM cells, whereas ana-
lysis of functional sequences failed to show mutations. Neverthe-
less, sequencing did reveal two polymorphisms, one of which (Ile
toVal at position 655 in the HER2 transmembrane domain) was
predicted to favor the formation of stable HER2 homodimers
(Fleishman et al, 2002). Although it still needs to be shown
whether the proposed model also holds for HER2 activation by
heterodimerization (following ligand binding), it would mean
that HER2 in MJM cells would be more easily activated than
in, e.g., Bowes melanoma cells, which is in contrast to our ¢nd-
ings. It thus seems unlikely that this polymorphism may provide
an explanation for the observed lack of HER2 activation in MJM
cells treated with HRG. A possible role for the other polymorph-
ism we identi¢ed in MJM cells has not been established yet. Re-
maining explanations for the lack of HER2 activation following
stimulation with HRG are the interference with ligand binding
by sterical hindrance, the constitutive association or action of in-
tracellular negative regulatory proteins or receptor mislocaliza-
tion (although transmembrane).
Here, we have shown by western blotting, RT-PCR, cloning,
and using functional assays the presence and function of HRG as
new growth factors produced by human melanoma cells. In addi-
tion to three known HRG isoforms, we could identify a new iso-
form, designated a4. This isoform combines the sequences that
normally lead to either a- or b-isoforms. A similar combination
was already described for the a3-isoform, which di¡ers from the
a4 -isoform because the latter contains the coding sequence for
the transmembrane domain (Wen et al, 1994) (Fig 1). Neverthe-
less, the resulting protein is the same, because this a^b combina-
tion leads to a frameshift, resulting in the generation of a stop
codon upstream of the sequence encoding the transmembrane
domain. This truncated protein is most likely cytosolic because
the transmembrane domain functions as a signal peptide (Burgess
et al, 1995).The presence of HRG in melanomas ¢ts with the neu-
roectodermal origin of melanocytes and the fact that HRG are
molecules typically expressed in neuroectodermal tissues (March-
ionni et al, 1993; Meyer and Birchmeier, 1995). Although melano-
cytes showed HRG expression at the mRNA level, HRG could
barely be detected at the protein level, suggesting the presence of
(post)translational negative regulatory mechanisms in these cells.
Activating mutations in H-ras have been shown to result in upre-
gulation of HRG in mammary epithelial cells (Mincione et al,
1996). Although two of the HRG-producing cell lines (BLM
and MJM) have an activating mutation in N-ras, transient trans-
fections using dominant-negative and constitutively active N-ras
constructs learned that this was unlikely to be the underlying
cause of the increased HRG expression (data not shown). Thus,
the molecular basis for the high HRG expression in some mela-
noma cell lines is not clear, yet. Although exogenous HRG did
not exert a signi¢cant antiapoptotic e¡ect, it potently stimulated
growth of cultured melanocytes and melanoma cells and could
even provide an additive growth stimulation over bFGF. Upregu-
lation of HRG expression in melanomas may result in the gen-
eration of an autocrine loop and in the independence from HRG
normally provided by the keratinocytes (Schelfhout et al, 2000).
This decreased dependence from paracrine growth factors is one
of the hallmarks of melanoma progression (LaŁ zaŁ r-MolnaŁ r et al,
2000). Our data clearly show that in the Bowes melanoma cell
line, in the absence of receptor overexpression, HER2 and
HER3 are permanently activated, leading to continuous MAPK
activation and stimulation of growth. This activation is due to
continuous ligand^receptor interactions and not to, e.g., activat-
ing mutations. Arguments hereto are that the phosphorylation
could be abolished by adding heparin to the culture medium
and that refreshing of the culture medium led to a transient, gra-
dual decrease in receptor phosphorylation, followed by a gradual
recovery to the initial levels (data not shown). Thus, the Bowes
melanoma cell line, with its autocrine loop, represents a third ex-
ample of how the HRG/HER system may be deregulated in
melanoma (Fig 9). Expression of the HRG/HER systemwas also
described in various other types of cancers (e.g., breast, lung, en-
dometrium, thyroid, head and neck, colon, ovarium) (Ethier et al,
1996; Fernandes et al, 1999; Srinivasan et al, 1999; Fluge et al, 2000;
O-Charoenrat et al, 2000; Gilmour et al, 2002;Venkateswarlu et al,
2002). Although in only some of these studies constitutive recep-
tor activation, owing to an autocrine loop, was looked at, it may
play a role in the other cases as well, rendering it a possible target
for future therapies. In line with this is the increased attention
that is being given toward receptor activation status in certain
cancers, rather than only taking into account receptor levels as a
criterium of malignancy (Thor et al, 2000).
Overall, it is striking that two of the three HRG-positive cell
lines, BLM and MJM, cannot use the secreted HRG in an auto-
crine loop, because of the absence of HER3 or because of an im-
paired HER2 activation, respectively. Still, in a physiologic
situation, the HRG secreted by such cells may have prominent
e¡ects on the surrounding cells, directly or indirectly contribut-
ing to malignant progression. Direct e¡ects may include an in-
creased motility of the surrounding keratinocytes (Schelfhout et
al, 2002), possibly rendering the environment in which the mela-
nocytes reside less tight. Indirect e¡ects may be the stimulation of
angiogenesis owing to a HRG-mediated upregulation of vascular
endothelial growth factor or increased expression of other
growth factors by the target cells (O-Charoenrat et al, 2000;
Talukder et al, 2000;Yen et al, 2000; Ruiter et al, 2002).
Figure 9. Schematic representation of the several deregulations of
the HRG/HER system found in human melanoma cells. In melano-
cytes and the majority of melanoma cell lines, HERs can be activated by
exogenous HRG. The absence of HER3 in BLM and FM45 cells or the
presence of functionally inactive HER2 in MJM hampers HRG respon-
siveness. Bowes melanoma cells show constitutive HER activation, owing
to the presence of an autocrine loop.
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In summary, we have shown the presence of HRG, including
one new isoform, as new factors produced and secreted by hu-
man melanoma cell lines. The HRG/HER system is functional
in melanocytes and in the majority of melanoma cell lines, lead-
ing to growth stimulation. Nevertheless, multiple deregulations
in this growth factor system may release the melanocytes from
their natural dependence on keratinocyte-derived factors and thus
represent a step toward melanoma progression. Lack of stimula-
tion by HRG in some melanoma cell lines is due to the loss of
expression of HER3 protein or to a severely impaired HER2 ac-
tivation. In contrast, the aberrant expression and secretion of
HRG by melanoma cells may serve as an autocrine and/or para-
crine signal, promoting cell growth and/or migration. These dis-
tinct types of deregulation of the HRG/HER system may
contribute to the malignant phenotype of melanoma cells. In
the future, it will be important to verify whether these deregula-
tions are present in tumor samples of melanoma patients and may
become a therapeutic target for this disease with ever increasing
incidence.
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Antiinvasive effect of xanthohumol, a prenylated chalcone present in hops
(Humulus lupulus L.) and beer
Barbara Vanhoecke1, Lara Derycke2, Veerle Van Marck2, Herman Depypere1, Denis De Keukeleire3 and Marc Bracke2*
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The female inﬂorescences of the hop plant (Humulus lupulus L.)
are essential during brewing to add taste and ﬂavor to beer and to
stabilize beer foam. Xanthohumol, the main prenylated chalcone
in hops, was investigated for its antiinvasive activity on human
breast cancer cell lines (MCF-7 and T47-D) in vitro. Xanthohumol
was able to inhibit the invasion of MCF-7/6 cells at 5 lM in the
chick heart invasion assay and of T47-D cells in the collagen inva-
sion assay. Xanthohumol inhibited growth of MCF-7/6 and T47-D
cells, but not of chick heart cells. Moreover, it induced apoptosis
of these tumor cells as demonstrated by the cleavage of nuclear
PARP after 48 hr treatment. To probe the mechanism of the anti-
invasive effect of xanthohumol, involvement of the E-cadherin/cat-
enin invasion-suppressor complex was investigated. An aggrega-
tion assay demonstrated stimulation of aggregation of MCF-7/6
cells in the presence of 5 lM xanthohumol and this could be com-
pletely inhibited by an antibody against E-cadherin. Xanthohumol
upregulates the function of the E-cadherin/catenin complex and
inhibits invasion in vitro, indicating a possible role as an antiinva-
sive agent in vivo as well.
' 2005 Wiley-Liss, Inc.
Key words: breast cancer; xanthohumol; invasion; E-cadherin
Beer has been brewed for thousands of years and has been an
integral part of the diet in many cultures. In recent years, research-
ers have been looking for hard scientiﬁc evidence for the potential
health beneﬁts of beer and its ﬂavoring component, hop. Xantho-
humol is a prenylated ﬂavonoid of the chalcone type, produced in
the lupulin glands of the hop cones (hops). Recent studies reported
a promising role for xanthohumol as a chemopreventive agent, as
it can modulate the carcinogen metabolism and act by cytotoxic/
static mechanisms.1,2 However, the information on chemopreven-
tive activities of xanthohumol is not conclusive.
Invasion is the hallmark of malignancy and the search for anti-
invasive agents remains a challenge. Within the large family of
ﬂavonoids, interesting molecules of different classes have been
shown to possess antiinvasive properties in vitro.3–5 A few anti-
invasive agents were detected among many hundreds of polyphe-
nolics tested at our laboratory in the chick heart invasion assay.6
We found that a number of prenylated chalcones with high homol-
ogy to xanthohumol were active at low concentrations ( 10 lM)
and those displayed a selective cytotoxic effect on the cancer cells,
but not on normal tissue. As xanthohumol is a naturally occurring
structural congener from hops, we wondered whether it would
inhibit invasion of human mammary adenocarcinoma cells in the
same organotypic invasion assay. The effect of xanthohumol was
tested on 3 cell lines derived from human mammary carcinomas
(MCF-7/6, MCF-7/AZ and T47-D). These cell lines were selected
because they have retained many morphologic and biochemical
characteristics of their mammary origin, such as the expression of
the estrogen receptor a.7,8
In addition, we investigated if xanthohumol could target spe-
ciﬁc activities implicated in breast cancer progression, namely,
growth, cell-cell adhesion and invasion. We focused on a direct
form of intercellular communication, namely, cell-cell adhesion
via the E-cadherin/catenin complex. This complex is a powerful
invasion suppressor and invasiveness has been correlated with its
downregulation or functional inactivity at the cell surface.9 We
were interested in the possible invasion-inhibitory action of xan-
thohumol, examining its effect on cell-cell adhesion mediated by
the E-cadherin/catenin complex of human mammary adenocarci-
noma cells.
Material and methods
Cell lines and culture media
The mammary adenocarcinoma cell lines were obtained as fol-
lows: MCF-7/6 from Dr. H. Rochefort (Unite d’Endocrinologie
Cellulaire et Moleculaire, Montpellier, France), MCF-7/AZ from
Dr. P. Briand (Fibiger Institute, Copenhagen, Denmark) and T47-
D from the American Type Culture Collection (Manassas, VA).
Cell lines were maintained in the following media (Invitrogen,
Merelbeke, Belgium): 50:50 D-MEM/HAMF12 (MCF-7/6 and
MCF-7/AZ) and D-MEM (T47-D). All media contained 10%
heat-inactivated fetal bovine serum (Invitrogen), 100 IU/mL peni-
cillin (Invitrogen), 100 lg/mL streptomycin (Invitrogen) and
2.5 lg/mL amphotericin B (Bristol-Meyers Squibb, Brussels,
Belgium). The cells were incubated in a 100% water-saturated
atmosphere of 10% CO2 in air at 37C. Chick embryonic heart cells
were obtained from precultured chick heart fragments (PHFs).10
Chemicals and antibodies
Xanthohumol was extracted and puriﬁed from hops using the
procedure of De Keukeleire et al.11 1H NMR spectral data were in
agreement with those reported in the literature.12 The compound
was dissolved in ethanol as a stock solution of 0.1 M, from which
further dilutions were made.
Afﬁnity-puriﬁed MB2 (2 lg/mL) is a murine antihuman E-cad-
herin monoclonal antibody, blocking the cell-cell adhesive func-
tion of E-cadherin after binding to the extracellular 80 kD frag-
ment.13 5D10,14 obtained from Dr. L. Plessers (Willems Instituut,
Diepenbeek, Belgium), is a murine monoclonal antibody against
MCF-7 cells, binding to a plasma membrane epitope unrelated
to E-cadherin. The primary antibodies for Western blotting were
a monoclonal mouse antihuman poly(ADP)-ribose polymerase
(PARP) antibody (Pharmingen, San Diego, CA) and monoclonal
mouse anti-a-tubulin clone B-5-1-2 (Sigma, St. Louis, MO). The
secondary antibody was an antimouse antibody linked to horserad-
ish peroxidase (Amersham Biosciences Europe, Roosendaal, The
Netherlands). Staurosporine (Sigma) was used as a positive con-
trol for cleavage of PARP.15
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Assays for invasion
Chick heart invasion assay. One assay for invasion was based
on the in vitro confrontation between cancer cell aggregates and
embryonic chick heart fragments in organ culture.16 Precultured
9-day-old PHFs were selected for a diameter of 0.4 mm and con-
fronted with aggregates of MCF-7/6, MCF-7/AZ, or T47-D cells
with a diameter of 0.2 mm. After an overnight incubation on top
of semisolid agar, the confronting pairs were cultured in suspen-
sion for 8 days. After ﬁxation in Bouin-Hollande’s solution, the
cultures were imbedded in parafﬁn, serially sectioned and stained
with hematoxylin and eosin. In alternating sections, the cancer
cells were stained immunohistochemically with the 5D10 mono-
clonal antibody in order to evaluate the interaction between the
cancer cells and PHF. Invasion was scored as follows: grade 0,
only PHF is found and no confronting cells can be observed; grade
1, the confronting test cells are attached to the PHF and do not
occupy the heart tissue; grade 2, occupation of the PHF is limited
to the outer ﬁbroblast-like and myoblast cell layers; grade 3, the
confronting cells have occupied the PHF, but have left more than
half of the original amount of heart tissue intact; grade 4, the con-
fronting cells have occupied more than half of the original volume
of the PHF.
Cultures were treated with xanthohumol at concentrations rang-
ing from 1029 and 1024 M for 8 days. To avoid breakdown or iso-
merization of the compound, the medium was refreshed every 2
days according to Stevens et al.17 Each group was tested 3 times.
The number of cultures examined for each group was between 15
and 21.
Collagen type I invasion assay. Another assay for invasion was
done with MCF-7/6, MCF-7/AZ and T47-D cells on a collagen
type I gel.18 Collagen type I is the main component of the extra-
cellular matrix and, as such, a suitable substrate for in vitro inva-
sion studies. Brieﬂy, neutralized collagen type I (0.09%; Upstate,
VA) was incubated for 1 hr at 37C to allow geliﬁcation. Single-
cell suspensions were prepared in corresponding medium mixed
with different concentrations of xanthohumol, placed on top of the
collagen gel and cultured at 37C for 24 hr. The number of cells
penetrating into the gel or remaining at the surface was counted
using an inverted microscope controlled by a computer program.
The invasion index, expressing the percentage of penetrating cells
divided by the total number of cells, was calculated. All experi-
ments were done 3 times.
Assays for aggregation
Slow aggregation assay (SAA). Conﬂuent monolayers were
detached by a standard trypsinization procedure. A total of 20,000
cells in 200 lL medium was seeded on solidiﬁed agar (Sigma) in a
96-well plate (Nunc, Roskilde, Denmark) and treated with test
agents. Aggregate formation was evaluated with an inverted
microscope after 24 hr incubation.19 The experiment was done
twice.
Fast aggregation assay (FAA). The assay was based on the
preparation of a single-cell suspension in E-cadherin-saving con-
ditions followed by quantiﬁcation of cell aggregation in a Ca21-
containing medium.19 The suspension was further treated with
varying xanthohumol concentrations for 30 min at 4C and incu-
bated at 37C for 30 min under continuous shaking. Untreated
cells were incubated with 0.1% EtOH. Cells were ﬁxed in 2.5%
paraformaldehyde at the start of the incubation (N0) and after
30 min (N30) and the particle size distribution was measured with
a Coulter Particle Size Counter LS 200 (Coulter, Miami, FL). All
experiments were done at least 3 times.
Western blotting
Lysates were made from cell cultures at approximately 70%
conﬂuency from aggregates of MCF-7/6 and from PHFs. Cells,
aggregates and PHFs were washed 3 times with ice-cold PBS
before lysis. Cells were lysed with lysis buffer containing 1% Tri-
ton X-100, 1% Nonidet P-40 and the following protease inhibitors:
aprotinin (10 lg/mL), leupeptin (10 lg/mL; ICN Biomedicals,
Asse-Relegem, Belgium), phenylmethylsulfonyl ﬂuoride (1.72 mM),
NaF (100 lM), NaVO3 (500 lM) and Na4P2O7 (500 lg/mL;
Sigma). Samples containing equal amounts of protein were prepared
by mixing lysates and sample buffer (Laemmli with 5% b-mercap-
toethanol) in appropriate amounts and boiling for 5 min. Proteins
were separated on a 8% SDS-polyacrylamide gel and transferred
onto nitrocellulose membranes. Immunostaining of the blots was
performed using the primary antibodies followed by the secondary
antibody conjugated to horseradish peroxidase and detection by
enhanced chemiluminescence reagent (Amersham Biosciences
Europe). Quantiﬁcation of the autoradiograms was done using the
Quantity One software (Bio-Rad, Nazareth, Belgium). Experiments
were performed at least in duplo.
Assays for growth
Measurement of growth in Erlenmeyer ﬂasks. For the chick
heart tissue, fragments with a diameter of 450.6 6 50.4 lm; for
MCF-7/6 cells, aggregates of 284.6 6 19.2 lm; for MCF-7/AZ
cells, aggregates of 217.8 6 19.5 lm; and for T47-D cells, aggre-
gates of 527.1 6 31.4 lm were transferred to 6 ml Erlenmeyer
ﬂasks in 1.5 ml medium in the presence or the absence of varying
xanthohumol concentrations and kept in suspension for 8 days on
a Gyrotory shaker (72 rpm). Ethanol was used as a solvent control.
To avoid breakdown or isomerization of the compound, the
medium was refreshed every 2 days.17 The larger (a) and the
smaller (b) diameter of the cultures were measured individually
using a macroscope. The volume (v) was calculated in accordance
with the formula of Attia and Weiss20 as follows: v 5 0.4 3 a 3
b2. All confrontations were done twice.
Measurement of growth in 96-well plates. A total of 5,000 cells
(MCF-7/6, MCF-7/AZ, T47-D and cultured embryonic chick heart
cells) were seeded in wells of a 96-well plate. After 2 days of
attachment and growth, cells were incubated with varying xantho-
humol concentrations and the protein content was measured with a
colorimetric assay.21 Brieﬂy, cells were ﬁxed by adding 50 lL
50% trichloroacetic acid to the medium. After 1 hr incubation at
4C, cells were rinsed with water, dried and stained with 100 lL
sulforhodamine B (0.4% in 1% acetic acid) for 30 min. After
4 wash steps with 1% glacial acetic acid, cells were dried and the
bound dye was dissolved in 200 lL 10 mM Tris buffer, pH 10.5.
The optical density of the solubilized protein-bound stain was
measured with an ELISA reader (Molecular Devices, Palo Alto,
CA) at 490 nm. Six replicate wells were tested for each condition.
Each condition was tested twice.
Morphologic measurement of apoptosis
The morphologic changes of cells during apoptosis were
observed with a ﬂuorescence microscope following staining with
Hoechst 33258 (ICN). The cells were seeded out on coverslips.
Before staining, cells were rinsed twice with PBS and ﬁxed in ice-
cold (220C) methanol for 10 min. After rinsing, cells were
stained with 5 mg/L Hoechst 33258 for 10 min at 37C in the dark
and then visualized with a ﬂuorescence microscope. Apoptotic
cells were deﬁned as cells showing nuclear and cytoplasmic
shrinkage, chromatin condensation and apoptotic bodies.
Statistics
Statistical evaluation of the data was performed with the Stu-
dent’s t-test except for proﬁle comparison in the FAA, where the
Kolmogorov-Smirnov method was used.
Results
Xanthohumol inhibits invasion of MCF-7/6 cells into the
precultured chick heart fragments in vitro
The invasive properties of 3 breast cancer cell lines (MCF-7/6,
MCF-7/AZ and T47-D) were assessed in the chick heart invasion
model. Histologic analysis of confronting cultures between MCF-
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7/6, MCF-7/AZ, or T47-D cell aggregates and PHF revealed strik-
ing differences in invasiveness. Earlier studies also demonstrated
the existence of invasive and noninvasive variants of the MCF-7
cell population.5 Indeed, MCF-7/6 cells did invade spontaneously
into the chick heart tissue (Fig. 1a and b), whereas MCF-7/AZ and
T47-D formed a multilayered epithelium covering the heart frag-
ments.
The effect of xanthohumol on invasion of breast cancer cell
lines into chick heart fragments was examined during 8 days of
treatment in the chick heart invasion assay. Varying xanthohumol
concentrations (0.1, 1, 5, 10, 20, 50 and 100 lM) were tested;
5 lM xanthohumol inhibited invasion of MCF-7/6 cells com-
pletely (Fig. 1c), and the effect could be described as grade 1.
Immunohistochemical staining with 5D10, a speciﬁc antibody
against the MCF-7 cells, conﬁrmed that no cancer cells had
invaded the chick heart (Fig. 1d), in contrast to the untreated cells
(Fig. 1b). On the other hand, 1 lM xanthohumol partially inhibited
invasion and could be scored as grade 3. Concentrations < 1 lM
did not inhibit invasion, as the cultures did not differ from control
conditions (grade 4). Higher concentrations (10, 20, 50 and
100 lM) were toxic for both MCF-7/6 cells and chick heart tissue.
We ruled out the possibility that the antiinvasive effect of 5 lM
xanthohumol was due to irreversible cytotoxicity, since the effect
was reversed on removal of xanthohumol from the medium after
8 days of treatment and further culturing the confrontation in xan-
thohumol-free medium. In addition, we investigated whether pre-
treatment of the heart tissue was sufﬁcient to block invasion, but
invasion did still occur. Thus, it is unlikely that xanthohumol
increases resistance of the chick heart tissue against the invasive
behavior of the MCF-7/6 cells on pretreatment. In parallel, pre-
treatment of the cancer cell aggregates alone was unsufﬁcient to
block their invasion; thus, treatment with xanthohumol during the
confrontation was necessary for the antiinvasive effect.
Furthermore, a selective effect of 5 lM X on the MCF-7/6 cells
could be observed: signs of nuclear pyknosis and vacuolization
were present in the MCF-7/6 cells but not on the chick heart cells
(Fig. 1e).
As proinvasive effects of xanthohumol could not be excluded,
we investigated this possible effect using MCF-7/AZ and T47-D
cells, which are noninvasive in the chick heart invasion assay.
However, invasion could not be induced on treatment with xantho-
humol. Interestingly, a reduction of T47-D cells could be observed
starting from 1 lM while the heart cells stayed intact (Fig. 2).
A second assay for invasion was done to evaluate whether the
antiinvasive effect of xanthohumol was restricted to MCF-7/6
cells. First of all, invasiveness of MCF-7/6, MCF-7/AZ and T47-
D cells was assessed in the collagen invasion assay. MCF-7/6 and
MCF-7/AZ cells were considered noninvasive (1–2%), whereas
T47-D invaded strongly the collagen gel (10–15%). Consequently,
T47-D cells were chosen to test varying xanthohumol concentra-
tions (5, 10 and 30 lM). A signiﬁcant concentration-dependent
antiinvasive effect could be observed after 24 hr (p  0.001;
Fig. 3). Trypan blue staining of the cells was done to screen cyto-
toxicity of the compound. However, no toxicity could be observed
after 24 hr of incubation.
To summarize, xanthohumol inhibits the invasive potential of a
panel of human breast cancer cells in vitro.
Xanthohumol inhibits growth of human breast cancer
cells in vitro
To examine if the antiinvasive effect of xanthohumol could be
at least partially attributed to a selective growth-inhibitory effect
on the cancer cells, we performed different growth assays. Solitary
cultures of PHF, MCF-7/6, MCF-7/AZ and T47-D aggregates
were brought into suspension separately in the presence of 5 lM
xanthohumol or solvent (0.1% EtOH). Volume measurements
were done every 2 days at the occasion of refreshment of the
medium. After 8 days, the experiment was stopped and cultures
were processed for histologic analysis. After 8 days, PHF control
FIGURE 1 – Light micrographs of sections from 8-day-old confront-
ing cultures of precultured heart fragments and MCF-7/6 cells.
Untreated confrontations (a and b) are compared with confrontations
treated with 5 lM xanthohumol (X; c and d). Sections on the left pan-
els were stained with hematoxylin-eosin; in (b) and (d), MCF-7/6 cells
were stained immunohistochemically with the monoclonal antibody
5D10 and appear dark. Scale bar 5 50 lm. (e) Detailed morphologic
analysis of the confronting cultures revealed a selective effect of X on
the MCF-7/6 cells. Nuclear pyknosis (arrowheads, black) and vacuo-
lization (arrows, white) could be observed in the MCF-7/6 cells but
not in the heart cells. Scale bar 5 50 lm.
FIGURE 2 – Light micrographs of sections from 8-day-old confront-
ing cultures of precultured heart fragments (arrowheads) and T47-D
cells. Untreated confrontations (a) are compared with confrontations
treated with 1 and 5 lM xanthohumol (X; b and c). Sections were
stained with hematoxylin-eosin. Scale bar 5 50 lm.
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cultures had decreased their initial volume by 6 30%. The volume
of solvent-treated cancer cell aggregates increased during 8 days
by 6 100% (MCF-7/6), 6 400% (MCF-7/AZ) and 6 450% (T47-
D; data not shown). Xanthohumol-treated PHF showed a signiﬁ-
cant increase in volume during the ﬁrst 2 days of incubation com-
pared to control cultures (p  0.01); however, after 8 days the vol-
ume did not differ from the solvent-treated PHF cultures (Fig. 4).
The effect of 5 lM xanthohumol on the volume of cancer cell
aggregates was dependent on the cell type. The xanthohumol-
treated MCF-7/6 aggregates did not differ from the untreated cul-
tures, in contrast to MCF-7/AZ and T47-D aggregates, where a
strong decrease could be observed in function of time. Volumes of
MCF-7/AZ aggregates were reduced 4 times compared to
untreated cultures. T47-D aggregates appeared to be even more
sensitive than MCF-7/AZ as after 2 days of incubation with 5 lM
xanthohumol, aggregates completely fell apart into single cells
(p  0.01).
Histologic staining of 2- and 8-day-old cultures of PHF showed
no morphologic changes of the xanthohumol-treated PHF tissue
when compared to the control cultures (data not shown). In con-
trast, nuclear pyknosis and large vacuoles were present in the xan-
thohumol-treated MCF-7/6 aggregates, although the volume did
not change during the treatment. This is in agreement with the
observations in the chick heart invasion assay (Fig. 1e).
A second growth assay was performed on MCF-7/6, T47-D and
chick embryonic heart cells cultured in a 96-well plate and stained
with sulforhodamine B. After 8 days of treatment with varying
xanthohumol concentrations (1, 5, 10 and 20 lM), a signiﬁcant
increased signal from the chick heart cultures was noted when
incubated with 1 and 5 lM xanthohumol (p  0.01) compared to
solvent-treated cultures (Fig. 5). This effect was already observed
after 24 hr (data not shown). However, higher concentrations dra-
matically decreased the growth of the heart cells. In contrast to a
growth-stimulatory effect on chick heart cultures, a growth-inhib-
iting effect of xanthohumol was evident on both breast cancer
cells. T47-D cells were, again, more sensitive in all conditions
than MCF-7/6, as treatment with concentrations as low as 1 lM
already reduced the proliferation with 6 40%.
To summarize, xanthohumol inhibited the growth of the breast
cancer cells, while the effects on chick heart were depending on
the assay type and the treatment dose.
Xanthohumol stimulates apoptosis of human breast cancer
cells in vitro
Reduced growth is the net result of reduced proliferation and/or
increased cell death. The chick heart invasion assay revealed a
strong selective effect on the morphology of the MCF-7/6 cells,
whereas chick heart cells remained intact. Nuclear pyknosis and
formation of vacuoles suggested signs of cell death (Fig. 1e).
Therefore, the effect of xanthohumol on apoptosis of a panel of
breast cancer cells was investigated. First, a Hoechst 33258 stain-
ing revealed the appearance of nuclear condensation in xantho-
humol-treated cultures (Fig. 6a and b). We additionally examined
cleavage of the nuclear protein, PARP, which is an indicator of
caspase-dependent apoptosis. MCF-7/6 and T47-D cells were
treated for 48 hr in the presence or the absence of varying xantho-
humol concentrations. Staurosporine (1 lM) was used as a posi-
tive control for PARP cleavage.15 Cell lysates were used for Wes-
tern blotting and blots were stained with an antibody against
FIGURE 3 – Effect of xanthohumol on invasion of T47-D cells into
collagen type I gel. Cells were treated with varying concentrations (5,
10 and 30 lM) during 24 hr. Results are presented as percentage (%)
of invasion (percentage of penetrating cells divided by the total num-
ber of cells; mean 6 standard deviation). The % of invasion of xan-
thohumol-treated T47-D cells is compared with the % of invasion of
solvent-treated cells (unt). Asterisks, p  0.001.
FIGURE 4 – Effect of 5 lM xanthohumol on the growth of PHFs
and MCF-7/6, MCF-7/AZ and T47-D aggregates. The volumes of cul-
tures treated for 8 days are presented as a percentage of the volumes
of untreated cultures (mean 6 standard deviation). The volume of
xanthohumol-treated cultures is compared with the volume of solvent-
treated cultures corrected for their initial main volumes. Asterisks,
p  0.01.
FIGURE 5 – Effect of xanthohumol on sulforhodamine B-staining of
T47-D (white bars), MCF-7/6 (dotted bars) and embryonic chick heart
cells (dashed bars). The cells were treated for 8 days with 0, 1, 5, 10
and 20 lM X. The effects are presented as a percentage of optical den-
sity (O.D.) of untreated cells (mean6 standard deviation). The protein
content of xanthohumol-treated cells is compared with the protein
content of the solvent-treated cells. p  0.01.
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human PARP. On treatment with xanthohumol, both cell lines
showed sensitivity to PARP cleavage, as illustrated for T47-D
cells (Fig. 6c). In parallel, PARP cleavage could be observed in
MCF-7/6 cells, although they are caspase-3-deﬁcient (data not
shown).
In addition, we examined the effect of xanthohumol on the pro-
teolysis of PARP in cancer cell aggregates (MCF-7/6) and PHFs.
The aggregates and PHFs were brought into suspension in the
presence of 25 lM xanthohumol or solvent (0.1% EtOH). After
48 hr, cell lysates were made and Western blotting was performed.
Treatment of PHFs did not increase the cleavage of PARP com-
pared to solvent-treated PHFs, where some spontaneous cleavage
could be observed after 48-hr culturing (Fig. 6d, PHF). In contrast,
a strong cleavage fragment of 85 kD was detected in the xantho-
humol-treated MCF-7/6 aggregates compared to the control aggre-
gates (Fig. 6d, Aggr MCF-7/6).
To summarize, xanthohumol appeared to induce apoptosis of
human breast cancer cells in vitro.
Xanthohumol stimulates E-cadherin-mediated cell-cell adhesion
of human breast cancer cells in vitro
In SAA, numerous irregular and small aggregates were formed
in the untreated cultures of MCF-7/6, whereas MCF-7/AZ and
T47-D cells aggregated spontaneously and showed compaction.
Treatment with varying xanthohumol concentrations did not
change the aggregation pattern, i.e., no stimulation of aggregation
of MCF-7/6 could be observed, nor inhibition of aggregation of
MCF-7/AZ and T47-D cells.
Consequently, the effect of xanthohumol on cell-cell aggrega-
tion was tested in FAA (Fig. 7). Cells were pretreated for 24 hr
with varying xanthohumol concentrations followed by trypsiniza-
tion in E-cadherin-saving conditions to preserve E-cadherin-medi-
ated cell-cell adhesion during the assay. In the presence of a
Ca21-containing aggregation buffer, cells were allowed to aggre-
gate for 30 min in the presence or the absence of varying xantho-
humol concentrations. The initial mean particle diameter of the
MCF-7/6 cells at time 0 was 27.65 lm (standard deviation 5
19.03) for solvent-treated cells (Fig. 7, T0 untreated) and
30.27 lm (standard deviation 5 21.68) for the 5 lM xantho-
humol-treated cells (Fig. 7, T0 5 lM Xanthohumol), indicating
suspensions of single cells or cell doublets in both conditions.
After 30 min, the mean particle diameter shifted toward 177.4 lm
(standard deviation 5 97.58) for solvent-treated cells, indicating
aggregates of around 6 cells (Fig. 7, T30 untreated). However, for
xanthohumol-treated cells, aggregates of around 11 cells were
formed and the mean particle diameter shifted toward 328.2 lm
(standard deviation 5 211.5; Fig. 7, T30 5 lM Xanthohumol).
Lower concentrations were not active. These increases were statis-
tically signiﬁcant as shown by the Kolmogorov-Smirnov statistics
(p < 0.05). A 24-hr pretreatment with xanthohumol was necessary
to stimulate aggregation.
The implication of E-cadherin was indicated by a neutralizing
monoclonal antibody, MB2, which functionally blocks the mole-
FIGURE 6 – Hoechst 33258 staining of the nuclei of MCF-7/6 cells:
(a) demonstrates the solvent-treated culture (EtOH) and (b) the 10 lM
xanthohumol-treated cultures. The appearance of nuclear condensa-
tion could be observed after 96 hr treatment with xanthohumol.
(c) Immunodetection of uncleaved and cleaved PARP in lysates of
T47-D cells. The cells were incubated with varying xanthohumol con-
centrations (5, 10 and 25 lM) for 48 hr. 0.1% EtOH-treated cells were
used as control (unt). 1 lM staurosporine (stauro) was used as a posi-
tive control for PARP cleavage. Western blotting and immunostaining
were performed. Note that the antibody recognizes both uncleaved
PARP (116 kD) and the larger cleavage fragment (85 kD). a-tubulin-
staining was used as a control for loading. (d) Immunodetection of
uncleaved and cleaved PARP in lysates of PHFs and MCF-7/6 aggre-
gates (aggr MCF-7/6). The PHFs and cancer cell aggregates were
brought into suspension and incubated with 0.1% EtOH (unt) or
25 lM xanthohumol (X) for 48 hr. Western blotting and immunostain-
ing was performed. a-tubulin-staining was used as a control for loading.
FIGURE 7 – Effect of xanthohumol (X) on cell-cell adhesion in the
FAA. The volume percentage distribution is presented plotted against
the particle diameter of MCF-7/6 aggregates at time 0 in the presence
(T0 5 lM Xanthohumol) and the absence (T0 untreated) of X and after
30 min in the presence (T30 5 lM Xanthohumol) and the absence (T30
untreated) of X. In addition, the effect of MB2, an antibody against
the extracellular part of E-cadherin, on cell-cell adhesion is evaluated
in the assay. The particle diameter of the MB2-treated MCF-7/6 aggre-
gates after 30 min in the presence (T30 5 lM xanthohumol 1 MB2)
and the absence (T30 untreated1MB2) of X is presented.
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cule. Cotreatment with xanthohumol and MB2 (Fig. 7, T30 5 lM
xantohumol 1MB2) during aggregation completely abrogated the
effect of 5 lM xanthohumol (Fig. 7, T30 5 lM Xanthohumol).
To summarize, xanthohumol appeared to stimulate E-cadherin-
mediated cell-cell adhesion of human breast cancer cells in vitro.
Discussion
Using the chick heart invasion assay, we have investigated the
action of xanthohumol on invasion in organotypic confrontations.
This differs from a cell culture by the fact that the cells are not
adherent to an artiﬁcial substrate, but present in a 3-dimensional
architecture. Our model involves fragments of normal chick heart
tissue, mainly composed of cardiomyocytes, ﬁbroblasts, endothe-
lial cells and extracellular matrix, to which the cancer cells adhere
to proliferate and invade. Factors produced by both the cancer
cells and the host cells, and also those present in the culture
medium, may affect different activities of both cancer and host
cells: proliferation, apoptosis, angiogenesis, proteolysis, cell-
matrix adhesion, cell-cell adhesion and motility. Our results
showed that, after 8 days of confrontation, the cancer cells had
already invaded extensively into the heart tissue of untreated cul-
tures, while in the xanthohumol-treated culture no cancer cell
invasion could be observed. Moreover, in contrast to the heart that
looked healthy, morphologic analysis of the cancer cells revealed
signs of pyknosis accompanied by intense vacuolization. We con-
cluded that xanthohumol inhibits invasion presumably by exerting
a selective growth-inhibiting effect on the cancer cells. Earlier
studies performed in our laboratory have shown a similar selecti-
vity, i.e., when B16-BL6 mouse melanoma cells are cocultured
with mouse PHF and treated with a combination of TNF-a and
INF-g.22 This treatment selectively killed the melanoma cells and
left the heart tissue intact.
Interestingly, we already described antiinvasive activity of
structural analogs of xanthohumol.6,23,24 Looking for alkaloids
and polyphenolics that could possibly affect invasiveness, com-
pounds belonging to various classes such as methoxyﬂavones,
chalcones and coumarins were evaluated by the chick heart inva-
sion assay. The antiinvasive activity was frequently found among
chalcones having a prenyl group. Our results add xanthohumol to
the list of prenylated chalcones with antiinvasive activity.
The disposal of invasive (MCF-7/6) and noninvasive variants
(MCF-7/AZ and T47-D) allowed us to investigate both inhibitory
and stimulatory effects on invasion by xanthohumol. A proinva-
sive effect on the tested breast cancer cell lines in the in vitro inva-
sion assays was absent. The noninvasive variants did not become
invasive (MCF-7/AZ and T47-D in the chick heart invasion assay;
MCF-7/6 and MCF-7/AZ in the collagen invasion assay). This dif-
fers from drugs such as retinoic acid25 and alkyllysophospho-
lipid,26 which have been evaluated in the same models.
In vitro, many activities of cancer cells can be downregulated
by ﬂavonoids. Effects on growth and on the mechanisms under-
lying this activity are being intensively studied. In particular, the
antiproliferative activity of prenylated chalcones on different can-
cer cell lines has been reported by different groups.1,2 To assess
the antiproliferative potential of xanthohumol on human breast
cancer cells, Gerhauser et al.1 investigated its inﬂuence on DNA
synthesis of MDA-MB-435 cells in an in vitro system and found
that xanthohumol inhibited the activity of human DNA polymer-
ase a with an IC50 of 23.0 6 3.5 lM. In addition, they found an
accumulation of the MDA-MB-435 cells in the S-phase of the cell
cycle and induction of terminal differentiation of HL-60 human
promyelocytic leukemia cells. Our growth studies and histologic
analyses conﬁrmed this antiproliferative effect on a panel of breast
cancer cells.
In addition, we found that xanthohumol induced apoptosis of
breast cancer cells and aggregates, as evidenced by the cleavage
of PARP. PARP (116 kD), a nuclear substrate of caspases, is
cleaved into 2 fragments, an N-terminal DNA-binding domain
(24 kD) and a C-terminal catalytic domain (85 kD). As MCF-7/6
cells are deﬁcient in caspase-3, one of the key executioners of the
intrinsic apoptotic pathway, PARP must be the target of other cas-
pases such as caspases-7 and -9 or of cathepsins on treatment with
xanthohumol.15,27,28 Additional tests are needed to unravel the
mechanism of this proapoptotic effect.
As epithelial cells are critically dependent on cell-matrix and
cell-cell adhesion for growth and survival, the effect of xantho-
humol on adhesion of breast cancer cells was also a subject for inves-
tigation. We examined the cell-cell adhesion of the human MCF-7/6
breast cancer cells with a functionally defective E-cadherin/catenin
complex. Xanthohumol was able to stimulate aggregation of MCF-
7/6 cells in suspension, restoring the function of the complex.
These effects could be inhibited by MB2, a monoclonal antibody
against the extracellular domain of E-cadherin. Previous experi-
ments have shown that IGF-I, tamoxifen and retinoic acid can
upregulate the function of this complex in the same aggregation
assay25,29,30 and are inhibitors of invasion. In addition, phytoestro-
gens such as genistein, daidzein and equol (data not shown) and
8-prenylnaringenin from hops5 were found to stimulate cell-cell
adhesion in vitro. However, these ﬂavonoids were unable to inhibit
invasion in chick heart fragments. In this respect, they mimicked
the effects of 17b-estradiol, which is a promotor of cell-cell adhe-
sion5 and growth of MCF-7/6 cells, but is unable to block invasion.
Other published inhibitory effects of xanthohumol, such as on
cyclooxygenase 1 and 2 activity and on estrogen reactivity,1 may
contribute to its antiinvasive activity. Many reports have pointed
toward the stimulating role of prostaglandins on mammary cancer
invasion,31–33 and inhibition of cyclooxygenases has been associ-
ated with inhibition of tumor invasion. The role of estrogens/anti-
estrogens in mammary cancer invasion, however, is a matter of
debate, but recent data indicate an antiinvasive, rather than pro-
invasive, effect of estrogens on mammary cancer cells.34,35
In conclusion, xanthohumol has multiple effects on human
breast cancer cells in vitro. It elicits an indirect effect on invasion
through a decrease in the number of invasive cells. However,
although growth and invasion are part of the invasion program of
tumors,36 growth inhibition is not per se linked to inhibition of
invasion. Although xanthohumol is present in beer, these effects
cannot be achieved by drinking beer as during the brewing proc-
ess, xanthohumol is mainly converted to its ﬂavanone isomer, iso-
xanthohumol, resulting in low xanthohumol concentrations in beer
(5–800 lg/L).17 However, agents that inhibit cancer cell invasion
by selective killing of cancer cells, inhibiting their growth, or
stimulating cell-cell adhesion between cancer cells should be con-
sidered as potential therapeutic drugs in cancer.
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ABSTRACT
P-cadherin expression in breast carcinomas has been associated with
tumors of high histologic grade and lacking estrogen receptor-, suggest-
ing a link between these proteins. In the MCF-7/AZ breast cancer cell line,
blocking estrogen receptor- signaling with the antiestrogen ICI 182,780
induced an increase of P-cadherin, which coincided with induction of in
vitro invasion. Retroviral transduction of MCF-7/AZ cells, as well as HEK
293T cells, showed the proinvasive activity of P-cadherin, which requires
the juxtamembrane domain of its cytoplasmic tail. This study establishes
a direct link between P-cadherin expression and the lack of estrogen
receptor- signaling in breast cancer cells and suggests a role for P-
cadherin in invasion, through its interaction with proteins bound to the
juxtamembrane domain.
INTRODUCTION
Classical cadherins are a superfamily of transmembrane glycopro-
teins responsible for calcium-dependent cell–cell adhesion, mediating
homophilic protein interactions (1). These are modulated by their
conserved cytoplasmic juxtamembrane domain and catenin-binding
domain, linking them to the actin cytoskeleton. -, -, p120-, and
-Catenins are the best-documented interaction partners (2). -Cate-
nin (and perhaps also -catenin) is a signaling molecule, implicated in
tissue patterning, of which the functions are regulated by binding to
the catenin-binding domain of cadherins and by interactions with
receptor tyrosine kinases and transcription factors of the lymphocyte
enhancer factor/T-cell factor family (2). P120-catenin was identified
as a substrate for Src and several receptor tyrosine kinases and
interacts directly with the juxtamembrane domain of cadherins, modu-
lating cadherin clustering and cell motility in a cell-type and phos-
phorylation state-dependent way (3). The cadherin/catenin junctional
complex is linked to the actin cytoskeleton via -catenin, thus
strengthening its adhesive force (1).
Reduced expression of E-cadherin is associated with tumor pro-
gression in many different cancers, including breast cancer (4), and
may result from mutations, loss of heterozygosity, promoter hyper-
methylation, or up-regulation of transcriptional repressors, as SIP1,
Snail, Slug, or Twist (1). Moreover, the invasion suppressor function
of normally expressed E-cadherin may be overcome by the aberrant
expression of N-cadherin (5) or cadherin-11 (6), which have been
associated with progression of breast carcinoma through interference
with E-cadherin function (7).
P-cadherin, another classical cadherin, is expressed in ectodermal
tissues, more specifically in the basal layers of stratified epithelia (8,
9) and in myoepithelial cells of the breast (10). P-cadherin is impli-
cated in growth and differentiation, as evidenced by knockout mice
displaying precocious differentiation of the mammary gland (11), and
is aberrantly expressed in mammary carcinomas of high histologic
grade and with a poor prognosis (12–16), as well as in other types of
carcinomas and proliferative inflammatory lesions (17–19). It has
been suggested that suppression of the P-cadherin gene is lost during
carcinogenesis (9), but the nature of this mechanism and the biological
role of the newly acquired P-cadherin remain to be investigated.
Because aberrant expression of P-cadherin identified a subgroup of
estrogen receptor--negative breast carcinomas (16), we raised the
hypothesis that the expression of P-cadherin in mammary epithelial
cells is hormonally regulated, as described for E-cadherin (20), N-
cadherin (21), and cadherin-11 (22).
In mammary epithelial cells, estrogen receptor- is a key regulator
of proliferation and differentiation and a crucial prognostic indicator
and therapeutic target in breast cancer. Estrogen receptor- is a
ligand-dependent transcription factor acting through direct transcrip-
tional target activation (23). Estradiol acts as a potent mitogen for
many breast cancer cell lines, and 70% of breast carcinomas are
estrogen receptor- positive. This mitogenic effect is blocked by
estrogen antagonists. Pure antiestrogens (like ICI 182,780) and selec-
tive estrogen receptor modulators (like tamoxifen; ref. 24) are used for
the treatment of osteoporosis, breast cancer, and other diseases. Con-
tinuous exposure of steroid–hormone-responsive breast cancer cell
lines to ICI 182,780 leads to resistant sublines, with signaling path-
ways alternative to estrogen receptor- (25). Similarly, in breast
cancer, a high number of patients eventually develop antiestrogen
resistance for unknown reasons.
Using the antiestrogen ICI 182,780, we investigated a putative
molecular and functional link between the absence of estrogen recep-
tor- signaling and P-cadherin expression in breast cancer cells. To
understand the relationship between P-cadherin and the aggressive
breast cancer phenotype, we studied the effect of wild-type P-cadherin
and several mutants on cell aggregation and invasion. We report that
aberrant expression of P-cadherin may result from a lack of estrogen
receptor- signaling and may induce cell invasion in a juxtamembrane
domain-dependent manner.
MATERIALS AND METHODS
Plasmids and cDNA Constructs. The hP-cad/pBR322–23-b expression
vector, containing the 3.2kb cDNA encoding full-length human P-cadherin (8),
was kindly provided by Prof. Keith R. Johnson (Department of Oral Biology,
College of Dentistry and the Eppley Cancer Center, Nebraska Medical Center,
Omaha, NE), with the permission from Prof. Yukata Shimoyama (Department
of Surgery, International Catholic Hospital, Nakaochiai, Shinjuku, Tokyo,
Japan). The cDNA encoding full-length mouse E-cadherin was kindly pro-
vided by Jolanda van Hengel (Department of Molecular Biomedical Research,
VIB-Ghent University, Ghent, Belgium). Both cDNAs (PC-WT and mEC-
WT) were transferred to the expression vector pIRES2-EGFP (Clontech, Palo
Alto, CA), allowing easy evaluation of transfection efficiencies due to co-
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expression of enhanced green fluorescent protein (EGFP). To generate P-
cadherin deletion mutants, P-cadherin was EcoRI subcloned into pBluescript
(Promega, Madison, WI) and NdeI/SalI digested to remove the region encod-
ing its COOH-terminal tail. PCR fragments corresponding to different lengths
of the removed tail, flanked by NdeI/SalI restriction enzyme digest sites at the
5 and 3 ends, respectively, were obtained always using the same sense primer
(5-AAGCAGGATACATATGACGTG-3) and different antisense primers for
the following constructs: PC-CT682: 5-CGTGCCGTCGACCTACTTCCG-
CTTCTT-3; PC-CT702: 5-CGTGCCGTCGACCTAGCCATAGTAGAA-3;
PC-CT711: 5-CGTGCCGTCGACCTACTGGTCCTCTTC-3; PC-CT719:
5-CGTGCCGTCGACCTAGTGGAGCTGGGT-3; PC-CT727: 5-CGTGC-
CGTCGACCTACTCCGGCCTGGC-3; and PC-CT762: 5-CGTGCCGTC-
GACCTACAGGTTCTCAAT-3. After NdeI/SalI digestion, these products
were ligated into NdeI/SalI digested pP-cad-Bluescript, and the resulting
construct was EcoRI/SalI transferred to pIRES2-EGFP. Additionally, a mutant
with a small deletion in the P120-catenin-binding sequence (lacking the
nucleotides coding EEGGG) and retaining the intact catenin-binding domain
was created (PC-703–707). Therefore, pP-cad-IRES2-EGFP was XhoI/SmaI
digested, and the removed fragment was cut with EarI. After removal of the
small fragment between the two EarI restriction sites (encoding EEGGG), the
two remaining fragments (XhoI/EarI and EarI/SmaI) were ligated into XhoI/
SmaI digested pP-cad-IRES2-EGFP. To create the P-cadherin point mutant
(PC-R503H), a PCR product, encompassing the point mutation, was obtained,
using the following primers: a sense primer (5-GGCACCCTCGACCAT-
GAGGATGAG-3), with the TaqI restriction site in italics and the point
mutation in bold; and the antisense primer used for generating PC-CT762. This
product was TaqI/NdeI digested and used in a three-point ligation with a
BamHI/TaqI and a BamHI/NdeI fragment of pP-cad-Bluescript, followed by
EcoRI transfer of the construct to pIRES2-EGFP. Direct sequencing (ABI,
Perkin-Elmer, Foster City, CA) was performed for all of the constructs to
confirm their integrity.
Restriction Enzymes, Antibodies, and Chemical Reagents. All of the
restriction enzymes were purchased from New England BioLabs (Beverly,
MA). Antihuman primary mouse monoclonal antibodies used were against
P-cadherin (clone 56) and P120-catenin (clone 98; BD Transduction Labora-
tories, Lexington, KY), N-cadherin (CH-19 and GC-4), -tubulin (B-5–1-2;
Sigma-Aldrich, Bornem, Belgium), E-cadherin (HECD-1; Takara Biochemi-
cals, Kyoto, Japan), and estrogen receptor- (NCL-L-ER-6F11; Novocastra,
Newcastle, United Kingdom). 17-Estradiol was purchased from Sigma-
Aldrich Quı´mica (Sintra, Portugal) and ICI 182,780 was kindly provided by
AstraZeneca (Barcarena, Portugal). Both drugs were dissolved in 100% EtOH
and added to the culture media. The concentrations used were 10 nmol/L for
17-estradiol and 100 nmol/L for ICI 182,780, unless mentioned otherwise.
Cycloheximide was obtained from Sigma and used at 25 g/mL. For the
control situations, cells were treated only with 100% EtOH.
Cells and Transient Transfection. Human cancer cell lines were obtained
as described: BT-20 from Peter Coopman (Laboratory of Molecular Biology,
Ghent University, Belgium), MCF-7/AZ (MCF7) from Per Briand (The
Fibiger Institute, Copenhagen, Denmark), ZR-75.1 and T47D from American
Type Culture Collection (Manassas, VA), and HEK 293T (HEK) cells from
Veerle De Corte (Department of Biochemistry, Faculty of Medicine and Health
Sciences, VIB-Ghent University, Belgium). Cell lines were routinely main-
tained at 37°C, 10% CO2, in the following media (Invitrogen, Merelbeke,
Belgium): 50% DMEM/50% HamF12 (MCF7), DMEM (BT-20, T47D, HEK),
or RPMI 1640 (ZR-75.1). All of the media for routine culture contained 10%
heat-inactivated fetal bovine serum (Greiner bio-one, Wemmel, Belgium), 100
IU/mL penicillin, 100 g/mL streptomycin, and 2.5 g/mL amphotericin B
(Invitrogen). To obtain transient transfectants, appropriate expression vectors
(2.5 g) were introduced into HEK cells (2  105) with Fugene (Roche
Molecular Biochemicals, Mannheim, Germany), and transfection efficiencies
were evaluated by measuring EGFP expression by flow cytometry.
Retroviral Transduction. The P-cadherin coding sequence was EcoRI
digested from pIRES2-EGFP and EcoRI subcloned into the LZRS-IRES-
EGFP vector to generate the LZRS-P-cad-IRES-EGFP vector. The LZRS-
IRES-EGFP retroviral vector, encoding only EGFP, was used as a control. For
the production of retroviral supernatant, the Phoenix-Amphotropic packaging
cell line (a kind gift from Dr. Garry P. Nolan, Stanford University School of
Medicine, Stanford, CA) was transfected with the LZRS-IRES-EGFP and
the LZRS-P-cad-IRES-EGFP plasmids using calcium-phosphate precipitation
(Invitrogen) to generate both retroviruses. The viral supernatant was spun (10
minutes at 350 g), and aliquots were stored at70°C until use. Transduction
of cell lines was performed as described before (26).
Flow Cytometry Staining and Cell Sorting. For analysis of E- and
N-cadherin surface expression, cells were detached under cadherin saving
procedures (27), and1 105 cells were used for staining. Cells were washed
with cold PBS containing bovine serum albumen (BSA) and incubated for 30
minutes with the anti-E-cadherin HECD-1 or anti-N-cadherin GC-4 antibodies.
This was followed by two washes with PBS/BSA, 30 minutes incubation with
biotinylated rabbit antimouse monoclonal antibody, two washes with PBS/
BSA, 20 minutes incubation with streptavidin-phycoerythrin, and a final wash
with PBS/BSA. For routine analysis of EGFP expression, cells were detached
with trypsin/EDTA. Flow cytometric analysis and/or cell sorting were per-
formed as described before (26).
Biotinylation, Immunoprecipitation, and Immunoblotting. Immunopre-
cipitation and immunoblotting experiments and quantification of bands, were
performed as published before (28). For biotinylation, the cells were washed
three times with cold PBS and incubated with 0.5 mg/mL of Biotinylation
Reagent (EZ-Link Sulfo-NHS-LC-Biotin, Pierce) during 30 minutes at 4°C,
followed by four washes with cold PBS before cell lysis. To control for equal
loading of total lysates, immunostaining with anti--tubulin was performed
routinely (not always shown). Each immunoblot was done at least three times,
and the ones that were selected to show are representative experiments.
Reverse Transcription-PCR. Reverse transcription-PCR (RT-PCR) ex-
periments were done as described previously (28). Primers specific for P-
cadherin cDNA included the following: sense 5-ACGAAGACACAA-
GAGAGATTGG-3 and antisense 5-CGATGATGGAGATGTTCATGG-3,
to generate a 287-bp product. PCRs were done in a Minicycler (Biozym,
Landgraaf, the Netherlands) with an annealing temperature of 55°C.
Slow Aggregation Assays. For semi-solid substratum, 2 104 cells in 200
L medium were seeded on solidified agar in a 96-well plate (27). Aggregate
formation was evaluated under an inverted microscope after 24, 48, and 72
hours. In suspension, 6  105 cells were added to 50 mL-Erlenmeyer flasks in
6 mL of medium. The flasks were incubated on a Gyrotory shaker (New
Brunswick Scientific Co., New Brunswick, NJ) at 72 rpm and continuously
gassed with humidified 10% CO2 in air. The particle size distribution of the
aggregates was measured with a Coulter Particle Size Counter (LS2000,
Coulter Company, Miami, FL). The diameter of the particles can be considered
as a measure for aggregate formation. Statistical analysis of differences be-
tween the particle size distribution curves was done with the Kolmogorov-
Smirnov method.
Invasion Assays. For collagen type I invasion assay (29), six-well plates
were filled with 1.3 mL of neutralized collagen type I (0.09% w/v, Upstate
Biotechnology, Inc., Lake Placid, NY) and incubated for at least 1 hour at 37°C
to allow gelification. 1  105 cells of a single-cell suspension were seeded on
top of the gel, and cultures were incubated at 37°C for 24 hours. Using an
inverted microscope controlled by a computer program, invasive and superfi-
cial cells were scored blind-coded in 12 fields of 0.157 mm2. The invasion
index expresses the percentage of cells invading into the gel over the total
number of cells counted. For Matrigel invasion assay, transwell chambers with
polycarbonate membrane filters (6.5 mm diameter, 8 m pore size, Costar,
Corning, NY) were coated with 20 L of a Matrigel solution (Becton Dick-
inson). 1  105 cells were added to the upper compartment of the chamber. In
the lower compartment, conditioned cell culture medium of the MRC-5 human
embryonic lung fibroblast cell line was added as a chemoattractant. After 24
hours of incubation at 37°C, the upper surface of the filter was cleared from
nonmigratory cells with a cotton swab and washes with serum-free DMEM.
The remaining (invasive) cells at the lower surface of the filter were fixed with
cold methanol and stained with 4, 6-diamidino-2-phenylindole (Sigma, 0.4
mg/mL). Invasive cells were scored by counting 50 fields per filter with a
fluorescence microscope, at 250 of magnification. Rat myofibroblast DHD-
FIB cells were routinely included as a positive control for invasion in both
assays. Each experiment was repeated at least three times. For collagen
invasion assay, data are expressed as mean SD; for Matrigel invasion assay,
a representative experiment is shown, with the SD for the number of cells
scored on the 50 microscopic fields. Statistical significance was determined by
t test, and differences between groups were analyzed using the ANOVA;
P  0.05 was considered significant.
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RESULTS
The Antiestrogen ICI 182,780 Up-Regulates P-Cadherin in Es-
trogen Receptor-–Positive Breast Cancer Cell Lines. To test the
hypothesis that estrogen receptor- negatively regulates P-cadherin,
we examined the expression of estrogen receptor- and cadherins in
breast cancer cell lines by Western blot (Fig. 1A). Interestingly, higher
levels of P-cadherin were found in estrogen receptor-–negative
BT-20 cells.
A 24-hour treatment with the antiestrogen ICI 182,780 (107
mol/L) increased P-cadherin protein levels in MCF7 and ZR-75.1
cells but not in BT-20 cells (Fig. 1B). There were no significant
changes in P-cadherin levels observed in T47D cells, bearing already
higher pretreatment levels of P-cadherin and lower levels of estrogen
receptor- than the responsive cell types. ICI 182,780-induced in-
crease of P-cadherin was associated with a decline of estrogen recep-
tor- levels (Fig. 1B).
For additional investigation, we chose the MCF7 cell line, because
it is estrogen receptor- positive, highly responsive to estrogen, and
extensively investigated as a model of breast cancer. In these cells, ICI
182,780 induced, respectively, up- and down-regulation of P-cadherin
and estrogen receptor- in a time- and dose-dependent way (Fig. 2, A
and B). A decrease of estrogen receptor- levels was already observed
after 6 hours of treatment, whereas P-cadherin levels nearly doubled
after 12 hours. After 24 hours of exposure to ICI 182,780, higher
P-cadherin and lower estrogen receptor- levels persisted for several
days, with normalization 96 hours after ICI 182,780 withdrawal (Fig.
2C). To examine whether or not the effect of ICI 182,780 on P-
cadherin expression was mediated via estrogen receptor-, we did a
competition experiment. As already described (30), 17-estradiol
readily decreased estrogen receptor- levels, although to a lesser
extent than ICI 182,780 (Fig. 2D). Importantly, 17-estradiol coun-
teracted the ICI 182,780-induced up-regulation of P-cadherin (Fig.
2D) and accelerated normalization of P-cadherin levels in cells treated
for 24 hours with ICI 182,780 (Fig. 2E). Together, these results
suggest that not the decrease in estrogen receptor-, but the lack of
estrogen receptor- signaling is responsible for the increase of P-
cadherin by ICI 182,780.
RT-PCR revealed an increase of P-cadherin mRNA after ICI
182,780 treatment, suggesting that the higher P-cadherin protein ex-
pression results from an up-regulation of P-cadherin transcripts (Fig.
2F). This was confirmed by a micro-array study performed on 17-
estradiol– or ICI 182,780-treated MCF7 cells, in which 17-estradiol
did not alter P-cadherin mRNA levels, whereas ICI 182,780 induced
an 8-fold increase. Finally, it remained to be determined whether
induction of the P-cadherin gene (CDH3) was a direct effect of ICI
182,780 or required prior induction of other genes. We addressed this
question by blocking protein synthesis in cells, because the induction
of primary target proteins or immediate early genes should not be
sensitive, whereas secondary targets should be blocked. The treatment
of MCF7 cells with cycloheximide, a de novo protein synthesis
inhibitor, largely blocked P-cadherin up-regulation by ICI 182,780
(Fig. 2G), which is consistent with a requirement for newly synthe-
sized proteins, probably induced by ICI 182,780, before CDH3 acti-
vation. In contrast, as expected, this drug did not block estrogen
receptor- down-regulation mediated by ICI 182,780 (Fig. 2G).
ICI 182,780 Decreases Cell–Cell Adhesion and Increases Inva-
siveness of MCF-7/AZ Cells. MCF7 cells formed compact aggre-
gates on top of soft agar or when incubated in Erlenmeyer flasks under
continuous shaking (Fig. 3A, panel i, and Fig. 3B). In presence of ICI
182,780, this effect was counteracted (Fig. 3A, panel ii, and 3B). Even
a 24-hour pretreatment with ICI 182,780, followed by testing these
cells in the absence of ICI 182,780, was sufficient to prevent the
formation of large aggregates (Fig. 3A, panel iii). On plastic substra-
tum, no changes in morphology or migrating behavior (as measured
by a wound healing assay) could be observed upon treatment with ICI
182,780 (data not shown).
Whereas MCF7 cells failed to invade in collagen type I and Ma-
trigel invasion assays, a 24-hour pretreatment with ICI 182,780 was
sufficient to induce invasion of these cells in both assays (Fig. 3, C
and D). These proinvasive effects of ICI 182,780 were counteracted
by 17-estradiol (Fig. 3, C and D), indicating that they are mediated
by interference with estrogen receptor- signaling.
Aggregation and invasion of MCF7 cells, in the presence of ICI
182,780, mimics the behavior of the poorly aggregating and invasive
estrogen receptor-–negative and P-cadherin–positive BT-20 cells
(Fig. 1A), which remained unchanged upon treatment with ICI
182,780 (Fig. 3, E and F).
P-Cadherin Expression Increases Invasiveness but Does Not
Alter Cell–Cell Adhesion of MCF-7/AZ cells. Cells, retrovirally
transduced to encode only EGFP (MCF7.LIE) or both P-cadherin and
EGFP (MCF7.P-cad), were sorted to 90% EGFP positivity (Fig.
4A). P-cadherin levels were higher at the cell surface in P-cadherin–
transduced cells (Fig. 4B). The levels of cell-surface E-cadherin were
the same in P-cadherin–transduced cells, as in vector-transduced cells
(Fig. 4, A and B), excluding an effect of the exogenous cadherin on the
levels of the major endogenous cadherin.
On plastic substratum, P-cadherin–transduced MCF7 cells, like
their parental or vector-transduced cells, formed epithelioid islands,
showing no morphotype differences (data not shown). Transduction
with P-cadherin did not interfere with E-cadherin–mediated cell–cell
adhesion (Fig. 4, C and D). However, in a wound healing migration
assay, P-cadherin–transduced cells migrated faster (data not shown)
and, in contrast to parental or vector-transduced (LZRS-IRES-EGFP)
controls, invaded into collagen type I and Matrigel (Fig. 4, E and F).
P-Cadherin-Induced Invasion Is Not Breast Cancer Cell or
Endogenous Cadherin-Specific. P-cadherin retroviral transduction
was also done on HEK cells, expressing at their surface low and
Fig. 1. A, analysis of E-cad, P-cad, N-cad, and ER expression, and in vitro invasion
into collagen type I, of the human cell lines used in this study. B, effect of ICI on P-cad
and ER expression in breast cancer cell lines. Immunoblotting, for P-cad and ER
analysis, of cell lysates derived from MCF7, ZR-75.1, T47D (50 g of protein loaded),
and BT-20 (30 g) breast cancer cell lines, after a 24-hour treatment with ICI. Band
quantification was done relative to the expression levels in control cells. An increase of
P-cad expression in MCF7 and ZR-75.1 cells was observed, whereas the levels in
ER-negative BT-20 cells were not altered. P-cad levels were not changed in T47D cells,
although ER levels declined in all positive cell lines. (cad, cadherin; ER, estrogen
receptor; ICI, ICI 182,780)
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high levels of E- and N-cadherin, respectively (Fig. 1A and Fig.
5A), and being invasive neither into collagen type I nor into
Matrigel. Sorting of vector- or P-cadherin–transduced cells
resulted in populations having either moderate or high EGFP
expression (HEK.LIE.Med, HEK.LIE.High, HEK.P-cad.Med, and
HEK.P-cad.High; Fig. 5, A and B). As for MCF7 cells, no differen-
ces in morphotype or aggregation were observed between parental
and transduced cells (Fig. 5, C and D). Although there was a
down-regulation of superficial N-cadherin in the highest P-
cadherin–expressing cells (Fig. 5B), this did not result in a significant
decrease in total levels of N-cadherin (Fig. 5A). P-cadherin–trans-
duced cells were significantly more invasive into collagen type I or
Matrigel than vector-transduced cells, with higher invasiveness of the
cells expressing more P-cadherin (Fig. 5, E and F). In both assays, the
control cells with higher LZRS-IRES-EGFP expression levels showed
an increased invasion index when compared with the ones with
moderate levels of expression. This may be due to the insertion of
viral promoters into the host genome, leading to the aberrant activa-
tion of host genes. However, although this observation highlights the
care that should be taken when using these systems, it does not
influence the interpretation of our results as such: the values of the
P-cadherin–transduced cells remain significantly different from those
of the respective vector-transduced cells.
P-Cadherin Mediates Invasion of HEK 293T Cells via Its Jux-
tamembrane Domain. To identify the P-cadherin domain(s) neces-
sary for its proinvasive effects, we used several P-cadherin constructs
(Fig. 6A) for transient transfection of the HEK cell line. Biotinylation
and immunoblotting confirmed expression of all of the constructs at
the plasma membrane (Fig. 6B). Transient transfection with P-
cadherin induced invasion into collagen type I, as observed with
stably transduced HEK cells (Fig. 6C).
The P-cadherin point mutant, PC-R503H (Fig. 6A), representing the
missense mutation in CDH3, found in hypotrichosis with juvenile
macular dystrophy (31), failed to support strong cell–cell adhesion
Fig. 2. Regulation of P-cad expression by an ER-dependent signaling pathway in MCF7 breast cancer cells. Immunoblotting, for P-cad and ER analysis, of cell lysates from MCF7
cells that had been treated with the indicated concentrations of ICI for the indicated time points. Band quantification was done relative to the expression levels in untreated cells.
Immunostaining for anti-–tubulin was done to control for equal loading. A, ICI induces up-regulation of P-cad and down-regulation of ER levels in a time-dependent manner, being
maximal after 12 hours of treatment. B, a 24-hour treatment with ICI induces up-regulation of P-cad and down-regulation of ER levels in a dose-dependent way, the higher
concentrations leading to a more pronounced effect. C, MCF7 cells were grown in the presence of ICI for 24 hours. At time 0 hours, ICI was withdrawn, and cell lysates were prepared
at the indicated time points. Immunoblotting was performed to analyze P-cad (o) and ER (f) expression. The levels of both proteins start to normalize again 96 hours after ICI
withdrawal, showing the reversibility of the effect. D. Cells were treated with ICI, E2, or a combination of both, for 24 hours. Although both ICI and E2 decreased ER levels, the
ICI-induced up-regulation of P-cad was counteracted by estradiol. E. MCF7 cells were grown in the presence of solvent control (lanes 1 and 2) or ICI (lanes 3 and 4) for 24 hours.
After that, ICI was withdrawn, all media were refreshed, and cells were treated (lanes 2 and 4) or not (lanes 1 and 3) with E2 for additional 24 hours. E2 accelerated the reversion
of P-cad expression to control levels in cells that had been treated with ICI. F, RT-PCR analysis of P-cad mRNA levels after ICI treatment of MCF7 cells for 24 hours. The analysis
was done after the indicated number of cycles of PCR amplification. P-cad mRNA increased in the presence of ICI (more evident at the 30-cycle point, in the exponential phase). Band
quantification is presented in the graph shown. G, immunoblotting, using anti-P-cad and anti-ER antibodies, of lysates from cells treated with CHX during 24 hours, alone or in
combination with ICI. Band quantification was done relative to the expression levels in untreated cells. CHX blocked P-cad up-regulation induced by ICI, suggesting the involvement
of de novo protein synthesis. (cad, cadherin; ER, estrogen receptor; ICI, ICI 182,780; E2, 17-estradiol; CHX, cycloheximide)
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unlike wild-type P-cadherin.6 Most likely, the reason for this failure is
the disruption of the strongly conserved LDRE Ca2	-binding motif in
the fourth extracellular domain of P-cadherin. Nevertheless, PC-
R503H still induced invasion (Fig. 6C).
Mutants of the P-cadherin cytoplasmic tail were also generated
(Fig. 6A). Transfection into HEK cells showed that PC-CT762, re-
taining the intact P-cadherin juxtamembrane domain, induced inva-
sion-like wild-type P-cadherin (Fig. 6C). Because this mutant is
truncated just before the catenin-binding domain, we assume that
-catenin, -catenin, or any other protein that binds to this region are
not needed for P-cadherin–mediated invasion.
With mutants within the juxtamembrane domain (Fig. 6A), statis-
tically significant invasion into collagen was seen only with the
truncation mutants that still retained the intact juxtamembrane domain
(PC-CT719 and PC-CT727; Fig. 6C). The somewhat decreased ability
of PC-CT719 to induce invasion (Fig. 6C) might be due to its lower
expression levels (Fig. 6B). In line with the results obtained with the
truncation mutants and confirming that the catenin-binding domain is
not involved in the proinvasive effects, the PC-703–707 mutant
(lacking EEGGG in the P120-catenin binding site), with impaired
P120-catenin binding (Fig. 6D), was not able to induce invasion of
HEK cells into collagen type I (Fig. 6C). In conclusion, P-cadherin
needs its intact juxtamembrane domain to induce invasion of HEK
cells into collagen type I.
To exclude that the gain of any exogenous cadherin, retaining its
juxtamembrane domain, would be sufficient for a proinvasive effect,
we demonstrated that HEK cells transfected with mouse wild-type
E-cadherin cDNA (Fig. 6A) failed to invade into collagen type I (Fig.
6C). In conclusion, the juxtamembrane domain of P-cadherin confers
to this molecule the specific ability to induce invasion of HEK cells,
in the presence of the endogenously expressed cadherin.
DISCUSSION
We demonstrated that the antiestrogen ICI 182,780 increased time-
and dose-dependently P-cadherin expression in estrogen receptor-–
positive breast cancer cells. This increase could be completely re-
verted by 17-estradiol, categorizing CDH3 as an estrogen-repressed
gene and pointing to 17-estradiol as a key regulator of this cadherin.
In addition to competing for binding to estrogen receptor-, ICI
182,780 also increases its breakdown (24). As a result, ICI 182,780
abrogates estrogen receptor- signaling and the subsequent regulation
of 17-estradiol responsive genes. Because the human P-cadherin
promoter (GI: 2950171) does not contain the consensus sequence
5-GGTCAnnnTGACC-3 of the estrogen-responsive elements (32),
17-estradiol is unlikely to have a direct inhibitory effect on tran-
scription of the CDH3 gene. Instead, the increase of P-cadherin by ICI
182,780, some hours after the decrease of estrogen receptor-, and its
6 V. Van Marck, C. Stove, V. Stove, J. Paredes, M. Bracke. P-cadherin promotes
cell-cell adhesion and counteracts invasion in human melanoma, manuscript in prepara-
tion.
Fig. 3. Effect of ICI on aggregation and on in vitro invasion of MCF7 and BT-20 cells. A, pictures, after 72 hours, of the slow aggregation assay on semi-solid substratum of MCF7
cells. Panel i, cells that were left untreated form compact aggregates, which are inhibited in cells cultured in presence of ICI (panel ii) and in cells that have been pretreated with ICI
before seeding on top of agar (panel iii). B, slow aggregation assay in suspension of MCF7 cells: the cells were pretreated with ICI for 24 hours before incubation in Erlenmeyer flasks.
A particle size distribution curve was generated using a particle size counter. Aggregates formed by ICI-treated cells were significantly smaller (, P 
 0.002) than control aggregates.
The arrow indicates the measurement of a single cell suspension at the beginning of the experiment. C and D, MCF7 cells that had been pretreated for 24 hours with the indicated
concentrations of ICI, E2, or the combination of both, were seeded as a single cell suspension on top of collagen type I gels (C) or on Matrigel-coated filters (D). In collagen type I
invasion assay, ICI-treated cells were significantly more invasive than control cells [, P 
 0.0081, P 
 0.02, and P 
 0.03 for ICI (107 mol/L, 106 mol/L, and 105 mol/L),
respectively]. In Matrigel, the differences were also statistically significant [, P  0.001 for ICI (107 mol/L and 106 mol/L) ]. E, pictures, after 72 hours, of the slow aggregation
assay on semi-solid substratum of BT-20 cells. Panel i, cells that were left untreated do not form compact aggregates; no alterations (panel ii) in cells cultured in presence of ICI and
(panel iii) in cells that have been pretreated with ICI before seeding on top of agar, in the absence of ICI. F. BT-20 cells that had been pretreated for 24 hours with ICI were seeded
as a single cell suspension on top of collagen type I gels (f) and on Matrigel (o). ICI-treated cells are as invasive as control cells; bars, SD. (ICI, ICI 182,780; E2, 17-estradiol)
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inhibition by cycloheximide, pleads for the existence of a CDH3-
regulating transcription factor. In the absence of estrogen receptor-
signaling (as in estrogen receptor-–positive cells treated with ICI
182,780 or in estrogen receptor-–negative cells), this 17-estradiol–
regulated factor might account for the high P-cadherin levels in some
breast cancer cell lines and for the inverse correlation between estro-
gen receptor- and P-cadherin expression in mammary tumors.
In MCF7 breast cancer cells, ICI 182,780 treatment led to a de-
creased cell–cell adhesion and promotion of invasion in vitro. This is
in line with the finding that 17-estradiol (33) and even the unligan-
ded receptor (34) may decrease in vitro invasiveness and motility of
breast cancer cells, suggesting that some estrogen-regulated genes
negatively control invasion. Because this control is lost in cells treated
with high concentrations of ICI 182,780, which up-regulate P-
cadherin, the effect of the latter was additionally investigated on in
vitro aggregation and invasion of cells retrovirally transduced with
P-cadherin. Surprisingly, retroviral transduction of MCF7 and HEK
cells with P-cadherin had no detectable influence on cell–cell adhe-
sion. This result suggests that P-cadherin does not shift the aggrega-
tion balance established by the other cadherins in these systems. By
contrast, such balance may well be changed for invasion, as demon-
strated with P-cadherin–transduced cells. It should be noted that this
Fig. 4. Cell aggregation and in vitro invasion of stably transduced MCF7 cells with P-cad cDNA. A, flow cytometric evaluation of EGFP expression (X axis) and E-cad expression
(Y axis) in MCF7.LIE and MCF7.P-cad cells. P-cad expression did not induce alterations in E-cad expression levels (right plot). The percentage of EGFP positivity is indicated for
each cell line. B, immunoblotting, using anti-E-cad and anti-P-cad antibodies, of lysates from biotinylated MCF7.LIE and MCF7.P-cad cells. C. In the slow aggregation assay in
suspension, both MCF7.LIE and MCF7.P-cad cells form similar compact aggregates after 48 hours. The arrow indicates the measurement of a single cell suspension at the beginning
of the experiment. D, pictures, after 48 hours, of the slow aggregation assay on semi-solid substratum. MCF7.LIE (panel i) and MCF7.P-cad (panel ii) cells form round and compact
aggregates, with no differences observed. E. In the collagen type I invasion assay, MCF7.P-cad cells invade significantly more (, P
 0.0024). F, representative experiment of Matrigel
invasion assay, where MCF7.P-cad cells invade significantly more than empty-vector transduced cells (, P  0.001). (cad, cadherin)
Fig. 5. Cell aggregation and in vitro invasion of stably transduced HEK cells with P-cad cDNA. A, immunoblotting, using anti-N-cad and anti-P-cad antibodies, of lysates from
biotinylated HEK, HEK.LIE.Med, HEK.P-cad.Med, HEK.LIE.High, and HEK.P-cad.High cells. Band quantification was done relatively to the expression levels in control cells. To
control for equal loading, immunostaining with anti--tubulin was done. B, flow cytometric analysis of EGFP expression (X axis) and N-cad expression (Y axis) in the indicated cell
lines. High levels of P-cad in the HEK.P-cad.High cell line induced down-regulation of endogenous N-cad. The percentage of EGFP positivity is indicated for each cell line. C. In the
slow aggregation assay in suspension, HEK.LIE.Med, HEK.P-cad.Med, HEK.LIE.High, and HEK.P-cad.High cell lines form similar compact aggregates after 48 hours. The arrow
indicates the measurement of a single cell suspension at the beginning of the experiment. D, pictures, after 48 hours, of the slow aggregation assay on semi-solid substratum.
HEK.LIE.Med (panel i), HEK.LIE.High (panel ii), HEK.P-cad.Med (panel iii), and HEK.P-cad.High (panel iv) cells form round and compact aggregates, with no differences observed.
E. A single cell suspension of these cell lines was seeded on top of collagen type I gels. After 24 hours of incubation, HEK.P-cad.Med and HEK.P-cad.High cells invaded significantly
more into the collagen type I matrix (, P 
 0.005 and P 
 0.02, respectively). Although HEK.LIE.High was statistically different from nontransduced cells (, P 
 0.003), the
comparison with HEK.P-cad.High still shows the significant effect of P-cad (P 
 0.03). F, representative experiment of Matrigel invasion assay. HEK.P-cad.Med and HEK.P-cad.High
cells invaded significantly more than empty vector-transduced cells (, P  0.001). Also here, although HEK.LIE.High differed significantly from control, the comparison with
HEK.P-cad.High still shows the significant effect of P-cad on invasion (P  0.001). (cad, cadherin)
8314
P-CADHERIN INVOLVED IN CELL INVASION
V. CADHERINS AS TARGET FOR (ANTI-) INVASIVE AGENTS
113
does not allow us to draw conclusions about the necessity of P-
cadherin up-regulation for ICI 182,780-induced invasion of MCF7
cells. In contrast to P-cadherin–transduced cells, which migrated
faster than controls in a wound healing migration assay, ICI 182,780-
treated cells did not. This might be due to the fact that the extent by
which P-cadherin is up-regulated by ICI 182,780 may not be sufficient
to promote motility as such or, alternatively, the growth-inhibitory
effect of ICI 182,780 nullified the promigratory effect of P-cadherin
in this assay. Furthermore, ICI 182,780 up-regulated additional pro-
invasive genes in MCF7 cells, such as MMP-2 and -9, of which the
expression was not influenced by P-cadherin (data not shown). Hence,
whereas high levels of P-cadherin may be sufficient for induction of
invasion, ICI 182,780-induced invasion might require the synergistic
action of multiple genes. This hypothesis, in which a critical level
of P-cadherin seems to be needed for its proinvasive activity, is
supported by the comparison between the invasive and highly P-
cadherin–positive BT-20 and T47D cells and the noninvasive and
weakly P-cadherin–positive MCF7 and ZR-75.1 cells (Fig. 1A). In
contrast to its proinvasive activity in our cells, transfection of other
cell lines with P-cadherin inhibited invasion (35, 36),6 suggesting that
P-cadherin may act both as an invasion promoter and suppressor,
depending on the cell type and its invasive status. Transgenic mice
expressing high levels of P-cadherin in the normal mammary epithe-
lium (37) contributed little to this issue, because they did not produce
tumors, and because neu oncogene-induced mammary tumors in P-
cadherin transgenic mice were always P-cadherin negative.
In the present study, the proinvasive action of P-cadherin is unlikely
to be the result of alterations in cell–cell adhesion, because the assays
score invasion of single cells into or through a matrix, the retroviral
transduction of MCF7 and HEK cells with P-cadherin did not change
aggregation, and the point mutant PC-R503H, incapable of supporting
strong P-cadherin mediated adhesion, still induced invasion. We pre-
sume that the proinvasive activity of P-cadherin is due to changes in
signaling pathways.
Recently, Wong and Gumbiner (38) attributed the anti-invasive
activity of wild-type E-cadherin to its interaction with -catenin. An
E-cadherin mutant, retaining the catenin-binding domain but with a
point mutation that abolishes P120-catenin binding, was still able to
suppress invasion. By contrast, in P-cadherin, maintenance of the
juxtamembrane domain is crucial for the induction of invasion, irre-
spective of the catenin-binding domain. Although the juxtamembrane
domain is highly conserved between cadherins, its function is very
context-dependent, being implicated in both positive and negative
regulation of cadherin activity. Cells expressing mutated E-cadherin
juxtamembrane domain are weakly adherent (39), more motile, but
still epithelioid. Upon formation of adhesive contacts, the juxtamem-
brane domain recruits and activates Rac, regulating the actin cytoskel-
eton (40). In another context, the juxtamembrane domain may inhibit
aggregation mediated by classical cadherins and induce cell motility
(41, 42) or, alternatively, exclude another cadherin from junctions and
regulate cell proliferation (43). Via its binding to P120-catenin, this
domain has been implicated recently in maintenance of the stability of
endogenous cadherins (44, 45). Thus, a possible mechanism for the
induction of invasion by P-cadherin might be its competition with the
endogenous cadherin for the available P120-catenin, leading to the
destabilization of pre-existing anti-invasive cadherin/catenin com-
plexes. Yet, we consider this possibility less likely. Although the
down-regulation of N-cadherin in HEK cells by high levels of the
several P-cadherin constructs coincided with stimulation of invasion
(Fig. 6C and Supplementary Data), moderate P-cadherin expression
levels, leaving the endogenous cadherin unchanged, were sufficient to
induce invasion. Furthermore, transfection of HEK cells with E-
cadherin did not induce invasion (Fig. 6C), despite decreased endog-
enous cadherin in highly expressing cells (Supplementary Data) and
expected competition for cadherin-binding proteins.
Alternatively, P-cadherin may generate a specific proinvasive sig-
nal via its juxtamembrane domain. In this hypothesis, the binding of
proteins to the P-cadherin juxtamembrane domain may differ from
their binding to E- or N-cadherin by strength, conformation, or re-
cruitment of other members of the complex. This, in turn, may result
in the activation of pathways that overcome the suppressive signals
mediated by the endogenous cadherins.
Fig. 6. In vitro invasion of HEK cells transiently
transfected with P-cad constructs. A, schematic di-
agram of the various constructs used for transient
transfection of HEK cells. B, immunoblotting, us-
ing anti-P-cad antibody, of streptavidin precipita-
tions of biotinylated HEK cells, transiently trans-
fected with P-cad constructs. C. A single cell
suspension of HEK cells, transiently transfected
with the indicated constructs, was seeded on top
of collagen type I gels. After 24 hours, invasive
cells were scored. Besides HEK.PC-WT cells,
also HEK.PC-R503H, HEK.PC-CT762, HEK.PC-
CT719, and HEK.PC-CT727 invaded significantly
more than empty-vector transfected cells (HEK-
.IRES) into the collagen (, P  0.001 for
HEK.PC-WT and HEK.PC-R503H, P 
 0.003 for
HEK.PC-CT762, P 
 0.015 for HEK.PC-CT719,
and P 
 0.023 for HEK.PC-727). D, I.P., using
anti-p120ctn antibody, of total lysates of HEK cells
transiently transfected with the empty vector
(IRES), with PC-WT and with PC-703–706 con-
structs. I.S. of these blots with anti-P-cad and anti-
p120ctn antibodies showed that PC-WT strongly
precipitates with p120ctn, as compared with PC-
703–706, where there is interference with this
binding (right two blots). The staining of total
lysates with P-cad indicates a similar expression of
the transfected P-cad constructs (left blot); bars,
SD. (I.P., immunoprecipitation; I.S., immuno-
staining; cad, cadherin; p120ctn, P120-catenin)
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Although binding of proteins to the juxtamembrane domain of
P-cadherin has just been documented for P120-catenin (46), other
molecules, like Hakai and presenilin-1 (PS-1), have been reported to
bind to the juxtamembrane domain of classical cadherins as well, to a
sequence adjacent to or overlapping the P120-catenin–binding do-
main, thereby competing with P120-catenin for binding (47, 48).
Although the significance of these interactions is not well known, we
cannot exclude the possibility that disruption of the P120-catenin–
binding sequence introduces conformational changes and/or uncou-
ples the interaction of these or other proteins, which could be respon-
sible for our observations. Striking examples of this were shown for
E-cadherin, where functional differences have been noted between
larger and minimal deletions of the juxtamembrane domain, with even
the minimal changes disrupting binding of multiple molecules (47).
Data about the role of P120-catenin in normal and cancer cells are
conflicting. Positive and negative regulation of cell–cell adhesion and
motility possibly reflect differences in cell type, cadherins, P120-
catenin isoforms, and shuttling between cadherin-bound and cytoplas-
mic pools (3). When overexpressed in the cytoplasm, P120-catenin
may regulate the actin cytoskeleton and cell motility, through Rho
GTPases (49). Similar to the differences seen between E-and N-
cadherin in terms of strength (3) and preference (50) of binding to
distinct P120-catenin isoforms, P120-catenin binding to P-cadherin
may be unique. This unique interaction may influence its impact on
the activity of the Rho GTPases, possibly making the cells more prone
to invade. Alternatively, the panel of molecules recruited by P120-
catenin may differ depending on the isoform or on the cadherin it is
bound to.
In conclusion, our study establishes an as yet unknown role for
P-cadherin in cancer: (1) P-cadherin expression is regulated through
estrogen receptor- signaling, suggesting that the inverse in vivo
correlation between these molecules stems from a causal relationship;
(2) P-cadherin induces invasion, in the context of endogenous E- or
N-cadherin expression; because P-cadherin expression in breast can-
cer is far more frequent than aberrant expression of N-cadherin, its
physiologic relevance is more likely to be higher (15); (3) except from
the presently demonstrated induction of invasion, no regulatory func-
tions have been described for the P-cadherin juxtamembrane domain.
This establishes a novel role for this domain and distinguishes P-
cadherin–mediated invasion from invasion induced by N-cadherin,
which depends on a physical interaction of its extracellular domain
with the fibroblast growth factor receptor (51). Remarkably, although
the P-cadherin juxtamembrane domain differs in only few amino acids
from the corresponding E-cadherin domain, it exerts an opposite
function: whereas the E-cadherin juxtamembrane domain suppresses
motility (52), the P-cadherin juxtamembrane domain is necessary for
induction of invasion. To understand why such related domains can
have opposite functions, it will be crucial to identify new interaction
partners and/or to study if the interaction of known partner molecules
differs between cadherins.
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VI. DISCUSSION AND PERSPECTIVES 
Part VI Discussion and perspectives 
 
Invasion is crucial step in the development of cancer and happens when cells are 
genetically transformed and become sensitive or insensitive for host and environmental 
factors (Mareel and Leroy 2003, Hanagan and Weinberg 2000). An important invasion 
suppressor in epithelial cancer is E-cadherin, and the regulation of this cell-cell adhesion 
molecule happens at the different levels (part 5) (Van Aken et al. 2001). Loss of this molecule 
can be associated with transactivation of another cadherin, like P-cadherin (part 5) and N-
cadherin (Derycke and Bracke 2004, part 2). Cells undergo changes and become fibroblastic, 
motile and invasive. A similar transition is observed during embryogenesis in the gastrulating 
stage. In the normal adult N-cadherin is expressed by neurons, (myo)fibroblast, endothelial 
cells, oocytes, spermatocytes and lens cells.  
Furthermore, cancer cells secrete many growth factors, for their survival, and several 
proteases to degrade the extracellular matrix (Mott and Werb 2004). Proteases are able to 
generate different fragments of the cadherin proteins. N-cadherin is sensitive to several 
proteases like ADAM 10, MT1-MMP, MT5-MMP and plasmin (part 3). All these enzymes 
are releasing the 90 kD extracellular fragment of N-cadherin, coined soluble N-cadherin or 
sN-CAD. This shedded fragment is still functional, because it was shown to stimulate neurite 
outgrowth (Utton et al. 2001). Literature data show the presence of soluble cadherin 
fragments in different human biological fluids. The most convincing report was the 
correlation of sE-CAD with gastric cancer and the prediction of disease recurrence (Chan et 
al. 2005). However, until now almost no data where found about the presence of sN-CAD in 
any biological fluid. The lack of good antibodies recognizing the extracellular part of N-
cadherin is probable one of the reasons why no data have been published so far. In the initial 
phase of this doctoral thesis we made some new monoclonal antibodies recognizing the HAV 
part in cadherin domain 1 and another one against cadherin domain 4 (in collaboration with 
Prof. J. Vandekerchove). However these were not suitable for ELISA, but the commercially 
available monoclonal antibody, GC-4, raised against the extracellular part of N-cadherin 
could be used for ELISA. Using this antibody an ELISA was established (part 3), which was 
applied to sera from persons with no evidence of disease (NED), cancer patients and patients 
suffering from other disease like heart disease, liver cirrhosis, arthritis, ... We could find ± 6 
times higher concentration of sN-CAD in the cancer patient group (median value of 584 
ng/ml) compared to NED group (median value 99 ng/ml). This difference between both 
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groups is higher than what was reported for sE-CAD, where the medians differenced by a 
factor 3, between the cancer group and the NED group. We also found a weak, but significant 
correlation with PSA. Now we are collecting well-documented serum samples from breast 
and prostate cancer patients, and we will test them to see if we can observe any correlation 
with the TNM staging or reaction to therapy. We assume that sN-CAD will be a better marker 
than sE-CAD because N-cadherin is not only expressed by the cancer cells but also 
reactionally by the stromal cells like (myo) fibroblast and endothelial cells, so different cells 
are a source of sN-CAD. Furthermore, sN-CAD can give idea if the tumour (cancer + stromal 
cells) is starting to be invasive and metastasize or give an idea how the tumour is reacting to 
the given therapy. We need to take into account that sN-CAD can also be elevated as a 
reaction to other diseases like inflammation. 
sN-CAD is not only a possible marker, the protein fragment also has a biological function. It 
stimulates the migration of N-cadherin positive cells that can be fibroblast, endothelial cells or 
cancer cells. We could show that sN-CAD stimulates angiogenesis by using 2 in vivo assays 
as model for angiogenesis: the chorioallantoic membrane assay and rabbit corneal 
micropocket assay (part 4). Angiogenesis is correlated with cancer cell metastasis. 
Angiogenesis is the result of endothelial cells that degrade the basement membrane, migrate 
and proliferate in the nearby stroma, differentiate and form new contacts with the pericytes. 
N-cadherin knockout mice die at day 10 of gestation and embryos display major heart defects 
and malformed neural tubes and somites (Radice et al. 1997). Furthermore, selective knock 
down of N-cadherin in the endothelial cells caused a significant decrease in VE-cadherin 
expression, motility and proliferation of the endothelial cells (Luo and Radice 2005). So it 
seems that N-cadherin plays an important role during angiogenesis, not at least because it 
anchors endothelial cells with the pericytes and vascular smooth muscle cells. We observed 
that sN-CAD has a pro-angiogenic effect and this effect was mediated by the fibroblast 
growth factor receptor (FGF-receptor). It has been pointed out that N-cadherin interacts with 
the FGF-receptor via its HAV–binding domain present domain 4 (Williams et al. 2001), and 
by this direct interaction it induces a continuous cell activation (Suyama et al. 2002). The 
FGF-receptor mediates numerous signalling pathways important in angiogenesis (Gerwins et 
al. 2000). By activation of the FGF-receptor proteases are upregulated via the zinc finger 
transcription factor Ets-1 (Sato et al. 2000) and allows proteolytic activity at the front of 
migration. We assume that sN-CAD has an autocrine and paracrine effect on the endothelial 
cells. Because the source of sN-CAD is not only the endothelial cells, but can also be cancer 
cells and the surrounding stromal cells. By this cancer cells are provided of factors which 
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mediate growth and dissemination. We could prove that the HAV-peptide exerts the same 
effect as the extracellular fragment on stimulation of angiogenesis. Several studies showed 
already that dimeric N-cadherin-peptides stimulated neurite outgrowth (Williams et al. 2002), 
while the antagonistic cyclic peptide induces apoptosis in endothelial cells (Erez et al. 2004). 
Finally, we can speculate about future therapeutic possibilities. One possibility would be the 
interference with the molecular cross talk between cancer cells and stromal cells, and between 
cancer cells and endothelial cells via blocking the N-cadherin signalling with N-cadherin 
antibodies or antagonistic peptides (Kelland 2005). The company Adherex Technologies 
already synthesized an N-cadherin antagonist (ADH-1, ExherinTM) and is now testing them in 
phase II trials. Another possibility might be the use of protease inhibitors, to halt the 
formation of cadherin fragments and their effects on invasion and angiogenesis. However, 
clinical trials using protease inhibitors were disappointing so far (Lah et al. 2006).  
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 Part VII Summary – Samenvatting -Résumé 
 
Summary  
 
 In the present thesis N-cadherin and its cleaved form soluble N-cadherin (sN-CAD) 
are studied in relation to cancer. Cadherins are calcium-dependent intercellular adhesion 
molecules that are often deregulated in cancer. E-cadherin, which is expressed by normal 
epithelial cells, is downregulated when cells become cancer cells and this sometimes 
coincides with transactivation of another cadherin, for example N-cadherin. As a result, cells 
change their phenotype and become fibroblastic, motile and invasive. The role of N-cadherin 
during cell adhesion, differentiation, embryogenesis and cancer is reviewed, and several 
examples are given of N-cadherin expression in tumour cell lines and biopsies. 
Extracellular proteases, also known as the cancer degradome, play an important role during 
tumour progression; they are involved in processes as invasion and metastasis but also cell 
proliferation, apoptosis and angiogenesis. The proteases, such as ADAM10, MT1-MMP and 
plasmin are able to shed a 90 kD extracellular fragment from N-cadherin. We could establish 
an ELISA for the detection of this sN-CAD. We tested body fluids from persons with no 
evidence of disease and cancer patients for the presence of sN-CAD. Significantly elevated 
levels of sN-CAD were measured in the cancer patient group and a weak but significant 
correlation was found with prostate specific antigen, which is the most frequently used 
circulating tumour marker for prostate cancer. 
Furthermore, sN-CAD also has a biological function: it was able to stimulate the motility of 
N-cadherin positive cells and more specifically of the endothelial cells. By using the 
chorioallantoic membrane assay and the rabbit corneal micropocket assay we could identify 
sN-CAD as a proangiogenic molecule. Unravelling the signalling pathway, we proved that the 
fibroblast growth receptor is an important player in the sN-CAD mediated effects. 
In conclusion, sN-CAD is a potentially interesting molecule in oncology, both as a circulating 
tumour marker and as a target for angiostatic treatment. 
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 Samenvatting 
 
 N-cadherine en zijn gekliefde vorm soluble N-cadherine (sN-CAD) in relatie met 
kanker zijn het onderwerp van deze thesis. Cadherines zijn calciumafhankelijke intercellulaire 
adhesie moleculen, en zijn meestal gedereguleerd in kanker. E-cadherine komt tot expressie 
op normaal epitheel cellen, maar gaat verloren wanneer de cellen muteren naar een kanker cel 
en dit fenomeen gaat dikwijls gepaard met de transactivatie van een ander cadherine, 
bijvoorbeeld N-cadherine. Door deze verandering verkrijgen de kanker cellen een 
fibroblastisch fenotype, worden motieler en invasief. Er is een overzicht gemaakt over de rol 
van N-cadherine in cel adhesie, differentiatie, embryogenese en kanker, en verschillende 
voorbeelden van N-cadherine expressie in kanker cellijnen en biopsies zijn weergegeven. 
Extracellulaire proteasen, ook het kanker “degradome” genoemd, spelen een belangrijke rol 
tijdens tumor progressie. Zij zijn van belang in invasie en metastase maar ook tijdens cel 
proliferatie, geprogrammeerde celdood en angiogenese. De proteasen, ADAM10, MT1-MMP 
en plasmine kunnen het extracellulaire fragment van N-cadherine afklieven. We konden een 
ELISA opstellen die ons de mogelijkheid gaf om sN-CAD te detecteren in verschillende 
biologische vochten. We testten sera van gezonde mensen en kanker patiënten voor de 
aanwezigheid van sN-CAD. Significant verhoogde waarden van sN-CAD werden 
waargenomen in sera van patiënten met kanker en een kleine maar significante correlatie met 
prostaat specifiek antigen (PSA) werd vastgesteld. PSA wordt frequent gebruikt als 
circulerende tumor merker in prostaat kanker. 
sN-CAD heeft ook een biologische functie, het stimuleert de migratie van N-cadherine 
positieve cellen, meer in het bijzonder van endotheel cellen. Door gebruik te maken van de 
kippen chorioallantoisch membraan en de konijn cornea micropocket test, konden wij sN-
CAD identificeren als een proangiogene molecule. Ontwarren van de signalisatie weg 
bevestigde ons dat de FGF-receptor een belangrijke rol speelt in de sN-CAD gemedieerde 
effecten. 
Tot besluit, sN-CAD is een mogelijk interessante molecule in de oncologie, als een 
circulerende tumor merker en als doel voor angiostatisch behandeling. 
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 Résumé 
 
Dans la présente thèse, la N-cadhérine et sa forme clivée, la N-cadhérine soluble (sN-
CAD), sont étudiées en relation avec le cancer. Les cadhérines sont des molécules d'adhésion 
intercellulaires calcium-dépendantes qui sont souvent dérégulées par le cancer. La E-
cadhérine, exprimée par des cellules épithéliales normales, est régulée vers le bas lorsque des 
cellules deviennent cancéreuses. Ce phénomène coïncide parfois avec la transactivation d'une 
autre cadhérine, par exemple la N-cadhérine. Le résultat est que les cellules modifient leur 
phénotype pour devenir fibroblastiques, motiles et invasives. Le rôle de la N-cadhérine dans 
l'adhésion et la différentiation cellulaires, l'embryogenèse et le cancer est étudié et nous 
donnons plusieurs exemples d'expression de N-cadhérine dans des lignées de cellules 
tumorales et de biopsies. 
Les protéases extracellulaires, connues également comme le "dégradome" du cancer, jouent 
un rôle important lors de la progression tumorale. Elles sont impliquées dans des processus 
comme l'invasion et la métastase, mais aussi dans la prolifération cellulaire, l'apoptose et 
l'angiogenèse. Les protéases comme ADAM10, MT1-MMP et la plasmine sont capables de 
séparer un fragment extracellulaire de 90kD de la N-cadhérine. Nous avons pu établir un 
ELISA pour la détection de cette sN-CAD. Nous avons examiné des fluides corporels de 
personnes sans signe de maladie et de patients cancéreux, à la recherche de la présence de sN-
CAD. Des taux significativement élevés de sN-CAD ont été mesurés dans le groupe de 
patients cancéreux et une corrélation faible mais significative a été trouvée avec l'antigène 
prostatique spécifique (PSA) qui est le marqueur tumoral circulant le plus utilisé dans le 
cancer de la prostate. 
En outre, sN-CAD exerce, elle aussi, une fonction biologique: elle stimule la migration de 
cellules positives pour la N-cadhérine et plus spécifiquement des cellules endothéliales. Par 
l'application du test de la membrane chorioallantoïque d'embryon de poulet et de la 
micropoche dans la cornée de lapin, nous avons pu établir que la sN-CAD était une molécule 
pro-angiogène. L'éclaircissement des voies de signalisation nous a permis de démontrer que le 
récepteur de croissance fibroblastique joue un rôle important dans les effets médiés par la sN-
CAD. 
En conclusion, la sN-CAD est une molécule potentiellement intéressante en cancérologie, en 
tant que marqueur tumoral circulant et comme cible d'un traitement angiostatique. 
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